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ABSTRACT

Cardiovascular disorders are the leading cause of death in the United States. Members
of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins)
class of lipid-lowering drugs are used worldwide for the prevention and treatment of
cardiovascular disorders. Cardiovascular disorders are the primary cause of morbidity
and mortality in patients with diabetes mellitus and obesity as well as renal and liver
transplantation. The rising global burden of these chronic disorders has resulted in
long-term use of statins to prevent and treat cardiovascular disorders in diverse patient
populations. Several statins are commercially available; however, atorvastatin calcium
(Lipitor®, Pfizer Pharmaceuticals, NY) is the world’s top selling medication of all
time; whereas, rosuvastatin calcium (Crestor®, AstraZeneca, DE) is the most
efficacious member of statin family.

Although, statins are well-tolerated, approximately 7% of patients on statin therapy
experience myotoxicity, which is ranging from a mild condition called myalgia to a
rare but potentially fatal rhabdomyolysis requiring hospitalization. A meta analysis
study reported by the United States FDA indicated three times higher incidence of
rhabdomyolysis in patients with diabetes mellitus. Previously published in vitro and
clinical studies identified the role of lactone metabolites in myopathy. Our group
found significantly elevated plasma concentrations of atorvastatin lactone metabolites
in the stable kidney transplant recipients with diabetes mellitus. Our study indicated
that reduced clearance of lactone could be attributed to decreased activity of
cytochrome P450 (CYP) 3A4, which is the main drug metabolizing enzyme. Prior

studies assessed the effect of genetic polymorphism in drug metabolizing enzymes and
transporters on pharmacokinetics and toxicological properties of parent drug and
lactone metabolite in healthy Finish and Korean populations.

Currently, limited information is available on the effect of concurrent diseases and
genetic polymorphisms of drug metabolizing enzymes and transporters on
pharmacokinetics of acid and lactone forms of atorvastatin. Altered pharmacokinetics
of atorvastatin acid or lactone in concomitant diseases possibly influences the clinical
outcome, resulting in unfavorable benefit/risk ratio. In this study, we have assessed the
impact of inherent demographic characteristics in conjunction with coexisting diseases
and genetic polymorphisms using a population pharmacokinetic analysis utilizing a
nonlinear mixed effect model to identify potential covariates that explain the
variability in pharmacokinetic properties of acid and lactone forms of atorvastatin.

A physiologically-based pharmacokinetic modeling approach was used for the
prediction of pharmacokinetics of orally administered atorvastatin acid and
rosuvastatin acid along with their major metabolites from in vitro data allowing
mechanistic characterization of the observed concentration-time profile. A mechanistic
modeling is needed to provide insights into the interplay of various phenomena
involved in oral absorption and metabolism of drugs. Additionally, simulations
through virtual patients using physiologically-based pharmacokinetic modeling will
allow to design a population pharmacokinetic study and to determine significant
covariates.

Manuscript I of this dissertation provides detailed information of pharmacokinetic
and pharmacological properties of atorvastatin and rosuvastatin acid. Moreover, it
describes the effect of various factors such as age, gender, race, food, liver and kidney
diseases, time of drug administration, and genetic polymorphism of drug
metabolizing enzymes and transporters on the pharmacokinetic properties of both
statins. Atorvastatin acid is significantly metabolized by CYP3A4, and it is more
likely to cause clinically important drug-drug interaction. Previously reported drugdrug interactions of atorvastatin are discussed in this manuscript. This manuscript will
be submitted for publication to “Clinical Pharmacokinetics” as a review article.

Due to lack of simple and sensitive methods for simultaneous quantification of
atorvastatin and its five metabolites in human plasma, a liquid chromatography
tandem-mass spectrometry (LC-MS/MS) bioanalytical method was developed.
Manuscript II explains in detail about the development and validation of a sensitive,
selective and simple LC-MS/MS assay for simultaneous quantitative determination of
parent drug and its five metabolites (published in Anal Bioanal Chem. 2011
Apr;400(2):423-33).

Esterase activity is a key reason of instability of ester-containing drugs in biological
matrices. The effect of several anticoagulants on lactone to acid interconversion was
investigated by comparing different types of plasma (sodium heparin, K2EDTA and
sodium fluoride/potassium oxalate) and serum. No, statistically significant difference
was found between serum and plasma with various anticoagulants; however, sodium
fluoride (esterase inhibitor) plasma was preferred to ensure stability of lactone upon

long-term storage of clinical study samples. Comprehensive stability studies were
conducted prior to the method validation to establish stability conditions for unstable
lactone analytes during the extraction steps as well as storage duration of clinical
samples. The method was validated according to recent FDA guidelines. The postcolumn infusion test was performed to assess matrix effect. Ortho- and para-hydroxy
analytes have similar precursor ion-product ion transitions. Additionally, the acid form
could possibly undergo in-source fragmentation and, following the loss of water, the
resulting product would interfere with their respective lactone forms. For these
combined reasons, chromatographic conditions that would assure baseline
chromatographic separation of the respective analytes were determined. This goal was
achieved using a narrow-bore Zorbax-SB phenyl column. Because this column
provided excellent peak focusing a high S/N was obtained that enabled us to use a
simple

protein

precipitation

extraction

procedure

without

performing pre-

concentration steps for sample clean up. The extraction method contained a simple
protein precipitation step requiring only 50 μL of plasma and achieved a lower limit of
quantification of 50 pg/mL for all six analytes.

To the best of our knowledge, no published bioanalytical method has described a fully
validated LC-MS/MS assay for the quantification of rosuvastatin lactone metabolite in
human plasma. A sensitive and simple LC-MS/MS assay was developed for the
simultaneous quantification of parent drug and its two metabolites in human plasma.
Manuscript III describes the development and validation of an LC-MS/MS method
for the simultaneous quantification of rosuvastatin acid and its two metabolites; N-

desmethyl rosuvastatin and rosuvastatin lactone (published in Anal Bioanal Chem.
2012 Jan; 402(3):1217-27).

Like atorvastatin lactone, rosuvastatin lactone is also very unstable. Stability of all the
three analytes was tested in various conditions such as non-buffered human plasma
and buffered human plasma (human plasma diluted 1:1 with 0.1 M, pH 4.0 sodium
acetate buffer). For the proposed assay, plasma was diluted 1:1 with 0.1 M, pH 4.0
sodium acetate buffer due to prevent the loss of lactone form (25%) that occurred in
non-buffered plasma after 1 month storage at -80 °C. Furthermore, to ensure stability
of rosuvastatin lactone metabolite during extraction of samples, 0.1% v/v glacial acetic
acid in methanol was used as precipitating agent to minimize the interconversion of
lactone to acid and vice versa. With the use of narrow-bore Zorbax-SB Phenyl
column, lower limit of quantification of 0.1 ng/mL for acid and lactone forms of
rosuvastatin, and 0.5 ng/mL for N-desmethyl rosuvastatin acid were achieved using 50
µL of buffered human plasma.

The impact of concurrent chronic disorders and polymorphisms in genes coding for
drug metabolizing enzymes and transporters involved in the parent drug and the major
metabolite elimination were investigated through a population pharmacokinetic
modeling approach using NONMEM software (Manuscript IV). The plasma
concentrations of parent drug and metabolite of one hundred and thirty two, male
(n=77) or female (n=55) non-transplant (diabetic, n=46; non-diabetic, n=53) or the
stable kidney transplant (diabetic, n=22; non-diabetic, n=11) recipients receiving a
single oral dose or multiple oral doses of Lipitor (atorvastatin calcium) were included

in the study. The study samples were analyzed using an LC-MS/MS method described
in Manuscript II.

A complex parent-metabolite combined population pharmacokinetic model was
developed by analyzing a total of 639 concentrations including both acid (n=322) and
lactone (n=317) forms of atorvastatin through a nonlinear mixed-effects modeling
approach to identify and interpret the genetic, demographic, physiological and
pathological factors that significantly affect the pharmacokinetic properties of
atorvastatin acid and its major metabolite. Concentration-time profiles of atorvastatin
acid and lactone metabolite were adequately described respectively, using a twocompartment model with first-order oral absorption and a one-compartment model
with linear elimination, with some degree of interconversion between the two forms.
Covariate model building was conducted to investigate and determine sources of
variability (covariates) that elucidate differences in pharmacokinetic parameters
between patients, through univariate analysis followed by stepwise forward addition
and backward elimination. Covariate analysis identified the kidney transplantation
status and lactate dehydrogenase (liver enzyme) as significant covariates affecting the
apparent clearance of atorvastatin lactone metabolite. Renal transplant recipients had
50%

lower

metabolite

clearance

than

non-transplant

patients.

However,

polymorphisms in genes coding for enzymes and transporters as well as biomarkers of
diabetes such as HbA1c and serum glucose levels did not significantly affect the
pharmacokinetics of either parent drug or metabolite. The final model was validated
using a visual predictive check method and nonparametric bootstrap analysis, which
guaranteed robustness of the present population pharmacokinetic model. The finding

of the study indicated the need of careful monitoring while prescribing atorvastatin
treatment to the kidney transplant population. This manuscript will be submitted for
publication to “Clinical Pharmacology and Therapeutics” as a research article.
Manuscript V (to be submitted to “Molecular Pharmaceutics”) presents a whole-body
physiologically-based

pharmacokinetic

(PBPK)

model

for

atorvastatin

and

rosuvastatin acid with their respective metabolites allowing a mechanistic
characterization of observed plasma concentration-time profiles of parent drug and its
metabolites. Plasma samples obtained from the stable kidney transplant recipients with
diabetes mellitus were analyzed using LC-MS/MS methods described in Manuscripts
II and III.

The GastroPlus (Simulations Plus, Inc., USA) advanced compartmental absorption
and transit (ACAT) model, generic PBPK module and population estimates for agerelated physiology feature were used to predict systemic exposure of both statins
following an oral administration in stable kidney transplant recipients with diabetes
mellitus. The required number of input parameters was obtained experimentally, in
silico and from the literature. Atorvastatin acid undergoes extensive gut and hepatic
metabolism mainly by CYP3A4. In vitro Km and Vmax values of metabolic clearance of
atorvastatin acid previously determined in our laboratory using diabetic human liver
microsomal fractions were implemented in the model. The model used a built-in utility
for conversion of in vitro Km and Vmax values to in vivo values. To predict observed
large volume of distribution of both statins, the Berezhkovskiy algorithm was utilized
to determine tissue distribution of perfusion-limited tissues. The observed mean

plasma concentration-time curves for both statins and their metabolites were
adequately described by the proposed PBPK model. A parameter sensitivity analysis
identified that systemic exposure of both statins is significantly affected by changes in
intestinal transit time. Part of the validation process included virtual trial simulations,
which allowed incorporation of inter-subject variability. The virtual trial simulation
results showed that the observed mean plasma concentration-time curves of both
statins lay between 90% confidence interval of simulated concentrations of ten virtual
patients. The present whole-body PBPK model demonstrated that in vitro metabolic
clearance data generated from a specific disease tissue were superior for adequate
prediction of systemic exposure of an extensively metabolized drug that might have
modified due to altered activity of drug metabolizing enzyme in a specific disease
state

In summary, the work presented in this dissertation evaluate the effect of preexisting
disease states including diabetes mellitus and renal transplant as well as genetic
polymorphisms in drug metabolizing enzymes and transporters that predominantly
contribute to overall disposition of atorvastatin acid and its lactone metabolite. The
study indicated that the clearance of lactone, a myotoxic metabolite of atorvastatin
acid, is significantly decreased by 50% in the stable kidney transplant recipients.
However, the unbalanced sample size in this study restricts to delineate the individual
influence of renal transplant and diabetes mellitus on clearance of parent drug and its
metabolite. In addition, for the first time the disposition of atorvastatin acid and
rosuvastatin acid as well as their respective metabolites was characterized using a
mechanistic modeling approach, to predict observed plasma concentration-time

profiles in the kidney transplant recipients with diabetes mellitus. The PBPK model
that integrated in vitro kinetic parameters for metabolic clearance of atorvastatin acid
measured in human liver microsomal fractions of diabetic livers were superior for the
prediction of observed plasma concentration-time curve of atorvastatin acid.

Overall, this study demonstrated a significant reduction of clearance of atorvastatin
lactone metabolite in patients with the kidney transplant and thus they might be at
higher risk of developing myotoxicity. This finding indicated the need of careful
monitoring of atorvastatin acid therapy in the kidney transplant recipients who are on
multiple medications and also have lifetime co-morbidities. Moreover, mechanistic
modeling suggested that the systemic exposure of both statins is very sensitive to
change in intestinal transit time. It would be beneficial to study the activity of
intestinal drug metabolizing enzymes and transporters in diabetes mellitus and its
impact on pharmacokinetics of statins.
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PREFACE
This dissertation was prepared according to the University of Rhode Island
‘Guidelines for the Format of Theses and Dissertations’ standards for Manuscript
format. This dissertation consists of five manuscripts that have been combined to
satisfy the requirements of the department of Biomedical and Pharmaceutical
Sciences, College of Pharmacy, University of Rhode Island.
MANUSCRIPT I: Clinical Pharmacokinetics of Atorvastatin and Rosuvastatin
This manuscript has been prepared for publication and will be submitted to “Clinical
Pharmacokinetics” as a review article.
MANUSCRIPT II: Development and Validation of a Sensitive, Simple and Rapid
Method for Simultaneous Quantitation of Atorvastatin and its Acid and Lactone
Metabolites by Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS)
This manuscript has been published in a peer-reviewed journal “Analytical and
Bioanalytical Chemistry”, April 2011.
MANUSCRIPT III: A Simple Assay for Simultaneous Determination of
Rosuvastatin acid, Rosuvastatin-5s-lactone and N-desmethyl rosuvastatin in
Human Plasma using Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS)
This manuscript has been published in a peer-reviewed journal “Analytical and
Bioanalytical Chemistry”, January 2012.

xiv

MANUSCRIPT IV: Development of a Combined Parent-Metabolite Population
Pharmacokinetic Model for Atorvastatin Acid and its Lactone Metabolite:
Implication of Renal Transplantation
This manuscript has been prepared for publication and will be submitted to “Clinical
Pharmacokinetics” as a research article.
MANUSCRIPT V: Development of Physiologically-Based Pharmacokinetic
Model for Atorvastatin Acid and Rosuvastatin Acid with their Metabolites: In
vitro and in vivo studies
This manuscript has been prepared for publication and will be submitted to
“Molecular Pharmaceutics” as a research article.

xv

TABLE OF CONTENTS

ABSTRACT .................................................................................................................. ii
ACKNOWLEDGMENTS .......................................................................................... xi
DEDICATION ........................................................................................................... xiii
PREFACE .................................................................................................................. xiv
TABLE OF CONTENTS .......................................................................................... xvi
LIST OF TABLES ................................................................................................... xvii
LIST OF FIGURES .................................................................................................. xix
MANUSCRIPT I .......................................................................................................... 1
MANUSCRIPT II ...................................................................................................... 37
MANUSCRIPT III ..................................................................................................... 70
MANUSCRIPT IV ................................................................................................... 104
MANUSCRIPT V ..................................................................................................... 138

xvi

LIST OF TABLES

Table I-1. Major polymorphisms in genes coding drug metabolizing enzymes and
transporters affecting the pharmacokinetics of atorvastatin acid (ATV) and atorvastatin
lactone (ATV-LAC). .................................................................................................... 27
Table I-2. Major polymorphisms of drug metabolizing enzymes and transporters
affecting the pharmacokinetics of rosuvastatin acid. ................................................... 28
Table II-1. Effect of Various Anticoagulants on Interconversion of Atorvastatin
(ATV) lactones; the first part represents ATV lactone %accuracy and %CV for blank
samples of serum or plasma with different anti-coagulants freshly spiked with ATV
lactones at high quality control level. The second part of the table represents the mean
and standard deviation of ATV and metabolite concentration from 5 patients at steadystate ATV with samples obtained as serum or plasma with different anti-coagulants. 63
Table II-2. Summary of Standards and Calibration Curve Parameters from Three
Individual Runs. ........................................................................................................... 64
Table II-3. Summary of Quality Control Samples from Three Individual Runs. ....... 65
Table III-1a. Results of stability studies and recovery (mean±%CV, n=3). .............. 98
Table III-1b. Stability studies after 1 week and 1 month at -80 °C (mean±%CV, n=3).
...................................................................................................................................... 98
Table III-2. Summary of standards and calibration curve parameters from three
individual runs.............................................................................................................. 99
Table III-3. Summary of quality control samples from three individual runs. ......... 100
Table IV-1. Characteristics of the patients included in the NONMEM analysis. ..... 131
Table IV-2. Significant covariates for the univariate and multivariate analyses. ..... 132
Table IV-3. The parameter estimates for the atorvastatin and metabolite population
models and the results of bootstrap validation of the final model. ............................ 133
Table V-1. The ACAT physiological model compartment parameters of default fed
human physiology used in simulations of atorvastatin acid and three metabolites in
GastroPlusTM . ............................................................................................................ 184
Table V-2. ACAT physiological model compartment parameters of default fed
human physiology used in simulations of rosuvastatin acid and lactone metabolite in
GastroPlusTM . ............................................................................................................ 185

xvii

Table V-3. Summary of key biopharmaceutical properties and in vitro data of
atorvastatin acid (ATV), atorvastatin lactone (ATV-LAC), ortho-hydroxy atorvastatin
acid (O-OH-ATV) and ortho-hydroxy atorvastatin lactone (O-OH-ATV-LAC). ..... 186
Table V-4. Summary of key biopharmaceutical properties and in vitro data of
rosuvastatin acid and rosuvastatin lactone used in the PBPK simulations. ............... 187
Table V-5. Summary of observed and predicted pharmacokinetic parameters of
atorvastatin acid and rosuvastatin acid following an oral administration. ................. 188

xviii

LIST OF FIGURES

Figure I-1. Proposed oxidative metabolic (Phase I) pathway of atorvastatin acid. .... 23
Figure I-2. Proposed glucuronidation (Phase II) metabolic pathway of atorvastatin
acid. .............................................................................................................................. 24
Figure I-3. Chemical structure of rosuvastatin calcium. ............................................. 25
Figure I-4. Chemical structures of metabolites of rosuvastatin acid a) N-desmethyl
rosuvastatin b) Rosuvastatin-5S- lactone. .................................................................... 26
Figure II-1. Proposed metabolism pathway of atorvastatin to atorvastatin lactone,
ortho-hydroxy-atorvastatin, para-hydroxy-atorvastatin, ortho-hydroxy-atorvastatin
lactone, and para-hydroxy-atorvastatin lactone. .......................................................... 59
Figure II-2. Chromatograms showing the integrated peaks of atorvastatin acid (A),
atorvastatin lactone (B), ortho-hydroxy-atorvastatin (C), para-hydroxy-atorvastatin
(D), ortho-hydroxy- atorvastatin lactone (E), and para-hydroxy-atorvastatin lactone (F)
from extracted calibration standard at the lower limit of quantitation (0.05 ng/mL). . 60
Figure II-3. Injection of matrix spiked with analyte and IS without post-column
infusion along with MRM transitions of key phospholipids. Chromatograms showing
the peaks of analytes and corresponding IS along with key phospholipids (A).
Chromatogram obtained with post-column infusion shows no matrix effect at the
retention times of analytes and IS. Arrow indicates region where the signal of
compounds infused post-column is suppressed during the elution of endogenous
matrix components (B). Chromatogram of a blank sample injected while the analytes
and IS are infused post column. Arrow indicates region where the signals of analytes
and IS infused post-column are suppressed during the elution of endogenous matrix
components (C). ........................................................................................................... 61
Figure II-4. Plasma concentration (ng/mL) versus time profiles of atorvastatin and
metabolites, in acid and lactone forms, from the four stable kidney transplant
recipients who received a 10 mg atorvastatin dose; data are expressed as mean and
error bars represent standard deviation (A) Metabolite/parent atorvastatin
concentration from the stable kidney transplant recipients (n=9) on a steady-state dose
of 10-40 mg atorvastatin (B). ....................................................................................... 62
Figure III-1a Structures of (i) rosuvastatin acid, RST (ii) N-desmethyl rosuvastatin,
DM-RST and (iii) rosuvastatin-5S-lactone, RST-LAC. .............................................. 90
Figure III-1b Structures of major product ions (i) rosuvastatin acid, RST and Ndesmethyl rosuvastatin, DM-RST and (ii) rosuvastatin-5S-lactone, RST-LAC. ......... 91
xix

Figure III-2a Chromatograms showing the integrated peaks of rosuvastatin acid (i),
N-desmethyl rosuvastatin (ii), and rosuvastatin-5S-lactone (iii) from extracted
buffered calibration standard at lower limit of the quantification (0.1 ng/mL for
rosuvastatin acid and rosuvastatin-5S-lactone and 0.5 ng/mL for N-desmethyl
rosuvastatin). ................................................................................................................ 92
Figure III-2b Chromatograms of extracted double blank buffered human plasma (RT
represents retention time), rosuvastatin acid channel (i), N-desmethyl rosuvastatin
channel (ii), and rosuvastatin-5S-lactone channel (iii). ............................................... 93
Figure III-3a Chromatogram obtained with post-column infusion shows no matrix
effect at the retention times of the analytes and the IS. Arrow indicates region where
the signal of compounds infused post-column is suppressed during the elution of
endogenous matrix components. .................................................................................. 94
Figure III-3b Chromatogram of a blank sample injected while the analytes and the IS
are infused post column. Arrow indicates region where the signals of the analytes and
the IS infused post-column are suppressed during the elution of endogenous matrix
components. From top to bottom, rosuvastatin-5S-lactone, d6-rosuvastatin acid, d6rosuvastatin-5S-lactone, rosuvastatin acid, N-desmethyl rosuvastatin, d6-N-desmethyl
rosuvastatin. ................................................................................................................. 95
Figure III-4a Individual plasma concentration-time profiles of rosuvastatin acid of the
stable kidney transplant recipients (n=4) who received a single oral dose of 20 mg of
rosuvastatin. ................................................................................................................. 96
Figure III-4b Individual plasma concentration-time profiles of rosuvastatin-5Slactone of the stable kidney transplant recipients (n=4) who received a single oral dose
of 20 mg of rosuvastatin. .............................................................................................. 97
Figure IV-1. Schematic diagram of the proposed structural combined parentmetabolite pharmacokinetic model for orally administered ATV and its major
metabolite, ATV-LAC. A two-compartment model with first-order oral absorption and
one-compartment with linear elimination was used to describe the PK of ATV and
ATV-LAC, respectively with some interconversion between two forms. Elimination of
ATV-LAC only from the central compartment was assumed and no other pathways of
elimination of ATV were accounted. Ka = absorption rate constant; V2/F = apparent
volume of distribution of the parent drug in the central compartment; CL/F = apparent
oral clearance of the parent drug to the metabolite; V3/F = apparent volume of
distribution of the parent drug in the peripheral compartment; Q/F = apparent intercompartmental clearance of the parent drug; CLM/F = apparent total oral clearance of
the metabolite; VM/F = apparent volume of distribution of the metabolite in the central
compartment; QM/F = apparent inter-compartmental clearance of the metabolite to the
parent drug. ................................................................................................................ 127
Figure IV-2. The goodness-of-fit plots of the final model for atorvastatin acid: (a)
OBS vs PRED (b) OBS vs IPRED (c) CWRESI vs PRED (d) CWRESI vs time postxx

dose at steady state. (e) CWRESI vs time after single dose. OBS = observed
concentrations of atorvastatin acid; PRED = population predicted concentrations of
atorvastatin acid; IPRED = individual predicted concentrations of atorvastatin acid;
CWRESI = conditional weighted residuals with interaction. Logarithmic scale was
used for clarity............................................................................................................ 128
Figure IV-3 The goodness-of-fit plots of the final model for atorvastatin lactone: (a)
OBS vs PRED (b) OBS vs IPRED (c) CWRESI vs PRED (d) CWRESI vs time postdose at steady state. (e) CWRESI vs time after single dose. OBS = observed
concentrations of atorvastatin lactone; PRED = population predicted concentrations of
atorvastatin lactone; IPRED = individual predicted concentrations of atorvastatin
lactone; CWRESI = conditional weighted residuals with interaction. Logarithmic scale
was used for clarity. ................................................................................................... 129
Figure IV-4. The plots of the visual predictive checks for the final model from the
simulated data for plasma concentrations of (a) atorvastatin acid at steady state (b)
atorvastatin acid after single dose (c) atorvastatin lactone at steady state (d)
atorvastatin lactone after single dose. Observed concentrations (○) compared to the
97.5th (upper dashed line), 50th (middle solid line) and 2.5th (lower dashed line)
percentiles of the 1000 simulated datasets. Logarithmic scale was used for clarity. . 130
Figure V-1a. Simulated and observed human oral mean plasma concentration-time
profiles for atorvastatin acid and atorvastatin lactone metabolite .............................. 177
Figure V-1b. Simulated and observed human oral mean plasma concentration-time
profiles for an acid and lactone from of ortho-hydroxy atorvastatin metabolites...... 178
Figure V-2 (a) Mean (n=3) dissolution profiles of atorvastatin acid in different pH
media. (b) Mean (n=3) concentrations of an acid form of atorvastatin in dissolution
media with pH 1.2, 3, 4.5, 6.8 and 8 (c) Mean (n=3) concentrations of lactone form of
atorvastatin in dissolution media with pH 1.2 and 3 .................................................. 179
Figure V-3. Virtual trial simulation for ten subjects following a 40 mg oral dose of
atorvastatin acid. Solid line shows the mean of simulated concentrations of ten
subjects. Square with error bar represents the clinical observations. The green
highlighted area represents 90% confidence interval of simulated concentrations data.
The solid blue, dashed, and dotted lines represent individual simulated results that
incorporate 100, 95, 90, 75, 50, 25, and 10% of the range of simulated data. ........... 180
Figure V-4. Simulated and observed human oral mean plasma concentration-time
profiles for rosuvastatin acid and its lactone metabolite. ........................................... 181
Figure V-5. (a) Mean (n=3) dissolution profiles of rosuvastatin acid in different pH
media. (b) Mean (n=3) concentrations of an acid form of rosuvastatin in dissolution
media with pH 1.2, 3, 4.5, 6.8 and 8 (c) Mean (n=3) concentrations of lactone form of
rosuvastatin in dissolution media with pH 1.2 ........................................................... 182

xxi

Figure V-6. Virtual trial simulation for ten subjects following a 20 mg oral dose of
rosuvastatin. Solid line shows the mean of simulated concentrations of ten subjects.
Square with error bar represents the clinical observations. The green highlighted area
represents 90% confidence interval of simulated concentrations data around mean. The
solid blue, dashed, and dotted lines represent individual simulated results that
incorporate 100, 95, 90, 75, 50, 25, and 10% of the range of simulated data. ........... 183

xxii

MANUSCRIPT I

To be submitted as review article to Clinical Pharmacokinetics
Clinical Pharmacokinetics of Atorvastatin and Rosuvastatin
Joyce S. Macwan1, Fatemeh Akhlaghi1
1

Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and

Pharmaceutical Sciences, University of Rhode Island, 7 Greenhouse Road, Kingston, RI
02881.

Running title: Pharmacokinetic properties of atorvastatin and rosuvastatin acid

Corresponding author and address for reprints:
Fatemeh Akhlaghi PharmD, PhD.
Clinical Pharmacokinetics Research Laboratory
Biomedical and Pharmaceutical Sciences
University of Rhode Island
Kingston, RI 02881, USA
Phone: (401) 874 9205
Fax: (401) 874 5787
Email: fatemeh@uri.edu

1

Keywords: | atorvastatin | rosuvastatin | statins | pharmacokinetics | genetic
polymorphism |drug interaction | lactone | metabolite

Abbreviations: 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), Area under the
plasma-concentration time curve (AUC), Atorvastatin acid (ATV), Atorvastatin lactone
(ATV-LAC), Breast cancer resistant protein (BCRP), Cytochrome P450 (CYP), Low
density lipoprotein-cholesterol (LDL-C), Maximum plasma concentration (Cmax), Organic
anion-transporting polypeptide (OATP), Paraoxonases (PON), P-glycoprotein (P-gp),
Pharmacokinetics (PK), Rosuvastatin acid (RST), Rosuvastatin-5S-lactone (RST-LAC),
Time to reach maximum plasma concentration (Tmax), Single nucleotide polymorphism
(SNP), UDP-glucuronosyltransferase (UGT)

2

Abstract
Dyslipidemia is the main risk factor for the development of atherosclerosis and coronary
artery diseases. Cardiovascular disorders are the first leading cause of death in the Unites
States and a major cause of morbidity and mortality in patients with diabetes mellitus,
obesity, renal or liver transplantation. 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors (statins) class of lipid-lowering drugs are the first choice for
prevention and treatment of cardiovascular diseases. The increasing global burden of
heart diseases resulted in extensive use of statin therapy in a diverse patient population.
Statin-associated skeletal muscle toxicity is the most common side effect with statin
therapy that sometimes results in life threatening rhabdomyolysis.

Among commercially available statins, worldwide, atorvastatin acid is the top-selling
prescribed medication; however, rosuvastatin acid is considered the most efficacious
statin. The present, review article summarizes the clinical pharmacokinetics properties of
two widely prescribed antihyperlipidemic agents, atorvastatin and rosuvastatin acid.

Atorvastatin

acid

is

a

biopharmaceutics

classification system

(BCS)

and

biopharmaceutical drug disposition classification system (BDDCS) class II drug and,
therefore, it is highly soluble and permeable and exhibits complete absorption following
an oral dosing. It is >98% bound to plasma proteins and display extensive peripheral
tissue distribution. Significant metabolism, both in the gut and liver, primarily by
cytochrome P450 (CYP) 3A4, plays a key role in the first-pass effect that explains its
remarkably low oral bioavailability (14%). It is also biotransformed into glucuronide
metabolites mediated by uridinediphosphoglucuronyl-transferase (UGT) enzymes and
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undergoes lactonization. The parent drug and its metabolites are mainly excreted into
bile. The drug is a substrate of several hepatic uptake transporters of organic aniontransporting polypeptide family. Moreover, it is believed to be a substrate of efflux
transporters including p-glycoprotein (MDR1) and breast cancer resistant protein
(BCRP), which may govern intestinal absorption and biliary excretion. Single nucleotide
polymorphism

of

drug

metabolizing

enzymes

and

transporters

modulates

pharmacokinetics and toxicological properties of the parent drug and metabolites. It is
more likely to cause CYP 3A4 mediated clinically relevant drug-drug interaction.

Rosuvastatin acid, a BCS and BDDCS class III drug is highly soluble and less permeable
and, therefore, demonstrate selective hepatic uptake. It is one of the most effective statins
due to its unique characteristics such as superior binding affinity, and tight binding
interactions at the enzyme active site. It is highly bound to plasma proteins mainly to
albumin. It undergoes minimal metabolism and hence eliminated unchanged in the feces.
Moreover, multiple hepatic organic anion-transporting polypeptide (OATP) uptake and
BCRP efflux transporters significantly contribute to hepatobiliary disposition of
rosuvastatin. Genetic polymorphisms in these transport proteins may significantly alter
systemic exposure of rosuvastatin acid. Because of insignificant metabolism, it is less
likely to cause clinically important metabolic drug-drug interactions.
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Introduction
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose
levels. The epidemic of diabetes has increased because of obesity and lifestyle changes.
In 2010, diabetes mellitus was ranked as the seventh leading cause of death in the United
States [1]. Moreover, worldwide the number of people with diabetes is projected to
increase to 366 million by 2030 in all-age groups [2].
Diabetes mellitus is the primary risk factor for coronary artery disease and stroke [3],
which are ranked as the leading causes of death in the United States [4, 5]. An update to
the guidelines of Adult Treatment Panel III, issued by the National Cholesterol Education
Program, indicates that a larger number of diabetic patients than non-diabetic individuals
were administered 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors (statins) for the treatment of hypercholesterolemia [6].

Several statins

including simvastatin, atorvastatin acid (ATV), rosuvastatin acid (RST) and pravastatin
acid are the commonly prescribed lipid-lowering agents. Atorvastatin calcium (Lipitor®,
Pfizer Pharmaceuticals, NY, USA) is the world’s best selling medication of all time [1].
A clinical trial conducted in patients with type 2 diabetes mellitus concluded that ATV is
effective in the primary prevention of serious cardiovascular events including stroke,
irrespective of low density lipoprotein-cholesterol (LDL-C) level before treatment [7] ;
therefore, ATV is widely prescribed in the diabetic population [6].
Atorvastatin is extensively metabolized by cytochrome P450 (CYP) 3A4/5 and
biotransformed into pharmacologically active ortho- and para- hydroxylated metabolites
[8] that remain in equilibrium with their respective pharmacologically inactive lactone
5

forms [9], which have 83-fold higher affinity for CYP3A4 [8, 10]. Although, statins are
well-tolerated, approximately 7% of patients on statins therapy experience mild or severe
skeletal muscle complaints. The incidence of statin-associated adverse effects is
dependent on the dose or plasma concentration of statins. Moreover, the risk is higher in
old age, metabolic disorders, renal and hepatic disorders as well as patients receiving
inhibitors of CYP enzymes and/or transporters [11]. Because of elevated incidence of
statin-associated rhabdomyolysis, cerivastatin was deliberately withdrawn from the
United States market in 2001 [12]. A meta-analysis study conducted by the United
States FDA, using data from 252,460 patients treated with lipid-lowering agents found in
average 0.44 incidences of rhabdomyolysis per 10,000 person-years with statin
monotherapy and the incidence is increased when statins are co-administered with
fibrates. Moreover, diabetic patients on statin monotherapy exhibited approximately 2.9
times higher relative risk of rhabdomyolysis requiring hospitalization [13].
Hermann et al. [14] showed significantly higher levels of concentration of atorvastatin
lactone metabolite in patients experiencing statin-associated myopathy. Moreover, an in
vitro study, using primary human skeletal muscle cells, showed that atorvastatin lactone
(ATV-LAC) had a 14-fold higher potency to induce myotoxicity as compared to the acid
form [15]. The lactone/acid concentration ratio could potentially be used as a specific
diagnostic tool for statin-induced muscle toxicity [16]. Recently, in vitro study published
by our group has shown a significant reduction in the expression and activity of CYP3A4
in human livers from donors with diabetes mellitus [17]. Moreover, CYP3A4 is the main
enzyme involved in metabolic clearance of ATV-LAC [17]. The oxidative
biotransformation of ATV-LAC is considered to be the primary pathway for ATV
6

elimination [8]. A previously published clinical study showed significantly lowered
clearance of ATV-LAC in stable kidney transplant recipients with diabetes mellitus and
indicated clinical significance of this finding while prescribing ATV treatment in this
population who have additional co-morbidities and are on multiple medications [17].
Rosuvastatin acid, a synthetic HMG-CoA inhibitor is also widely prescribed medication
due to its unique properties including selective liver uptake and increased potency. It
exhibits minimal metabolism and thus is less likely to cause CYP3A4 mediated metabolic
drug-drug interactions. However, it is a substrate of multiple hepatic OATP uptake
transporters and may cause transporter mediated drug-drug interactions with oral
antidiabetic drugs [18].
Increased plasma levels of statins and their metabolites may elevate the risk of clinically
significant side effects especially in a diabetic population receiving concomitant
medications [17]. Therefore, it is essential to better characterize the pharmacokinetics
(PK) of the most commonly prescribed statins and the factors that possibly affect PK
properties as well as clinically significant drug-drug interactions.
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Atorvastatin calcium (Lipitor®)
1.1. Physicochemical properties of atorvastatin calcium
Currently, ATV is used as calcium salt of an active acid. Atorvastatin calcium [(3R,5R)7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isoprotopyl-4-phenyl-1H-pyrrol-1-yl]-3,5dihydroxyheptanoic acid, calcium salt], C66H68CaF2N4O10 has a molecular weight of
558.62 and pKa of 4.46. It is white to off-white crystalline powder; soluble in methanol,
dimethyl sulfoxide and slightly soluble in water. It is insoluble in aqueous solution of pH
4 and below and it is very slightly soluble in pH 7.4 phosphate buffer and water [19].
1.2. Clinical uses
Atorvastatin acid is a synthetic drug from the most efficient statin class of lipid lowering
agents and is widely used to treat dyslipidemia and cardiovascular disorders. Atorvastatin
acid blocks cholesterol biosynthesis by reversible, competitive inhibition of the ratelimiting enzyme, HMG-CoA reductase. It is used as a monotherapy and/or fixed dose
combination therapy along with exercise and diet to reduce the risk of heart attacks and
stroke. It is contraindicated in pregnant and nursing females, and patients with liver
diseases [20].
1.3. Mechanism of action
Atorvastatin acid is a competitive inhibitor of HMG-CoA, the main enzyme, catalyzing
the rate limiting step of endogenous cholesterol biosynthesis and thus reduces the
cholesterol content of the hepatocytes. This results in an up-regulation of LDL-Creceptors, which subsequently increases the uptake and catabolism of LDL-C and lowers

8

its plasma levels. The pleiotropic effects of ATV include anti-inflammatory actions,
reduction

of

platelet

aggregation,

improvement

of

endothelial

function

and

antiproliferative activity on smooth muscle [21].
1.4. Side effects
Skeletal muscle related problems are the common side effects that develop with statin
treatment. Myotoxicity ranging from a mild condition called myalgia (muscle ache or
weakness without creatine kinase elevation) to rare but potentially fatal rhabdomyolysis
(severe muscle breakdown with marked creatine kinase elevation [>10 times above the
upper limit of normal] resulting in hospitalization [11]. Liver injury is another serious
side effect associated with the use of ATV. Patients are generally monitored especially
when they experience skeletal muscle or liver related problems. In this situation, to
minimize the risk of side effects, dose adjustment or discontinuation of therapy is
initiated by clinicians. The other common side effects of ATV are diarrhea, nausea, runny
or stuffy nose, mild sore throat, and stomach upset [20].
1.5. Pharmacokinetics properties
A. Absorption
Oral absorption of a drug reflects the movement of drug from the gastrointestinal tract
into the blood stream. It is significantly affected by the physicochemical properties of the
drug and formulation including dissolution rate, stability in the gastrointestinal tract and
permeability. Moreover, physiological factors including gastric emptying time, peristaltic
movement and gastric pH also affect the oral bioavailability of drug. Complete
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absorption of ATV is expected due to its high solubility and permeability at intestinal pH
(pH=6).
Upon oral administration, ATV undergoes extensive first pass metabolism through the
gut wall and liver and exhibits very low absolute bioavailability (14%). The extensive gut
wall extraction of ATV is the result of intestinal CYP3A4, UDP-glucuronosyltransferase
(UGT) enzymes and P-glycoprotein (P-gp) efflux transporter interplay [22].
Atorvastatin acid reaches maximum plasma concentration (Cmax) of 3.61 µg/L after 10 mg
of an oral dose and time to Cmax (Tmax) is 1.5 hr. It exhibits the linear PK for both Cmax
and area under plasma-concentration time curve (AUC) over the dose range of 5-40 mg.
The net transport of drug across the membrane is governed mainly by intestinal P-gp
efflux transporter, the active uptake transporter H+ monocarboxylic carrier and to a lesser
extent by passive diffusion. However, the role of organic anion-transporting polypeptide
(OATP) uptake transporters for intestinal absorption is not known yet [22]. A secondary
peak in an individual plasma concentration-time profile indicates enterohepatic
recirculation of ATV [23].
B. Distribution
The volume of distribution of a drug reflects the extent of extravascular tissue binding. It
is affected most importantly by binding affinity of the drug to plasma proteins, blood
elements and by permeability into tissue and membrane. The plasma protein binding of
ATV is >98%, and its volume of distribution is 381L, which is higher than the total
volume of body water indicating extensive tissue binding [22].
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C. Metabolism
Atorvastatin acid undergoes complete metabolism and the liver is the major site for its
elimination despite the significant first-pass effect through the gut wall. The detailed
metabolic pathways for phase I and II are shown in Figure I-1 and I-2, respectively. It is
extensively metabolized through Phase I enzymes primarily by CYP3A4/5 in the
intestine and liver and it forms pharmacologically active ortho- and para- hydroxylated
metabolites [8]. The parent drug and its active acid metabolites remain in equilibrium
with their respective inactive lactone forms [9], which have 83-fold higher affinity for
CYP3A4 and exhibit higher metabolic clearance [8, 10]. The results of in vitro study
conducted using human liver microsomes indicated a predominant role of CYP3A4 in the
biotransformation of ATV-LAC [24].
The study published by Prueksaritanont et al. demonstrated the role of phase II enzymes
in the clearance of ATV through glucuronidation as a novel route. The formation of
ATV-LAC is also attributed to glucuronidation metabolic pathway, which is mediated
mainly through UGT1A1 and 1A3 enzymes [25, 26].
Lactones are hydrolyzed either chemically or enzymatically mainly by paraoxonase
(PON1 and PON3) enzymes and esterases [27, 28]. Lactonization of an acid form is also
mediated by Coenzyme A-dependent pathway through the formation of acyl-CoA
thioester [29]. Moreover, glucuronidation and a low pH environment are also responsible
for lactonization [26].
Hepatic uptake transporters, OATP1B1 and OATP1B3 play a significant role in the
active uptake of ATV and its metabolites. Atorvastatin acid and its metabolites are also
11

substrates of efflux transporters including P-gp and BCRP, which govern their intestinal
absorption and liver elimination [30].
D. Elimination
Biliary route is the major elimination pathway of the parent drug and its metabolites and
approximately 1% of the administered dose is excreted through renal route.

This

indicates that the liver is the primary site for ATV metabolism and elimination. The
clearance of ATV is 625 mL/min in human [22].
1.6. Effect of age and gender
The clinical PK of ATV is affected by age and gender; however, dose adjustment is not
required. The Cmax and AUC of ATV were 42.5% and 27.3 % higher, respectively in an
elderly population aged between 66-92 years compared to young individuals (age 19-35
years). Similarly, Cmax and AUC of ATV were 17.6 % higher and 11.3% lower
respectively, in women and male subjects. The terminal half-life is 36.2% longer, and
Tmax is 5.5% shorter in elder participants than young subjects. The terminal half-life and
Tmax were 19.9% and 39.1 % shorter, respectively in women as compared to men. The
differences in the PK of ATV could be age-related effects on intestinal and liver
enzymatic activity [31].
1.7. Effect of race
No difference in the PK of ATV was observed between Asian and Caucasian population,
therefore modifications of dosing recommendations are not required for either race [32].
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1.8. Effect of food
In a clinical study assessing the influence of food on the rate and extent of ATV
absorption found that Cmax and AUC of ATV decreased by 47.9 % and 12.7%,
respectively when administered with food. The Tmax of ATV increased from 2.6 h to 5. 9
h when administered with food. Moreover, the mean elimination half-life decreased from
37.5 h to 32 h with food. Food with medium fat content significantly decreased the rate of
absorption (Tmax) but had a minor effect on the extent of absorption [33]. Therefore, food
does not appear to affect ATV therapeutic efficacy.
1.9. Effect of renal and hepatic impairment
Urinary route is a minor route of excretion and thus renal impairment had no effect on the
PK of ATV. Moreover, haemodialysis did not have any effect on the PK of ATV.
However, Cmax and AUC were 5 fold and ≥11 fold greater, respectively in patients with
Child-Pugh Class A and B liver impairment, respectively. Therefore, dose adjustment is
not required in renal impairment, but the dosing schedule should be carefully determined
for patients with liver dysfunctions [34].
1.10.

Effect of time of administration

The rate and extent of absorption of ATV were lowered when it was administered in the
evening

as

compared

to

the

morning

administration

to

patients

with

hypercholesterolemia. No difference was noted for mean elimination half-life between
times of administration. Moreover, time of administration also had no effect on the
efficacy of ATV [23].
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1.11.

Effect of genetic polymorphism

Genetic polymorphism of various transporters and drug metabolizing enzymes involved
in the disposition of ATV significantly affects its PK. The effect of single-nucleotide
polymorphism (SNP) of OATP1B1 (SLCO1B1), P-gp (ABCB1), BCRP (breast cancer
resistant protein, ABCG2) and UGT1A3 enzyme on the PK of ATV and ATV-LAC are
summarized in Table I-1. Moreover, a genome-wide association study has provided
compelling evidence for strong association of myopathy with SNP located within
SLCO1B1 [35]. In addition, Riedmaier et al. have demonstrated that polymorphisms of
PON1 and PON3 esterase enzymes are associated with changes in ATV-LAC hydrolysis
and increased the expression of PON1 mRNA in human liver tissues [28].
1.12.

Drug-drug interaction

The U.S. FDA database reviewed by Thompson et al. reported approximately 58% cases
of rhabdomyolysis related to statins are associated with the concomitant medication
affecting statin metabolism [11]. The potential of a serious clinical drug interaction is
highest when concomitant medications are metabolized by the same CYP enzyme [36].
Metabolism of 60% of marketed medications is dependent on the activity of CYP3A.
Concomitant drugs that are inhibitors of CYP3A4 or UGT enzymes increase plasma
levels of ATV and its metabolites therefore may enhance the risk of statin-induced
rhabdomyolysis [13, 37-40].

Moreover, several cases reported severe statin-related

rhabdomyolysis with concurrent use of drugs including cyclosporine, colchicine, fusidic
acid, delavirdine, diltiazem, esomeprazole, clarithromycin, antiretroviral drugs,
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gemfibrozil and fluconazole that inhibit enzymes or transporter systems, which are
involved in the disposition of ATV [41-49].
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2. Rosuvastatin calcium (Crestor ®)
2.1. Physicochemical properties of rosuvastatin calcium
Rosuvastatin is a synthetic drug and is available as white to off-white crystalline calcium
salt of an active acid. Chemical formula of rosuvastatin calcium is (E,3R,5S)-7-[4-(4fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5dihydroxyhept-6-enoate), C44H54CaF2N6O12S2. It is sparingly soluble in water, having
logP and pKa values of 2.52 and 4.44 respectively [50]. The molecular weight of RST is
481.54. The chemical structure of rosuvastatin calcium is shown in Figure I-3.
2.2. Clinical uses
Rosuvastatin calcium (Crestor®) is widely used as an adjunct therapy to diet for lowering
elevated plasma levels of total cholesterol, LDL-C and triglycerides for the treatment of
various cardiovascular related disorders including primary hyperlipidemia, mixed
dyslipidemia, hypertriglyceridemia and homozygous familial hypercholesterolemia [51].
2.3. Mechanism of action
Rosuvastatin acid is relatively hydrophilic and therefore exhibits selective hepatic uptake
with limited access to non hepatic tissues. It competitively inhibits HMG-CoA reductase
enzyme, a rate-limiting enzyme of the mevalonate pathway for cholesterol biosynthesis.
It thereby decreases intracellular levels of cholesterol, which results in increased LDL-C
receptors in the liver facilitating the plasma clearance of LDL-C. Rosuvastatin acid also
exerts non-lipid lowering action like vasculoprotective effects possibly by reducing
inflammation of endothelial cells [52].
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2.4. Side effects
Skeletal muscle-related complaints, nausea, headache, abdominal pain and asthenia are
the most common adverse effects that develop with RST treatment [51].
2.5. Pharmacokinetic properties
A. Absorption
Upon oral administration, RST undergoes moderately rapid absorption that is estimated
to be approximately 50%. The modest absolute bioavailability (approximately 20%) and
a high hepatic extraction ratio (0.63) suggest significant first pass metabolism [53, 54].
After a single 20 mg post-dose, a Cmax of 6.1 ng/mL was measured at approximately 5 h
(Tmax). The Cmax and AUC are linear over the dosage range of 5 to 80 mg after both single
and seven daily doses; moreover, it does not accumulate following repeated dosing. It
also exhibits enterohepatic recirculation suggested by secondary peak in plasma
concentration time profile [53, 54].
B. Distribution
Rosuvastatin acid is reversibly bound to plasma proteins mainly albumin with a bound
fraction of 88%. The large mean volume of distribution at steady state (134L)
demonstrated extensive peripheral tissue distribution primarily in the liver [53].
C. Metabolism
Rosuvastatin acid undergoes limited metabolism mainly by CYP2C9 isoenzyme and to a
lesser extent through CYP2C19 and CYP3A4 [55]. It is biotransformed into its
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pharmacologically active main metabolite, an N-desmethyl derivative which has sevenfold lower inhibitory effect on HMG-CoA [54]. A previously published in vitro study has
shown that upon incubation of RST with human liver microsomes, RST underwent
significant glucuronidation through UGT1A1 and 1A3 to form acyl glucuronide
conjugates and lactonization to pharmacologically inactive 5S-lactone (RST-LAC)
metabolite [55]. The chemical structures of both the metabolites are shown in Figure I-4.
The average Cmax values for RST-LAC and N-desmethyl rosuvastatin were 12–24% and
<10% of the parent RST Cmax, respectively [54].
D. Elimination
Fecal (approximately 90% of the dose) and renal (approximately 10% of the dose) are the
major and minor routes of excretion of RST, respectively. Rosuvastatin acid mainly
excretes unchanged (76.8% of the dose) in feces with elimination half-life of 20 h [54].
2.6. Effect of age and gender
The effect of age and gender on the PK of RST was studied in young (18-35 years) and
elderly (>65 years) healthy volunteers, with an average age of 24 years and 64 years,
respectively. An average AUC

(0-t)

was 6% and of Cmax was 12% greater in the young

subjects as compared to the older subjects. Similarly, the mean of AUC(0-t) was 9% and of
Cmax was 18% lower in male as compared to female groups. These minor differences are
not considered clinically important and therefore no dose adjustment is recommended
[56].
2.7. Effect of race
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Systemic exposure of RST and the two metabolites were significantly higher in white
subjects as compared with Chinese, Malay and Asian-Indian living in the same
environment. The PK differences could be due to genetic polymorphisms of SLCO1B1
gene resulting in altered transport activity of RST by OATP1B1 hepatic uptake
transporter [57].
2.8. Effect of food
The extent of absorption of RST is not affected by food; while the rate of absorption is
decreased by 20%, the efficacy of the drug remains unchanged. Therefore, RST can be
administered with or without food [58].
2.9. Effect of hepatic and renal impairment
The clinical PK of RST at steady state were similar between patients with mild (ChildPugh class A) to moderate (Child-Pugh class B) hepatic impairment and subjects with
normal hepatic functions. However, severe hepatic impairment may increase plasma
systemic exposure of RST [59]. The systemic exposure of RST was similar between
patients with mild-to-moderate renal impairment (creatinine clearance ≥ 30 ml/min/1.73
m2) and healthy volunteers at steady state. Nevertheless, the exposure was three fold
higher in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73
m2) as compared to healthy subjects [51]. Rosuvastatin acid plasma concentrations were
approximately 50% higher in patients undergoing haemodialysis therapy as compared
with healthy controls [60].
2.10.

Effect of time of administration
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The PK and pharmacodynamic properties of RST were not different between the morning
and evening time of oral administration in healthy volunteers who received a daily dose
of 10 mg for 14 days [61].
2.11.

Effect of genetic polymorphism

Various clinical studies conducted in healthy Finish and Korean population have
described the impact of SNP in OATP1B1 and BCRP transporters on the PK of RST,
which is summarized in Table I-2.
2.12.

Drug interactions

Rosuvastatin acid has a limited metabolism and is less likely to interact with other
clinically used drugs. Administration of azole antifungal drugs including itraconazole
[62], fluconazole [63] and ketoconazole [64] had no or very small effect on the systemic
exposure of RST and thus these interactions are not considered clinically relevant. These
clinical drug interactions studies supported the previous findings regarding limited
metabolism of RST through CYP2C9, CYP2C19 and CYP3A4. Similar results were
obtained when RST was administered with the macrolide antibiotic, erythromycin, which
is a potent CYP3A4 inhibitor and demonstrated the minor role of CYP3A4 in RST
metabolism [65].
Upon oral co-administration of RST with HIV protease inhibitors including
atazanavir/ritonavir or fosamprenavir/ritonavir [66] and liponavir/ritonavir, [67] several
fold increase of AUC and Cmax may occur following the inhibition of BCRP mediated
intestinal uptake and/or biliary efflux and OATP1B1 mediated hepatic uptake. A
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combined therapy of RST and HIV protease inhibitors warrants careful administration.
Gemfibrozil [68, 69] and cyclosporine [70] significantly increased plasma concentrations
of RST by inhibiting OATP meditated hepatic uptake. A minimal change in the systemic
exposure of RST was observed with simultaneous administration of fenofibrate [71],
rifampicin [72], dalcetrapib [73] and silymarin supplements [74] and therefore these
interactions are not considered clinically relevant. The herbal medicine baicalin
decreased AUC of RST due to induction of OATP1B1 mediated hepatic uptake [75].
Simultaneous administration of RST with antacid preparation containing aluminum
hydroxide and magnesium hydroxide reduced systemic exposure of RST by
approximately 50%, and the effect was decreased upon administration of antacid 2 hrs
after RST dosing [76]. Rosuvastatin acid can increase anticoagulant activity of warfarin,
and thus careful monitoring is required upon co-administration of both drugs. The exact
mechanism of the PD interaction between these two drugs is not known yet [77].
Coadministration of ezetimibe with RST significantly reduces LDL-C and triglyceride
levels in serum however; no significant PK interaction was noticed [78].
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Figure I-1. Proposed oxidative metabolic (Phase I) pathway of atorvastatin acid.
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Figure I-2. Proposed glucuronidation (Phase II) metabolic pathway of atorvastatin acid.
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Table I-1. Major polymorphisms in genes coding drug metabolizing enzymes and transporters affecting the pharmacokinetics
of atorvastatin acid (ATV) and atorvastatin lactone (ATV-LAC).

Gene

Enzyme or

name

transporter

ABCB1

P-gp

SNP

dbSNP

Population

Effect

Analytes

Ref

ID
c.1236 C>T

rs1128503

Healthy finish

AUC:TTT/TTT>CGC/CGC

c.2677 G>T/A rs2032582

volunteers

t ½: TTT/TTT>CGC/CGC

c.3435C>T

Koreans

t ½: TTTT>GGCC/GTCT

rs1045642

ATV

[79]

ATV

[80]

ATV-LAC
ABCG2

BCRP

c.421C>A

rs2231142
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SLCO1B1

OATP1B1

OATP1B1*5

rs4149056

(521T>C)

Healthy finish

AUC:AA>(C/C)

ATV

[81]

volunteers

AUC:AA>(C/C and C/A)

ATV-LAC

Healthy white

AUC:CC>(T/T and T/C)

ATV

[82]

volunteers

AUC:TC>(T/T)

Koreans

AUC: *15/*15>*1a/*1a, *1b/*1b ,

ATV

[80]

[83]

*1b/*15,*1a/*15, *1a/*1b
UGT1A3

UGT1A3

UGT1A3*1
UGT1A3*2
UGT1A3*3
UGT1A3*6

NA

Healthy finish

t1/2:*1/*6< *1/*1,*1/*2,*2/*2,*1/*3

ATV

volunteers

t1/2:*2/*3< *1/*1,*1/*2,*2/*2

ATV-LAC

AUC ratio (L/A):*1/*1<*1/*2,*2/*2

Table I-2. Major polymorphisms of drug metabolizing enzymes and transporters affecting the pharmacokinetics of
rosuvastatin acid.

Gene

Enzyme or

name

transporter

ABCG2

BCRP

SNP

dbSNP

Population

Effect

Ref

ID
c.421 C>A

rs2231142 Healthy finish

AUC:AA>(C/C and C/A)

volunteers

Cmax :AA>(C/C and C/A)

Koreans

AUC: CC< (C/A and A/A)

[81]

[84]

C max: CC>(C/A and A/A)
CL/F: CC>(C/A and A/A)
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SLCO1B1

OATP1B1

OATP1B1*5
(521T>C)

rs4149056 Healthy white

AUC:CC>(T/T )

volunteers

Cmax:CC>(T/T)

Koreans

AUC: *15/*15,*1a/*15> *1a/*1a
Cmax: *15/*15,*1a/*15> *1a/*1a
AUC: *15/*15> *1b/*15
Cmax:*15/*15> *1b/*15 or *1b/*1b

[82]

[57, 85]
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Abstract
The aim of the proposed work was to develop and validate a simple and sensitive assay
for the analysis of atorvastatin (ATV) acid, ortho- and para-hydroxy-ATV, ATV lactone,
ortho- and para-hydroxy-ATV lactone in human plasma using liquid chromatographytandem mass spectrometry.
All six analytes and corresponding deuterium (d5) labeled internal standards were
extracted from 50 µL of human plasma by protein precipitation. The chromatographic
separation of analytes was achieved using a Zorbax-SB Phenyl column (2.1 mm × 100
mm, 3.5 µm). Mobile phase consisted of a gradient mixture of 0.1% v/v glacial acetic
acid in 10% v/v methanol in water (solvent A) and 40% v/v methanol in acetonitrile
(solvent B). All analytes including ortho- and para-hydroxy metabolites were baseline
separated within 7.0 min using a flow rate of 0.35 mL/min. Mass spectrometry detection
was carried out in positive electrospray ionization mode, with multiple reaction
monitoring scan.
The calibration curves for all analytes were linear (R2 ≥ 0.9975, n=3) over the
concentration range of 0.05-100 ng/mL and with LLOQ of 0.05 ng/mL. Mean extraction
recoveries ranged between 88.6-111%.

Intra- and inter-run mean %accuracy were

between 85-115% and %imprecision was ≤15%. Stability studies revealed that ATV acid
and lactone forms were stable in plasma during bench top (six hours on ice-water slurry),
at the end of 3 successive freeze and thaw cycles, and at -80 ºC for 3 months. The
method was successfully applied in a clinical study to determine levels of ATV and its
metabolites over 12-hour post dose in patients receiving atorvastatin.
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Introduction
According to the American Heart Association and Centers for Disease Control and
Prevention, cardiovascular diseases are the leading cause of death in the United States
[1,2]. Hypercholesterolemia is a major risk factor for the progression of atherosclerosis,
the principal cause of the development of coronary heart diseases. The 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used
for the treatment of hypercholesterolemia. Statins induce a significant reduction in total
plasma cholesterol concentration by reversible inhibition of the rate limiting enzyme,
HMG-CoA reductase of the mevalonate pathway, which is responsible for the
endogenous biosynthesis of cholesterol [3].
Worldwide, atorvastatin (ATV) calcium (Lipitor®, Pfizer Pharmaceuticals, NY) is the top
selling prescribed medication [4]. Upon oral administration, the pharmacologically
active calcium salt of ATV undergoes mainly cytochrome P450 3A4 (CYP3A4) mediated
oxidative metabolism and forms two active metabolites, ortho-hydroxy-ATV and parahydroxy-ATV [5]. The parent drug and its acid hydroxy metabolites are in equilibrium
with their corresponding inactive lactones forms, ATV lactone, ortho-hydroxy-ATV
lactone and para-hydroxy-ATV lactone [6]. The metabolism pathway of atorvastatin, as
described by Kantola et al. is shown in Figure II-1 [7]. Atorvastatin is the only statin
with active metabolites since 70% of the ATV HMG-CoA reductase inhibition has been
attributed to its hydroxy acid (ortho and para) metabolites [8].
Atorvastatin is clinically administered with a once daily dose of 10 to 80 mg [3]. The
drug undergoes extensive first-pass metabolism in the gastrointestinal tract and/or liver,
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with ~14% absolute oral bioavailability after a 10 mg oral dose. The peak plasma
concentrations (Cmax) are reached within 1 to 3 hour after oral administration of ATV.
Food intake decreases ATV area under the concentration-time curve and Cmax by ~25%
and 9 %, respectively. Atorvastatin is highly bound to plasma protein (≥98%) with an
average volume of distribution of 381 L and total clearance of 625 mL/min. After 40 mg
oral dose, Cmax (mean±SD) of ATV, ATV lactone, ortho-hydroxy-ATV, ortho-hydroxyATV lactone and para-hydroxy-ATV lactone were 13.4 ± 9.5, 3.8 ± 2.6, 9.8 ± 6.1, 4.5 ±
6.0 and 1.8 ± 1.0 ng/mL, respectively [7].
Although statins are well tolerated, skeletal muscle toxicity is the main adverse effect
associated with statin treatment that results in decreased adherence to the therapeutic
regimen [9]. Several hypotheses based on depletion of the products of the mevalonate
pathway have been proposed to explain the molecular mechanism of statin-related
myopathy; however, the underlying mechanism for statin-induced myopathy has not been
fully elucidated [10].

Hermann et al. observed significantly higher levels of ATV

lactone, para-hydroxy-ATV, ortho-hydroxy-ATV, and para-hydroxy-ATV lactone
metabolites in patients experiencing ATV-induced myopathy. The authors suggested
potential clinical utility of metabolite to parent concentration ratio as a new diagnostic
marker to assess the risk of ATV-associated myopathy [11]. Moreover, an in vitro study
using primary human skeletal muscle cells found that ATV lactone has a 14-fold higher
potency to induce myotoxicity as compared with its acid form further corroborating the
usefulness of ATV lactone concentration as a marker for statin-induced myopathy [12].
The plasma levels of para-hydroxy-ATV is almost 10–fold lower as compared with
ortho-hydroxy-ATV [7]; thus, it is necessary to achieve an adequate LLOQ to be able to
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quantify the concentration of para metabolites in plasma, especially when ATV is
administered at low dose.
To date, several methods have been published for quantification of ATV and its
metabolites in a biological matrix (plasma or serum), bulk drug, pharmaceuticals
products, and aqueous samples. Various techniques employed include an electrochemical
method [13], high-performance liquid chromatography with ultra violet detection [1417], enzyme inhibition [18,19], liquid chromatography-mass spectrometry [20],
microbore liquid chromatography/electrospray ionization-tandem mass spectrometry
[21], and liquid chromatography-tandem mass spectrometry [22-30].
High-performance liquid chromatography with ultra violet or electrochemical detection
methods typically have a higher limit of quantification and are more time consuming.
Gas chromatography meets the required LLOQ for most analytes; however, it needs
complex derivatization steps.

Enzyme inhibition assays are sensitive and easy to

implement but are non-specific and do not provide any information on the metabolite
concentrations. Undeniably, mass spectrometry has become the method of choice for
quantification of metabolite concentration in biological matrices due to its superior
selectivity.

However, few methods [20,25,26] have been reported for simultaneous

determination of ATV and the five ATV metabolites (ortho- and para-hydroxy-ATV,
ATV lactone, ortho- and para-hydroxy-ATV lactone). Moreover, most reported methods
require time-consuming extraction procedures, and they did not provide the sensitivity
required to quantify para-hydroxy-ATV, that is present at ~10% of the total
concentration, after administration of low dose ATV [20,25,26]. Furthermore, most
methods require 500-1000 µL plasma volume [25,26]. In this manuscript, we describe
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the development and validation of a highly sensitive method for determination of ATV
and its five metabolites using 50 µL of plasma.
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Experimental
Reagents and chemicals
ATV calcium hydroxy acid (ortho-hydroxy-ATV and para-hydroxy-ATV) and lactone
metabolites (ATV lactone, ortho-hydroxy-ATV lactone and para-hydroxy-ATV lactone)
and corresponding deuterium (d5) labeled internal standards (IS) (d5-ATV, d5-ATV
lactone, d5-ortho-hydroxy-ATV, d5-para-hydroxy-ATV, d5-ortho-hydroxy-ATV lactone
and d5-para-hydroxy-ATV lactone) were purchased from Toronto Research Chemicals
(Toronto, Ontario, Canada).

HPLC grade acetonitrile and glacial acetic acid were

obtained from Fisher Scientific (Fair Lawn, NJ, USA). HPLC grade methanol was from
Pharmco Products Inc. (Brookefield, CT, USA). A Milli Q50 (Millipore, Bedford, MA,
USA) water purification system was used to generate HPLC grade water. Human drugfree plasma with sodium fluoride/potassium oxalate as an anticoagulant was purchased
from Bioreclamation Inc (Westbury, NY, USA). Human plasma from individuals on
ATV therapy was obtained by venipuncure in sodium heparin, fluoride/potassium oxalate
or K2EDTA vacutainers (BD, Franklin lakes, NJ, USA) after obtaining informed consent.
Chromatographic conditions
The separation of analytes was performed on a Zorbax-SB Phenyl, Rapid Resolution HT
(2.1 mm × 100 mm) column with 3.5 µm particle size from Agilent Technologies
(Wilmington, DE, USA), preceded by a 0.5 µm filter (Supelco, Bellefonte, PA). The
analytical column was maintained at 40 °C temperature. Mobile phase, consisting of a
gradient mixture of 0.1% v/v glacial acetic acid in 10% v/v methanol in water (solvent A)
and 40% v/v methanol in acetonitrile (solvent B), was used at a flow rate of 0.35 mL/min
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for separation and rapid elution of analytes from the extracted matrix within 7.0 min.
During the first 0.3 min of the gradient, %B increased from 10% to 60% where it was
kept until 0.8 min and then gradually increased to 75% until 4.6 min. At 4.61 min, %B
was decreased to 10% and kept to re-equilibrate the column until 7.0 min.
Mass spectrometric conditions
The LC-MS/MS system consisted of an Agilent Technologies 1200 series HPLC system
with binary pumps, autosampler, thermostatted column compartment and micro vacuum
degasser (Santa Clara, CA) coupled to an API 4000 triple quadrupole mass spectrometer
(AB Sciex, Toronto, Canada), equipped with Turbo VTM ion source. Mass spectrometric
detection and quantitation of all analytes were carried out using multiple reaction
monitoring (MRM) scan in electrospray positive ion mode. Q1 and product ion scans
were obtained by infusing solutions of individual analytes and their respective IS using
an infusion pump.
The following MRM transitions were selected: (m/z, Q1→Q3) of ATV (m/z,
559.2→440.2), d5-ATV (m/z, 564.2→445.2), ATV lactone (m/z, 541.2→448.2), d5ATV lactone (m/z, 546.2→453.2), ortho-hydroxy-ATV (m/z, 575.2→440.2), d5-orthohydroxy-ATV (m/z, 580.2→445.2), para-hydroxy-ATV (m/z, 575.2→440.2), d5-parahydroxy-ATV (m/z, 580.2→445.2), ortho-hydroxy-ATV lactone (m/z, 557.2→448.2)
and d5-ortho-hydroxy-ATV lactone (m/z, 562.2→453.2), para-hydroxy-ATV lactone
(m/z, 557.2→448.2), d5-para-hydroxy-ATV lactone (m/z, 562.2→453.2).

Source

temperature and gas parameters were optimized after the chromatographic conditions
were finalized by infusing a solution of para-hydroxy-ATV in T junction with the mobile
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phase consisting of 70% of solvent B. All peak areas were obtained using Sciex Analyst
1.5.1 data processing software.
Standards/QCs preparation
Separate stock solutions of ATV (0.4 mg/mL), ortho-hydroxy-ATV (1.0 mg/mL) and
para-hydroxy-ATV (1.0 mg/mL) were prepared in acetonitrile:water mixture (90:10,
v/v). Similarly, 1.0 mg/mL separate stock solutions of ATV lactone, ortho-hydroxyATV lactone and para-hydroxy-ATV lactone were prepared in acetonitrile. Intermediary
stock solutions of composite mixtures of acids only and lactones only (100 µg/mL for
each compound) were prepared in acetonitrile:water mixture (90:10 v/v) and acetonitrile,
respectively, and were used to spike calibrators and quality control samples (QCs) in
drug-free human plasma kept on an ice-water slurry.
Individual deuterated (d5) IS of acid and lactone stock solutions of 1.0 mg/mL were
prepared in acetonitrile:water (90:10 v/v) and acetonitrile, respectively. Intermediary
internal standard solutions containing 50 ng/mL of either acids or lactones were prepared
in acetonitrile. All stock and working standard solutions were stored at -20 °C until use.
Eight calibration standards with concentrations ranging from 0.05 ng/mL to 100 ng/mL
and quality control samples at four concentration levels (0.05, 0.15, 5.00 and 75.0 ng/mL)
were prepared in drug-free human plasma by using respective spiking solutions and were
stored at -80 °C.
Sample extraction
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Calibrators, QCs, control blank, double blank, and patient samples were thawed on icewater slurry and vortex-mixed thoroughly for 10 seconds. A 50 μL aliquot of each
plasma sample was aliquoted into 1.5 mL polypropylene tube; all samples were treated
with 200 μL of 0.1% acetic acid in acetonitrile (as a protein precipitation reagent)
containing 0.8 ng/mL of the combined acids and combined lactone IS, except for double
blank. All tubes were vortex-mixed for 10 seconds and thereafter all precipitated proteins
were separated by centrifugation for 15 min at 14,000 g and 4°C temperature. The
supernatant was transferred to a fresh glass vial and 10 μL was injected onto LC-MS/MS.
Validation of the assay
The validation of the method was performed according to general recommendation
guidelines for bioanalytical methods by U.S. Food and Drug Administration (FDA) [31].
Validation parameters including selectivity, sensitivity, accuracy, precision, recovery and
stability were determined.
Stability
The stability studies aimed to establish the conditions in which the analytes are stable and
the degree of inter-conversion of acid to lactone or lactone to acid forms. The first set of
QC samples contained composite mixture of all six analytes. In the second set, QC
samples contained only ATV and its two hydroxy acid metabolites.

The third set

comprised lactone–only QC samples containing only ATV lactone and its two hydroxy
metabolites. All three sets of QC samples were prepared at low level quality control
(LQC) (0.15 ng/mL) and high level quality control (HQC) (75.0 ng/mL) concentration
levels. The following stability studies were carried out:
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I.

Post preparative stability (autosampler stability): The stability of the analytes in
processed samples, kept in the autosampler at 4°C, was tested by reinjecting one of
the three validation runs 24 hours after extraction.

II.

Bench-top stability: Triplicate LQC and HQC kept on ice-water slurry for six hours
were extracted along with freshly spiked calibrators.

III.

Long-term stability: Long-term stability at -80 °C was established by analyzing six
replicates of LQC and HQC for all three sets of QC samples, after two weeks, one
month and three months.

IV.

Freeze and thaw stability: Freshly spiked triplicates of LQC and HQC of all three
sets of QC samples were stored at -80 °C for at least 12 hours and were thawed on ice
water slurry. At the end of three successive freeze and thaw cycles, QC samples were
extracted along with freshly spiked calibrators and QCs.
Linearity, accuracy and precision
Eight-point calibration curves were obtained using 0.05, 0.10, 0.50, 2.00, 10.0, 50.0, 90.0
and 100 ng/mL calibrators. All calibrators, six replicates of the first set of QC samples at
four concentration levels, double blank (without IS) and control blank (with IS) were
tested in three runs to evaluate the intra- and inter-run imprecision and accuracy of the
method.
Limit of quantitation
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Lower limit of quantitation (LLOQ) is defined as the lowest concentration of an analyte,
which has at least five times higher response (signal-to-noise, S/N=5/1) compared to
blank response and can be analyzed with an acceptable accuracy and imprecision
(accuracy within 80- 120% and imprecision ≤ 20%). Five serial dilutions of plasma
sample containing 0.200 ng/mL of each analyte were made by mixing equal volumes of
spiked plasma with blank plasma. Six replicates of each spiked sample were extracted
and S/N of peak and %CV of the analyte/IS ratio were calculated. The sample with S/N
at least five and %CV below 20% for each analyte was selected as potential LLOQ for
the validation.
Selectivity
Drug-free human plasma samples from six different donors were evaluated for the
presence of endogenous matrix components that may interfere with quantitation of the
analytes or the IS. Area of the peaks eluting at the same retention time as the analytes
and internal standards of interest, in extracted selectivity samples, were compared with
those in chromatograms obtained from LLOQ samples.
Recovery and matrix effect
Triplicates of LQC and HQC from the first set of QC samples along with blank plasma
samples were extracted and were used to evaluate recovery and matrix effect
(enhancement or suppression of ionization). Solutions with concentrations equivalent to
100% recovery of the extracted LQC (0.03 ng/mL) and HQC (15 ng/mL) containing all
analytes and IS were prepared in water: 0.1% acetic acid in acetonitrile, 1:4 (v/v)
(reference for matrix effect) and in extracted blank plasma (reference for recovery). In
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addition, matrix effect was also evaluated using a post-column infusion method. This test
was performed by infusing a solution containing 20 ng/mL of analytes and IS prepared in
solvent B:solvent A (70:30 v/v) at 10 µL/min along with the injections of the blank
solvent, double blank matrix extract and extracted HQC to identify the region of
ionization suppression.
To investigate the potential of interference and matrix effect from co-administered
medications and their metabolites, specific to transplanted population, a pool plasma
sample was prepared from samples collected from the three stable kidney transplant
patients treated with sirolimus (2, 2, or 4 mg/day), mycophenolic acid (2000 mg/day) and
prednisone (5 mg/day), but not with atorvastatin. The pool sample was obtained by
mixing equal volumes of plasma from samples collected at 1, 2, 4, 8 and 12 hours after
the morning dose of the co-administered medications. The pooled plasma samples were
spiked with LQC and six replicates were extracted along with calibration STD, QCs, and
a non-spiked pool.
Application of the method in a clinical pharmacokinetic study
The proposed method was successfully applied to determine the levels of acid and
lactone forms of ATV and hydroxy metabolites in human plasma samples obtained from
a pharmacokinetic study conducted to investigate ATV disposition in the stable kidney
transplant recipients who received ATV.
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Results and discussion
Sample collection and preparation
Lactonization of an acid form and hydrolysis of lactone to an open-acid form of ATV is
mediated

through

UDP-glucuronosyltransferase

(paraoxonases) [33], respectively.

(UGTs)

[32]

and

esterases

Esterase activity is the most important cause of

instability of ester-containing drugs in biological matrices.

We tested the effect of

several anticoagulants on lactone to acid interconversion by comparing different types of
plasma (sodium heparin, K2EDTA and sodium fluoride/potassium oxalate) and serum. In
addition, one blood sample was collected for each anticoagulant and serum from five
representative patients who were on 10-40 mg daily dose of ATV. The plasma and serum
were separated by centrifugation at 1500 g and concentrations of all analytes were
determined using the validated assay. Moreover, freshly spiked HQC containing lactone
only analytes that was freshly prepared in serum or plasma with different anti-coagulants
were analyzed. We could not find statistically significant difference (One-way ANOVA,
p>0.9) between serum and various anticoagulants (Table II-1); however, we preferred to
use sodium fluoride (esterase inhibitor) plasma to ensure stability of lactone upon longterm storage [34].
Liquid-liquid and solid phase extractions usually involve tedious and time-consuming
extraction steps such as drying and the addition of pH modifiers, which in this case may
lead to undesirable acid-lactone interconversion.

A previously reported LC-MS/MS

assay for ATV and metabolites (27) extensively studied the known stability issues of
highly unstable lactone and showed that the possible interconversion between lactone and
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acid forms can be minimized by lowering the working temperature to 4 °C and lowering
the plasma pH to 4-6. Non-acidified acetonitrile as a precipitating agent resulted in
significant interconversion of lactone to acid form during the resident time of the
extracted samples in an autosampler. Therefore, 0.1% glacial acetic acid in acetonitrile
was used to minimize the interconversion of lactone to acid.
LC-MS/MS detection
Ortho- and para- analytes have the same precursor ion-product ion transitions.
Additionally, the acids could potentially undergo in-source fragmentation and, following
the loss of water, the resulting product would interfere with their respective lactones. For
these combined reasons, we sought chromatographic conditions that would assure
baseline chromatographic separation of the respective analytes. To achieve this goal,
various reverse phase analytical columns were tested and the required selectivity, as well
as the excellent peak shape (in terms of sharpness and symmetry), were achieved using a
narrow bore Zorbax-SB phenyl column. Because this column provided excellent peak
focusing, a high S/N was obtained that enabled us to use a simple protein precipitation
extraction without performing pre-concentration steps for sample clean up. Total elution
of analytes using a gradient mixture of mobile phase resulted in a run time of 7.0 min,
including the re-equilibration of the column. The retention times of ATV, ATV lactone,
ortho-hydroxy-ATV, para-hydroxy-ATV, ortho-hydroxy-ATV lactone and parahydroxy-ATV lactone were 3.9, 4.4, 3.8, 3.2, 4.2 and 3.5 min, respectively (Figure II-2).
The MS was operated using electrospray ionization probe in positive ion mode to obtain
high signal intensity. For each analyte, [M+H]+ was the major precursor ion used to
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obtain the product ion spectra. The major product ions are formed by the neutral loss of
the (phenylamino)carbonyl group and phenylamino group, from acid and lactone
compounds, respectively. Temperature and gas parameters of the source were optimized
based on para-hydroxy-ATV, since the plasma concentration of this analyte is typically
lower than other analytes.
The compound specific parameters i.e. declustering potential (DP), entrance potential
(EP), collision cell exit potential (EXP) and collision energy (CE) and similarly, gas
parameters including curtain gas (CUR=30 psi), gas 1 (GS1=60 psi), gas 2 (GS2=30 psi),
and collision gas (CAD=10 psi), ionspray voltage (IS=5500 V), and temperature
(TEM=550 °C), were optimized to achieve maximum signal. No significant in-source
inter-conversion was observed from acid to lactone form.
Method validation
The analytes were stable in the conditions described above. The post preparative stability
assessment proved that extracted samples can be injected after being kept at 4°C for 24
hours post extraction, the anticipated resident time in autosampler; furthermore, analytes
were stable after three cycles of freeze and thaw and during bench top stability carried
out on ice-water slurry. The data obtained also revealed that the samples were stable in
the matrix after 3 months storage at -80 °C.

No interference was observed from

endogenous components with analytes and IS in blank plasma from six different donors,
demonstrating the specificity of the method.
The calibration curves obtained from analyte/IS peak area ratios vs. nominal
concentration were linear using weighted (1/x2) linear regression over the concentration
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range, with correlation coefficients (R2) ≥ 0.9975. According to FDA guidelines, the
accuracy of calibration standards and quality control samples (n>5) should be between
85-115%, and imprecision below 15%, except at the LLOQ level, for which accuracy
may be between 80-120% and imprecision below 20%.

For the current assay, the

measured mean values (n=3) were within 91.6-106% of their nominal values for
calibrators (Table II-2), 89.2-110% for intra-run QCs (results not presented) and 91.7107% for inter-run QCs (Table II-3), which indicates acceptable accuracy of the proposed
method.
A lower limit of quantitation of 0.05 ng/mL was achieved for all analytes and a
chromatogram of an extracted LLOQ is shown in Figure II-2. The extraction recovery
for all analytes was within 88.6-111%. No significant matrix effect was observed for
each analyte upon calculating the ratio of average area response of reference for recovery
to reference for the matrix effect at LQC and HQC concentration levels.
Evaluation of the matrix effect is essential to assure the reliability of quantitative assays
using HPLC-MS/MS and the integrity of the resulting pharmacokinetics data. We used
stable isotope labeled internal standards for each of the analytes, as they compensate
reasonably well during variations in sample analysis. However, due to their slightly
different elution times compared to their respective non-labeled species, deuterated
internal standards may not always compensate well for ionization enhancement or
suppression due to coelution of matrix endogenous components, such as phospholipids
[35].

Phosphatidylcholine and lyso-phosphatidylcholine are major human plasma

phospholipids that produce matrix effect.

Zhang and colleagues reported the key

phospholipids in human serum extracts that can cause matrix effects by identifying the
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precursor ions generating fragment with m/z 184 [36]. Following the same technique, we
determined the retention time of phospholipids with MRM transitions: Q1 m/z 496, 520,
522, 524, 544, 758 and 782 and Q3 m/z 184. We have then adjusted the chromatographic
conditions to ensure that the analytes do not co-elute with these phospholipids. To study
matrix effect, post-column infusion of a solution containing the analytes and their
respective IS, concomitantly with injecting extracted blank plasma were carried out. We
monitored retention times of the major phospholipids as shown in Figure II-3A, and
found that no significant ion suppression occurred at the retention time of the analytes or
IS.
The post-column infusion chromatogram shown in Figure II-3B indicates that ATV and
metabolites were eluted at retention times different from the retention time of key
phospholipids. Post-column infusion of analytes and IS, concomitantly with injecting an
extracted blank plasma, shows that the signal intensity of each analyte of interest does not
change in the region of their respective elution period (Figure II- 3C). The mean of the
calculated concentrations of six LQC samples prepared in pooled plasma from patients
treated with an immunosuppressive regimen and who did not receive atorvastatin was
between 92–97% of the expected nominal concentration. No interfering peaks were
eluting at the retention times of the analytes of interest. This demonstrates that sirolimus,
mycophenolic acid, prednisone, and their metabolites, do not interfere with the
quantitation of atorvastatin and its metabolites.
Application of the method

55

The method was successfully applied to measure the concentration of ATV and its
metabolites in the stable kidney transplant recipients who received atorvastatin for the
treatment of hypercholesterolemia. The study protocol was approved by the Institutional
Review Board of Rhode Island Hospital, Providence RI, USA. Written informed consent
was obtained from all subjects after verbal explanation of the study protocol prior to
enrolling in the study.
In Figure II- 4A, ATV and metabolites steady-state 12-hour concentration-time profile,
obtained from the four kidney transplant recipients is shown. All patients received a 10
mg dose of ATV in the morning along with a triple immunosuppressive regimen that
included oral sirolimus, mycophenolic acid and prednisone.

The concentration-time

profiles for ATV and metabolites show that the method has an acceptable LLOQ for
quantitation of all analytes including the para-hydroxy metabolites. Moreover, in Figure
II-4B, metabolite to parent ATV concentration ratio obtained from the nine kidney
transplant recipients treated with 10, 20 and 40 mg of ATV dose is shown.

The

concentration of ATV and metabolites were measured in nine plasma samples over a 12hour post dose period and the average ratio for each metabolite is presented. As shown in
Figure II-4B, in our patient population, the concentration of ATV, ortho-hydroxy-ATVlactone and para-hydroxy-ATV-lactone were greater than the parent ATV, whereas, the
concentration of ortho-hydroxy-ATV and para-hydroxy-ATV was lower than the parent
ATV concentration
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Conclusion
We describe a reproducible, reliable, sensitive and simple bioanalytical method. The
major advantages of the present method, as compared with previous reports, are low
LLOQ, 50 µL plasma volume and simple extraction method. The proposed validated
bioanalytical technique accomplishes the required selectivity, sensitivity, accuracy, and
imprecision to be applied to various studies involving pharmacokinetics, drug
metabolism, clinical pharmacology/toxicology, bioavailability/bioequivalence, and drugdrug interactions for accurate quantitative analysis of ATV and its five metabolites. This
method offers an easy and convenient way to conduct routine clinical monitoring of toxic
metabolites, therefore, it can be used by toxicologists and clinical chemists who wish to
implement the metabolite/parent drug ratio as a new diagnostic marker for identifying
patients at risk of developing ATV-induced myotoxicity.
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Adapted from Kantola et al. (1998)

Figure II-1. Proposed metabolism pathway of atorvastatin to atorvastatin lactone, orthohydroxy-atorvastatin, para-hydroxy-atorvastatin, ortho-hydroxy-atorvastatin lactone, and
para-hydroxy-atorvastatin lactone.
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Figure II-2. Chromatograms showing the integrated peaks of atorvastatin acid (A),
atorvastatin lactone (B), ortho-hydroxy-atorvastatin (C), para-hydroxy-atorvastatin (D),
ortho-hydroxy- atorvastatin lactone (E), and para-hydroxy-atorvastatin lactone (F) from
extracted calibration standard at the lower limit of quantitation (0.05 ng/mL).
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A

B

C

Figure II-3. Injection of matrix spiked with analyte and IS without post-column infusion
along with MRM transitions of key phospholipids. Chromatograms showing the peaks of
analytes and corresponding IS along with key phospholipids (A). Chromatogram
obtained with post-column infusion shows no matrix effect at the retention times of
analytes and IS. Arrow indicates region where the signal of compounds infused postcolumn is suppressed during the elution of endogenous matrix components (B).
Chromatogram of a blank sample injected while the analytes and IS are infused post
column. Arrow indicates region where the signals of analytes and IS infused postcolumn are suppressed during the elution of endogenous matrix components (C).
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A

B

Figure II-4. Plasma concentration (ng/mL) versus time profiles of atorvastatin and
metabolites, in acid and lactone forms, from the four stable kidney transplant recipients
who received a 10 mg atorvastatin dose; data are expressed as mean and error bars
represent standard deviation (A) Metabolite/parent atorvastatin concentration from the
stable kidney transplant recipients (n=9) on a steady-state dose of 10-40 mg atorvastatin
(B).
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Table II-1. Effect of Various Anticoagulants on Interconversion of Atorvastatin (ATV)
lactones; the first part represents ATV lactone %accuracy and %CV for blank samples of
serum or plasma with different anti-coagulants freshly spiked with ATV lactones at high
quality control level. The second part of the table represents the mean and standard
deviation of ATV and metabolite concentration from 5 patients at steady-state ATV with
samples obtained as serum or plasma with different anti-coagulants.

Analytes added
ATV lactone
Para-hydroxy-ATV lactone
Ortho-hydroxy-ATV lactone
Concentration of analytes
in representative patients

%Accuracy
%CV
%Accuracy
%CV
%Accuracy
%CV

Type of anticoagulants
Sodium
K2EDTA Serum
heparin
98.8
102
101
3.3
4.3
3.5
101
102
102
4.1
3.2
3.2
98.0
101
99.4
3.5
3.7
6.2

Sodium
fluoride
104
4.5
105
4.8
102
5.0

Concentration
(ng/mL)

ATV

Mean
Std dev

2.94
3.7

2.51
3.2

2.80
3.5

2.20
2.7

ATV lactone

Mean
Std dev

2.43
2.2

2.32
2.1

2.38
2.2

2.16
2.0

Para-hydroxy-ATV

Mean
Std dev

0.33
0.3

0.32
0.3

0.34
0.3

0.22
0.2

Mean
Std dev

0.35
0.3

0.34
0.3

0.35
0.3

0.32
0.3

Ortho-hydroxy-ATV

Mean
Std dev

2.91
4.0

2.57
3.5

2.78
3.8

2.25
2.9

Ortho-hydroxy-ATV lactone

Mean
Std dev

4.87
5.5

4.46
5.2

4.87
5.8

4.24
4.7

Para-hydroxy-ATV lactone

n=3
% accuracy=100- [(mean-nominal)/nominal]*100
%CV calculated as (standard deviation/mean)*100
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Table II-2. Summary of Standards and Calibration Curve Parameters from Three Individual Runs.
Analyte

STD 1 STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 STD 8
STD (ng/mL) 0.05
0.10
0.50
2.00
10.0
50.0
90.0
100

R2

%Accuracy
%CV

100
3.2

100
7.7

98.7
9.6

97.0
0.1

104
0.1

98.5
4.1

99.0
4.3

103
6.2

0.9983

ATV lactone

% Accuracy
%CV

97.6
5.1

104
8.7

102
7.5

100
1.4

98.0
2.0

103
8.2

93.1
5.6

102
6.4

0.9975

Para-hydroxy-ATV

% Accuracy
%CV

97.7
2.2

106
3.9

94.2
1.2

95.5
2.4

104
3.1

103
5.2

95.8
6.0

104
4.4

0.9987

Para-hydroxy-ATV lactone

% Accuracy
%CV

100
3.4

99.4
8.3

103
7.5

98.5
3.2

102
2.7

104
4.5

94.4
2.6

98.6
0.6

0.9981

Ortho-hydroxy-ATV

% Accuracy
%CV

98.6
1.2

103
2.3

97.8
1.5

95.0
4.0

103
2.1

99.5
5.7

97.1
4.4

105
4.1

0.9980

Ortho-hydroxy-ATV lactone

% Accuracy
%CV

98.2
4.6

104
9.1

98.3
3.2

101
0.6

100
3.2

105
1.9

91.6
1.8

102
3.0

0.9984
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ATV

n = 3 (1 replicate for each of the three validation runs)
% accuracy=100- [(mean-nominal)/nominal]*100
%CV calculated as (standard deviation/mean)*100

Table II-3. Summary of Quality Control Samples from Three Individual Runs.
Analyte
QC (ng/mL)

0.05

QCs
0.15

5.00

75.0

ATV

%Accuracy
%CV

100
9.2

105
6.2

97.6
4.0

91.7
4.6

ATV lactone

%Accuracy
%CV

105
9.4

100
8.1

99.5
4.9

96.4
4.4

Para-hydroxy-ATV

%Accuracy
%CV

97.4
7.4

107
5.5

95.6
6.6

94.0
3.2

%Accuracy
%CV

103
8.6

98.5
6.5

101
4.8

97.0
3.8

%Accuracy
%CV

98.1
13

106
7.9

95.8
4.4

93.9
4.7

%Accuracy

98.0

98.2

100

97.4

%CV

12

7.8

4.5

3.8

Para-hydroxy-ATV lactone

Ortho-hydroxy-ATV

Ortho-hydroxy-ATV lactone

n = 18 (6 replicates for each validation run).
% accuracy=100- [(mean-nominal)/nominal]*100
%CV calculated as (standard deviation/mean)*100
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Abstract
A simple and sensitive assay was developed and validated for the simultaneous
quantification of rosuvastatin acid (RST), rosuvastatin-5S-lactone (RST-LAC), and Ndesmethyl

rosuvastatin

(DM-RST),

in

buffered

human

plasma

using

liquid

chromatography-tandem mass spectrometry (LC-MS/MS).
All the three analytes and the corresponding deuterium-labeled internal standards were
extracted from 50 µL of buffered human plasma by protein precipitation.

The

chromatographic separation of the analytes was achieved using a Zorbax-SB Phenyl
column (2.1 mm×100 mm, 3.5 µm). The mobile phase consisted of a gradient mixture of
0.1% v/v glacial acetic acid in 10% v/v methanol in water (solvent A) and 40% v/v
methanol in acetonitrile (solvent B). All the analytes were baseline-separated within 6.0
min using a flow rate of 0.35 mL/min. Mass spectrometry detection was carried out in
positive electrospray ionization mode.
The calibration curves for all the analytes were linear (R≥0.9964, n=3) over the
concentration range of 0.1-100 ng/mL for RST and RST-LAC, and 0.5-100 ng/mL for
DM-RST. Mean extraction recoveries ranged within 88.0-106%. Intra- and inter-run
mean percent accuracy were within 91.8-111% and percent imprecision was ≤15%.
Stability studies revealed that all the analytes were stable in matrix during bench top (6 h
on ice-water slurry), at the end of three successive freeze and thaw cycles and at -80 °C
for 1 month. The method was successfully applied in a clinical study to determine the
concentrations of RST and the two metabolites over 12-h post-dose in patients receiving
rosuvastatin.
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Introduction
Rosuvastatin acid (RST) is a synthetic and relatively hydrophilic lipid lowering agent [1].
It is widely used to treat hypercholesterolemia and to prevent progression of coronary
artery diseases. Rosuvastatin decreases the concentration of low-density lipoproteincholesterol by reversible, competitive inhibition of 3-hydroxy-3-methylglutarylcoenzyme A, the rate-liming reductase enzyme that is responsible for cholesterol
biosynthesis [1]. It is one of the most effective and potent statins due to its unique
characteristics such as selective uptake into hepatocytes, superior binding affinity, and
tight binding interaction at the enzyme active site [2].
Rosuvastatin (Crestor®, AstraZeneca, Wilmington, DE, USA) is available as 5-40 mg
tablets. It is orally administered as a calcium salt of the active hydroxy acid form with an
absolute oral bioavailability of ~20%. Parent RST is biotransformed to two metabolites:
rosuvastatin-5S-lactone (RST-LAC, inactive metabolite) and N-desmethyl rosuvastatin
(DM-RST, active metabolite) [3] primarily by cytochrome P450 (CYP) 2C9, and to the
lesser extent, by CYP 2C19, and CYP 3A4 isoenzymes [1]. Up to 50% of HMG-CoAreductase inhibitor activity of RST has been attributed to DM-RST [3]. The chemical
structures of RST and its two metabolites are shown in Figure III-1. After a single oral
dose of RST, 90% of the dose was recovered in feces and 77% of the dose was excreted
unchanged as the parent drug [3]. After an oral dose of 20 mg, the average peak plasma
concentrations (Cmax) of RST was ~6 ng/mL [3]. The average Cmax values for RST-LAC
and DM-RST were 12–24% and <10% of the parent RST Cmax, respectively [3].
Statins are generally well tolerated. However, skeletal muscle toxicity is the major
adverse effect associated with statin treatment that results in decreased adherence to the
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therapeutic regimen. In addition, a few cases of RST-induced fatal rhabdomyolysis have
been reported to date [4]. Several hypotheses based on depletion of the products of the
mevalonate pathway have been proposed to explain the molecular mechanism of statinrelated myopathy; though, the underlying mechanism for statin-induced myopathy has
not been fully elucidated [5]. A clinical pharmacokinetic (PK) study of atorvastatin [6]
proposed higher concentration of atorvastatin metabolites, as one of the possible
mechanisms for statin-associated myopathy. In addition, an in vitro study [7] indicated
that the lactone forms of statins are more myotoxic as compared to their respective acid
forms. No information is currently available on the association between RST metabolite
concentrations and drug related adverse effects.
To date, several methods have been reported for the quantification of parent RST. These
methods have utilized high-performance liquid chromatography with ultra-violet
detection (HPLC-UV) [8,9] or liquid chromatography-tandem mass spectrometry (LCMS/MS) [10-18] techniques. The maximum plasma concentration of RST is usually
below 10 ng/mL [19]; thus, a sensitive analytical method is required for the quantification
of RST in human plasma. Previously reported HPLC-UV methods are less sensitive with
a lower limit of the quantification (LLOQ) in µg/mL levels and also are more time
consuming [8,9].

Quantification of RST and its metabolites in biological fluids is

important

respect

with

to

understanding

either

the

PK

characteristics

or

pharmacological/toxicological properties. Specifically, the quantification of statin lactone
may prove to have some diagnostic value as a possible marker for the development of
myopathy. However, only two methods were previously reported for the quantification
of DM-RST metabolite in human plasma, including individual estimation of DM-RST
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[11] and simultaneous estimation of RST and DM-RST [15]. To the best of our
knowledge, currently no published bioanalytical method has described a fully validated
LC-MS/MS assay for the quantification of RST-LAC metabolite in human plasma.
Rosuvastatin lactone is highly unstable and the possible interconversion between lactone
and acid forms can be minimized by lowering the working temperature to 4 °C and
plasma pH to 4-6.

Liquid-liquid and solid phase extractions usually involve time-

consuming extraction steps such as drying and the addition of pH modifiers, which in this
case may lead to undesirable acid-lactone interconversion. Several methods employed
solid phase extraction for sample purification utilizing expensive automated
[11,12,15,20] or manual manifold [16]. Plasma samples were concentrated more than
two times in these methods to achieve adequate LLOQ [11,12,20,16]. Some methods
have utilized traditional one or multi step liquid-liquid phase extraction for sample clean
up using solvents such as ethyl-ether [10,18], methyl-tertiary-butyl ether [13] and ethyl
acetate [17] and typically report low recovery. Lan et al. used tetrabutyl ammonium
hydroxide (TAH) for ion pair liquid-liquid extraction to improve lipophilicity of RST;
however, reported mean recoveries ranged within 47.5-62.2 % [21]. Moreover, addition
of TAH to plasma may change its relatively neutral pH to a more alkaline pH; this
condition may favor interconversion between lactone and acid forms in clinical samples.
Most of the methods require a large sample volume (500 µL-1,700 µL) [10-14,8,21].
We report, for the first time, a fully validated LC-MS/MS assay for the simultaneous
quantification of RST and its two metabolites, RST-LAC and DM-RST in a small volume
(50 µL) of buffered human plasma.
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Experimental
Reagents and chemicals
RST, RST-LAC, DM-RST and corresponding deuterium labeled internal standards (IS),
d6-RST, d6-RST-5S-lactone and d6-DM-RST were obtained from Toronto Research
Chemicals Inc. (North York, ON, Canada). HPLC-grade acetonitrile and glacial acetic
acid were purchased from Fisher Scientific (Fair Lawn, NJ, USA).

HPLC-grade

deionized water was purified with a Milli Q50 (Millipore, Bedford, MA, USA) water
purification system. Sodium acetate trihydrate (99%) and methanol d1 (CH3OD) were
obtained from Sigma-Aldrich (St. Louis, MO, USA).

HPLC-grade methanol was

purchased from Pharmco Products Inc. (Brookefield, CT, USA).

Drug-free human

plasma, with heparin as an anticoagulant, was obtained from Bioreclamation Inc.
(Westbury, NY, USA).
Chromatographic conditions
The analytical column was a Zorbax-SB Phenyl, Rapid-Resolution HT (2.1 mm×100
mm) with 3.5-µm particle size from Agilent Technologies (Wilmington, DE, USA),
preceded by a 0.5 µm filter (Supelco, Bellefonte, PA). The column was maintained at 40
°C. Mobile phase, consisting of gradient mixture of 0.1% v/v glacial acetic acid in 10%
v/v methanol in water (solvent A), and 40% v/v methanol in acetonitrile (solvent B), was
used at a flow rate of 0.35 mL/min for separation and rapid elution of the analytes from
the extracted matrix within 6.0 min. The following mobile phase gradient scheme was
used:
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Total Time (min)
0.00
0.30
0.80
4.50
4.51
6.00

A (%)
90
40
40
25
90
90

B (%)
10
60
60
75
10
10

Mass spectrometric conditions
The LC-MS/MS system consisted of an Agilent Technologies 1200 series HPLC system
comprising of a binary pump, an autosampler, a thermostatted column compartment, and
a micro-vacuum degasser (Santa Clara, CA). The LC was coupled to an API 4000™
triple quadrupole mass spectrometer (AB Sciex, Toronto, Canada), equipped with Turbo
V™ source.
Triple-quadrupole MS/MS detection and the quantification of all the analytes were
carried out in positive electrospray ionization mode using multiple-reaction monitoring
(MRM) scan. Q1 and product ion scans were obtained by infusion of the individual
analytes and the IS solutions using an infusion pump. The following MRM transitions
(m/z, Q1 →Q3) were selected: RST (m/z, 482.2→ 258.2), d6-RST (m/z, 488.2→264.2),
RST-LAC (m/z, 464.2→270.2), d6-RST-LAC (m/z, 470.2→ 276.2), DM-RST (m/z,
468.2→258.2), and d6-DM-RST (m/z, 474.2→264.2) for the best sensitivity and
minimum interference from matrix components. The compound specific parameters i.e.
declustering potential (DP), entrance potential (EP), collision cell exit potential (EXP)
and collision energy (CE) were optimized to achieve maximum signal.

Source

parameters were set at curtain gas (CUR=20 psi), gas 1 (GS1=45 psi), gas 2 (GS2=20
psi), and collision gas (CAD=12 psi), ionspray voltage (IS=5500 V), and temperature
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(TEM=450 °C) to achieve the optimal signal. Peak areas were obtained using AB SCIEX
Analyst® 1.5.1 data processing software.
Preparation of standards and quality control solutions
Separate stock solutions of RST (1.00 mg/mL), and DM-RST (1.00 mg/mL) were
prepared in methanol, while RST-LAC (0.50 mg/mL) was prepared in acetonitrile.
Lactone forms ester by reaction with alcohols such as methanol. Thus, methanol was
avoided in the preparation of the stock solution of the lactone compounds [22,23].
Intermediary individual stock solutions containing 100 µg/mL concentration of RST,
DM-RST or RST-LAC were prepared in respective solvents and were used to spike
calibrators and quality control (QC) samples (QCs) in buffered plasma kept on ice-water
slurry. Drug-free heparin human plasma diluted 1:1 with 0.1 M, pH 4.0 sodium acetate
buffer was used to prepare calibrators and QCs samples.
Individual stock solutions of 1.0 mg/mL of d6-RST and d6-DM-RST were prepared in
CH3OD to avoid deuterium-hydrogen exchange. Stock solution of 1.0 mg/mL of d6RST-LAC was prepared in acetonitrile. An intermediary IS solution containing 1 µg/mL
of each IS was prepared in CH3OD.
All stock and working standard solutions were stored at -20 °C until use.

Eight

calibration standards with concentrations ranging from 0.1 ng/mL to 100 ng/mL for RST
and RST-LAC and 0.50 ng/mL to 100 ng/mL for DM-RST and QC samples at four
concentration levels (0.10, 0.50, 7.50, and 76.0 ng/mL for RST and RST-LAC and 0.50,
2.50, 10.0 and 76.0 ng/mL for DM-RST) were prepared in drug-free buffered human
plasma by using respective spiking solutions and were stored at -80 °C.
Sample extraction
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Calibrators, QCs, zero standard, double blank and buffered patient samples were thawed
on ice-water slurry and vortex-mixed thoroughly for 10 seconds. A 50-μL aliquot of each
buffered plasma sample was aliquoted into 1.5 mL polypropylene tube; all samples were
treated with 200 μL of 0.1% acetic acid in methanol (as a protein precipitation solvent)
containing 2.00 ng/mL of d6-RST, 2.00 ng/mL of d6-RST-LAC and 20.0 ng/mL of d6DM-RST except double blank.

All tubes were vortex-mixed for 10 seconds and

thereafter, centrifuged for 15 min at 14000xg and 4 °C. The supernatant was transferred
to a clean glass vial and 15 μL was injected onto LC-MS/MS.
Validation of the assay
The validation of the method was performed according to general recommendation
guidelines for bioanalytical methods by the United States Food and Drug Administration
[24].

Validation parameters including selectivity, sensitivity, accuracy, precision,

recovery, matrix effect and stability were determined.

The accuracy of calibration

standards and QC samples (n≥5) should be within 85-115%, and imprecision should not
exceed 15%, except at the LLOQ level, for which accuracy may be within 80-120% and
imprecision should not exceed 20%.
Stability. Stability studies aimed to establish the conditions in which the degree of
interconversion between acid and lactone was minimal. The first set of QC samples
contained composite mixture of all the three analytes. In the second set, QC samples
contained only RST and N-desmethyl RST. The third set comprised only RST-LAC. All
three sets of QC samples were prepared at low-level quality control (LQC), 0.50 ng/mL
for RST and RST-LAC and 2.50 ng/mL for DM-RST and high- level quality control
(HQC), 76.0 ng/mL for all the three analytes concentration levels.
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1. Post-preparative stability (autosampler stability): The capability of injecting
processed samples after being kept in the autosampler at 4°C, was tested by
reinjecting one of the three validation runs 24 h after extraction.
2. Bench-top stability: Triplicate LQC and HQC kept on ice-water slurry for 6 h were
extracted along with freshly spiked calibrators.
3. Long-term stability: It was established for up to 1 month at -80 °C by analyzing six
replicates of LQC and HQC, after 1 week and 1 month.
4. Freeze and thaw stability: Freshly spiked triplicates of LQC and HQC were prepared
and stored at -80 °C for 24 h and were thawed on ice-water slurry. At the end of three
successive freeze and thaw cycles, QC samples were extracted along with freshly
spiked calibrators and QCs samples.
Linearity, accuracy, and precision. Eight-point calibration curves were obtained using
0.10, 0.20, 2.00, 10.0, 25.0, 50.0, 90.0, and 100 ng/mL for RST and RST-LAC and 0.50,
1.00, 5.00, 15.0, 30.0, 50.0, 90.0 and 100 ng/mL for DM-RST calibrators.

All

calibrators, six replicates of first set of QC samples at four concentration levels, double
blank (without the IS), and zero standard (with the IS) were tested in three runs to
evaluate intra-run and inter-run precision and accuracy of the method.
Limit of detection and quantification. LLOQ is defined as the lowest concentration of an
analyte, which has at least five times higher response (signal-to-noise, S/N=5/1)
compared with blank response and can be analyzed with an acceptable accuracy and
imprecision (accuracy within 80-120% and imprecision ≤ 20%). Five serial dilutions of
buffered plasma samples containing 0.500 ng/mL of RST and RST-LAC and 2.50 ng/mL
of DM-RST were made by mixing equal volumes of spiked buffered plasma with
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buffered blank plasma. Six replicates of each spiked sample were extracted, and S/N of
peak and percent CV of the analyte/IS ratio were calculated. The sample with a S/N of at
least five and percent CV below 20% for each analyte was selected as potential LLOQ
for the validation.
Selectivity. The presence of endogenous matrix components that may interfere with the
quantification of the analytes or the IS was evaluated using drug-free human buffered
plasma containing heparin as anticoagulant (from six donors). The analytes and the IS
responses in extracted selectivity samples were compared with the chromatograms
obtained from LLOQ samples containing all the three analytes.
Recovery and matrix effect. Triplicates of LQC and HQC from first set of QC samples
along with blank buffered plasma samples were extracted and were used to evaluate
recovery and matrix effect (enhancement or suppression of ionization). Solutions with
concentrations equivalent to 100% recovery of extracted LQC (0.5 ng/mL for RST and
RST-LAC and 2.5 ng/mL for N-desmethyl RST) and HQC (15.2 ng/mL) containing all
the analytes and the IS were prepared in water / 0.1% acetic acid in methanol, 1:4 (v/v;
reference for matrix effect) and in extracted blank buffered plasma (reference for
recovery).
In addition, matrix effect was also evaluated using a post-column infusion method. This
test was performed by infusing a solution containing 20 ng/mL of the analytes and the IS
prepared in solvent A/solvent B (30:70 v/v) at 10 µL/min along with injections of the
blank solvent, double blank matrix extract, and extracted HQC to identify the regions of
ionization suppression. To investigate the potential interference from co-administered
medications and their metabolites specific to the kidney transplant population, a pooled
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buffered plasma sample was prepared from the three kidney transplant patients treated
with tacrolimus, mycophenolic acid, and prednisone but not with RST. The pooled
sample was obtained by mixing equal volumes of plasma (diluted 1:1 with 0.1 M, pH 4.0
sodium acetate buffer) from samples collected 1, 2, 4, 8, and 12 h after the morning dose
of the co-administered medications. The pooled buffered plasma sample was spiked with
working standard solution of analytes at LQC level, and six replicates were extracted
along with calibration calibrators, QCs samples, and a non-spiked pool.
Application of the method in a pharmacokinetic study
The assay was utilized in a preliminary PK study aiming to study disposition of RST in
the kidney transplant recipients. The study protocol was approved by the Institutional
Review Board of Rhode Island Hospital, Providence, RI, USA.

Written informed

consent was obtained from all subjects after verbal explanation of the study protocol.
The blood samples were collected at various time points during a period of 12 h postdose from the four kidney transplant recipients treated with 20 mg of a single oral dose of
Crestor® along with a triple immunosuppressive regimen including oral tablets of
tacrolimus, mycophenolate mofetil and prednisone as well as several other medications
including proton pump inhibitors, antidiabetic agents, antibacterial agents, levothyroxin
and cardiovascular drugs. Plasma sample was separated from whole blood with heparin
as an anticoagulant at 1,500xg for 15 minutes and were immediately buffered with an
equal volume of 0.1 M sodium acetate buffer (pH 4.0).
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Results and discussion
Sample preparation, chromatography and MS detection
Various reverse phase analytical columns were tested. The required selectivity, as well
as excellent peak shape (in terms of sharpness and symmetry), were achieved using a
narrow bore Zorbax-SB phenyl column. This column exhibited good stability under a
low pH mobile phase, and capability to decrease run times. Due to good peak focusing,
the high S/N ratio obtained using this column enabled us to use a simple protein
precipitation extraction without performing pre-concentration steps during sample clean
up.
Methanol was chosen over acetonitrile as a precipitating agent because it provides
excellent peak shape and resulted in an optimal signal of the analytes. Non-acidified
methanol as a precipitating agent led to significant interconversion of lactone to acid
form during the resident time of the extracted samples in the autosampler. Therefore,
0.1% glacial acetic acid in methanol was used to minimize the interconversion of lactone
to acid and vice versa. Rapid elution of the analytes using a gradient mixture of mobile
phase was obtained within a 6.0 min run time, including the re-equilibration time of the
column. The retention times of RST, RST-LAC, and DM-RST were 3.3, 2.8 and 3.8
min, respectively (Figure III-2).
The MS/MS detection for RST can be achieved both in positive and negative ion mode,
as it contains carboxyl and tertiary amine groups. Few of the published methods [10,15]
suggested the use of a negative ion mode for the determination of RST to achieve a better
LLOQ. We observed high signal intensity when using electrospray in positive ion mode,
therefore, all analytes and the IS were monitored in positive ion mode. Rosuvastatin acid
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gave its precursor ion at m/z 482.2. The principal product ion for RST was at m/z 258.2,
with two minor fragments at m/z 300 and m/z 272. The most abundant product ion for
DM-RST was at m/z 258.2 therefore, m/z 468.2→258.2 was chosen for the MRM
transition. The structures of major product ions of RST and DM-RST monitored are
shown in Figure III-1b [11,12]. For RST-LAC, the most intense product ion was at m/z
270.2 and minor was at m/z 282.2 and thus transition of m/z, 464.2→270.2 was selected.
The proposed structure of major product ion of RST-LAC monitored is illustrated in
Figure III-1b.
Method validation
The analytes were stable in the conditions described above. The post-preparative stability
assessment proved the stability of extracted samples at 4°C for 24 h post-extraction, the
anticipated resident time in the autosampler. No interconversion of analytes had occurred
when they were monitored by re-injecting the HQCs spiked with each compound
individually after 24 h. The analytes were found stable after three cycles of freeze and
thaw and during bench top stability carried out on ice-water slurry (Table III-1a).
Stability of all the three analytes was tested in various conditions such as non-buffered
human plasma and buffered human plasma (human plasma diluted 1:1 with 0.1 M, pH
4.0 sodium acetate buffer). Rosuvastatin acid and DM-RST were found stable in both
kinds of plasma but approximately 25% loss of RST-LAC occurred in non-buffered
plasma after 1 month storage at -80 °C (Table III-1b). Interconversion of acid to lactone
or vice versa was also negligible in the buffered plasma.

For the proposed assay

validation, plasma was diluted 1:1 with 0.1 M, pH 4.0 sodium acetate buffer. No
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interference was observed from endogenous components with the analytes and the IS in
blank buffered plasma from six different donors, proving the specificity of the method.
The calibration curves obtained from the analyte/IS peak area ratios vs. nominal
concentration were linear using weighted (1/x2) linear least squares regression over the
concentration range, with correlation coefficients (R) ≥ 0.9964. The measured mean
values (n=3) were within 92.4-111% of their nominal values for calibrators (Table III-2),
88.7-109% for intra-run QCs samples (results not presented), and 91.8-105% for inter-run
QCs samples (Table III-3), which proves acceptable accuracy of the proposed method.
A LLOQ of 0.1 ng/mL was achieved for RST and RST-LAC, and 0.5 ng/mL for DMRST. Chromatograms of an extracted LLOQ and blank plasma are shown in Figure III2a and 2b, respectively. The mean extraction recoveries for all the analytes were within
88.0-106%, as shown in Table III-1a. No significant matrix effect was observed for
each analyte upon calculating the ratio of average area response of reference for recovery
to reference for the matrix effect at LQC and HQC concentration levels.
Matrix effect is defined as the effect of co-eluting matrix components on ionization
efficiency of the target analyte. Hence, suppression or enhancement of analyte response
may have deleterious effects both on sensitivity and on the reproducibility of a particular
assay. The integrity of resulting data could be adversely affected by lack of specificity,
selectivity, accuracy and precision and may not be absolute [25]. Evaluation of the
matrix effect is essential to insure reliability of quantitative assays using HPLC-MS/MS,
and the integrity of PK data. Hence, the matrix effect was thoroughly studied as required
by the FDA guidelines. We used the stable isotope labeled IS for each of the analytes, as
they compensate reasonably well during variations in sample analysis. However, due to
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their slightly different elution times compared with their respective non-labeled species,
the deuterated internal standards IS may not always compensate for ionization
enhancement or suppression due to co-elution of matrix endogenous components, such as
phospholipids [26]. Phosphatidylcholine and lyso-phosphatidylcholine are the major
phospholipids in human plasma causing significant matrix effect. Zhang et al. reported
the key phospholipids in human serum extracts that can cause matrix effects by
identifying the precursor ions generating fragment with m/z 184 [27]. Following the same
technique, we determined the retention times of phospholipids with MRM transitions: Q1
m/z 496, 520, 522, 524, 544, 758 and 782 and Q3 m/z 184. We adjusted the
chromatographic conditions to ensure that the analytes do not co-elute with the
phospholipids.
To study the matrix effect, a post-column infusion of a solution containing the analytes
and the IS, concomitantly injected with extracted blank matrix, was carried out. We
monitored retention times of the major phospholipids, and we found that no significant
ion suppression occurred at the retention times of the each analyte and the IS (data are not
shown). The post-column infusion chromatogram shown in Figure III-3a indicates that
RST and metabolites were eluted at retention times different from the retention times of
key phospholipids. This shows that the signal intensity of each analyte of interest does
not change in the region of their respective elution period (Figure III-3b). No significant
matrix effect was observed for each analyte upon calculating the ratio of average area
response of reference for recovery to reference for the matrix effect at LQC and HQC
concentration levels.
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The mean of the calculated concentrations of six LLQC samples prepared in pooled
buffered plasma from patients treated with an immunosuppressive regimen and who did
not receive RST was between 91–96% of the expected nominal concentration. No
interfering peaks were eluting at the retention times of the analytes of interest. This
demonstrates that tacrolimus, mycophenolic acid, prednisone and their metabolites do not
affect the quantification of RST and its metabolites.
Application of the method
The present method was successfully applied in a clinical study for quantitative
determination of RST and lactone metabolite over 12 h post-dose in the stable kidney
transplant recipients after receiving a single dose of rosuvastatin. Individual plasma
concentration-time profiles of RST and RST-LAC (12 h post-dose) are shown in Figure
III-4a and 4b, respectively. The plasma concentrations for DM-RST are not shown in
the figure as these concentrations were below the LLOQ for most of the time points.
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Conclusion
In summary, we describe a reproducible, reliable, sensitive, and simple bioanalytical
technique for the simultaneous determination of RST and metabolites in human plasma.
The major advantages of the present method are the requirement for small plasma volume
(50 µL) and simple sample preparation.
The proposed validated bioanalytical technique accomplishes the required LLOQ,
accuracy, and precision to be applied in various studies involving PK, drug metabolism,
clinical pharmacology/clinical toxicology, bioavailability/bioequivalence and drug-drug
interactions for accurate quantitative analysis of RST and its metabolites.
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Figure III-3a Chromatogram obtained with post-column infusion shows no matrix effect at the retention times of the analytes
and the IS. Arrow indicates region where the signal of compounds infused post-column is suppressed during the elution of
endogenous matrix components.
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Figure III-3b Chromatogram of a blank sample injected while the analytes and the IS are infused post column. Arrow
indicates region where the signals of the analytes and the IS infused post-column are suppressed during the elution of
endogenous matrix components. From top to bottom, rosuvastatin-5S-lactone, d6-rosuvastatin acid, d6-rosuvastatin-5Slactone, rosuvastatin acid, N-desmethyl rosuvastatin, d6-N-desmethyl rosuvastatin.
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stable kidney transplant recipients (n=4) who received a single oral dose of 20 mg of
rosuvastatin.
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Table III-1a. Results of stability studies and recovery (mean±%CV, n=3).
Analyte
Rosuvastatin (RST)
Rosuvastatin-5Slactone (RST-LAC)
N-desmethyl
rosuvastatin (DMRST)

Freeze &
Thaw

Bench
top

Autosampler
stability

Recovery

LQC
HQC
LQC
HQC
LQC

107±3.8
98.7±2.1
101±14
106±7.4
103±7.4

99.0±12
105±3.0
98.3±12
109±5.6
105±3.6

111±7.0
107±0.7
95.6±3.4
105±2.9
114±8.1

106±5.5
88.0±4.1
98.8±10
89.0±3.1
99.3±1.5

HQC

106±3.0

108±3.9

107±2.5

90.2±4.5

Sample
ID

Table III-1b. Stability studies after 1 week and 1 month at -80 °C (mean±%CV, n=3).
after 1 week at -80 °C
Analyte

Rosuvastatin (RST)
Rosuvastatin-5Slactone (RST-LAC)
N-desmethyl
rosuvastatin (DMRST)

Sample
ID
LQC
HQC
LQC
HQC
LQC

94.4±3.7
95.4±5.9
99.4±3.1
104 ±12
93.0±1.9

Nonbuffered
plasma
95.8±12
97.6±5.5
81.5 ±12
84.2 ±5.6
95.9 ±11

HQC

92.7±5.7

95.9 ±5.7

Buffered
plasma

% accuracy= (mean concentration/nominal concentration) x100
%CV calculated as (standard deviation/mean) x100
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after 1 month at -80 °C

98.8±5.4
103±3.0
105±1.9
95.6±8.9
108 ±1.6

Nonbuffered
plasma
100 ±5.2
93.4±4.5
74.8±6.1
75.2±3.1
109±5.6

94.6±0.6

92.0±8.9

Buffered
plasma

Table III-2. Summary of standards and calibration curve parameters from three individual runs.
Analyte
Rosuvastatin
(RST)
Rosuvastatin-5Slactone
(RST-LAC)
N-desmethyl
rosuvastatin
(DM-RST)

STD 1 STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 STD 8
STD (ng/mL) 0.10
0.20
2.00
10.0
25.0
50.0
90.0
100
102
96.6
93.0
101
97.3
111
102
97.8
%Accuracy
4.8
10
2.7
5.5
9.7
3.6
2.1
9.6
%CV
STD (ng/mL) 0.10
0.20
2.00
10.0
25.0
50.0
90.0
100
102
96.3
101
102
98.2
101
98.5
102
%Accuracy
0.6
0.9
5.9
3.9
4.6
5.8
1.2
9.6
%CV
STD (ng/mL) 0.50
1.00
5.00
15.0
30.0
50.0
90.0
100
100
101
92.4
99.4
100
101
107
99.2
%Accuracy
1.4
1.8
6.2
4.0
4.5
5.2
6.3
5.6
%CV
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n = 3 (one replicate for each of the three validation runs)
% accuracy= (mean concentration/nominal concentration) x100
%CV calculated as (standard deviation/mean) x100

R
0.9964

0.9980

0.9980

Table III-3. Summary of quality control samples from three individual runs.

Analyte
QC (ng/mL)
Rosuvastatin (RST)
%Accuracy
%CV
QC (ng/mL)
Rosuvastatin-5S-lactone (RST-LAC) %Accuracy
%CV
QC (ng/mL)
N-desmethyl rosuvastatin (DM-RST) %Accuracy
%CV

Quality control samples
0.10 0.50 7.50 76.0
96.8 105 97.5 99.0
13
11
9.9 6.8
0.10 0.50 7.50 76.0
97.0 91.8 93.6 101
10
12
8.1 6.3
0.50 2.50 10.0 76.0
102 101 95.3 93.1
15
12
9.2 8.2

n = 18 (six replicates for each validation run)
% accuracy= (mean concentration/nominal concentration) x100
%CV calculated as (standard deviation/mean) x100

100
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Abstract
Aim:

Atorvastatin

calcium

(Lipitor®,

Pfizer

Pharmaceuticals,

NY)

is

an

antihyperlipidemic agent from the statins class of drugs is the top-selling prescribed
medication in the prevention and treatment of cardiovascular disorders. The aim of the
present study was to develop a combined parent-metabolite population pharmacokinetic
(PK) model of atorvastatin acid (ATV) and to investigate potential associations between
clinical and demographic covariates on the population PK parameters.
Subjects and methods: Atorvastatin parent and metabolite plasma concentrations (1-11
per patient) of one hundred and thirty two, male or female non-transplant (diabetic, n=46;
non-diabetic, n=53) or the stable kidney transplant recipients (diabetic, n=22; nondiabetic, n=11) who administered single or multiple oral doses of atorvastatin calcium
were included in the study. Plasma concentrations of ATV and atorvastatin lactone
(ATV-LAC) were quantified using previously validated liquid chromatography-tandem
mass spectrometry assay. A total of 639 concentrations including both an acid (n=322)
and lactone (n=317) forms of atorvastatin were analyzed by nonlinear mixed-effects
modeling approach (NONMEM®, version 7.2.0) to identify the influence of patients’
specific characteristics on PK properties of both the parent drug and its lactone
metabolite. The first-order conditional estimation with interaction method was used to fit
the data. The inter-subject variability was assessed using additive, exponential and
proportional models. Likewise, the residual variability was evaluated using additive,
exponential, proportional and combined additive-proportional error models. The
influential covariates affecting pharmacokinetic parameters of both the parent and major
metabolite were examined thorough PLT Tools (PLTsoft, San Francisco, CA, USA). A
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stepwise covariate model building approach, forward addition (<3.84, p<0.05, df=1)
followed by backward elimination (≥7.9, p<0.005) was used. The final model was
validated using visual predictive check and nonparametric bootstrap analysis (n=1000).
Results: Pharmacokinetic characteristics of ATV and ATV-LAC were well described
using a two-compartment model with first-order oral absorption and a one-compartment
with linear elimination, respectively with some degree of interconversion between the
two forms.
The inter-individual and the residual variability of pharmacokinetic parameters for both
the parent drug and metabolite were modeled using an exponential and proportional error
model, respectively. The population mean estimates of the final model parameters
including absorption rate constant (Ka), apparent volume of distribution of ATV in the
central compartment (V2/F), apparent oral clearance of ATV to ATV-LAC (CL/F),
apparent volume of distribution of ATV in the peripheral compartment (V3/F), apparent
inter-compartmental clearance of ATV (Q/F), apparent oral clearance of ATV-LAC to
ATV (CLM/F), apparent volume of distribution of ATV-LAC in the central compartment
(VM/F) and apparent inter-compartmental clearance of ATV-LAC (QM/F) were 0.771 h-1,
481 L, 1126 L/h, 5462 L, 343 L/h, 506 L/h, 2349 L and 748 L/h, respectively.
The goodness-of-fit plots indicated good agreement between observed and individual as
well as population predicted plasma concentrations of the parent and metabolite. In this
study, we found renal transplantation, lactate dehydrogenase (LDH) liver enzyme and
gender as the significant covariates, respectively for clearance and volume of distribution
of ATV-LAC. Renal transplant recipients had 50% lower metabolite clearance compared
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to non-transplant patients. The bootstrap analysis and visual predictive check
demonstrated robustness of the present population pharmacokinetic model.

Conclusion: In summary, a combined parent-metabolite population pharmacokinetic
model of ATV was developed. The pharmacokinetic analysis indicated significantly
reduced clearance of lactone metabolite in the stable kidney transplant recipients. Greater
risk of statin-related skeletal muscle toxicity is possibly because of decreased clearance
of lactone metabolite. This finding should be taken into account while prescribing ATV
treatment in the kidney transplant population who have additional co-morbidities and are
on multiple interacting medications.
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Introduction
Chronic kidney disease (CKD) is a major health issue that is common among the adult
population in the United States. It is an irreversible and progressive disease, and if left
untreated, chronic renal failure can advance to end stage renal disease. Chronic kidney
disease is ranked as the eighth leading cause of death in the United States. At present,
more than 20 million people are suffering from CKD in the United States [1]. Moreover,
more than 35% of adults with diabetes, another growing global burden of diseases, have
CKD [1].
Patients with CKD are at significantly greater risk of cardiovascular diseases mainly
because of higher prevalence of diabetes mellitus, oxidative stress [2] and lipid
abnormalities [3]. Statins [3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors] class of lipid lowering drugs are the choice of treatment for
cardiovascular disorders in patients with or at a risk of CKD due to potential benefits
attributed to its cardioprotective and nephroprotective properties [4]. Statins block
cholesterol biosynthesis by reversible and competitive inhibition of the rate limiting
enzyme, HMG-CoA reductase. A calcium salt of atorvastatin acid (ATV) (Lipitor®,
Pfizer Pharmaceuticals, NY) is the best-selling statin of all time. It is administered as an
active acid form, which undergoes extensive first-pass effect after oral administration [5].
Atorvastatin acid is extensively metabolized mainly by intestinal and liver cytochrome
P450 (CYP) 3A4/5 and generates pharmacologically active ortho and para hydroxylated
metabolites [6]. The parent drug and its active acid metabolites remain in equilibrium
with their respective inactive lactone forms [7]. Atorvastatin lactone (ATV-LAC) has 83
fold greater affinity for CYP3A4 and exhibits higher metabolic clearance [6]. The
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formation of lactone form is attributed to the glucuronidation metabolic pathway, which
is mediated through UDP-glucuronosyltransferases (UGT) 1A1 and predominantly
through 1A3 [8]. The enzymatic interconversion between acid and lactone forms is
governed by esterases, paraoxonase (PON), UGT1A1 and 1A3 enzymes [8, 9].
Organic anion-transporting polypeptide (OATP) uptake transporters, OATP1B1 and
OATP1B3, play a major role in the hepatic uptake of ATV and its metabolites [5].
Atorvastatin acid and its metabolites are also substrates of efflux transporters including Pglycoprotein (P-gp) [10] and breast cancer resistant protein (BCRP), which govern their
intestinal absorption and liver elimination [11].
Statins are well tolerated; however, statin-related minor or severe skeletal muscle toxicity
is the common adverse effect associated with statin therapy [12]. Several factors such as
concomitant medications, metabolic disorders and hepatic or renal function aggravate the
risk of statin-induced muscle complaints [13]. Hermann and colleagues [14], revealed
significantly higher levels of ATV-LAC metabolite in patients experiencing statinassociated myopathy. Moreover, an in vitro study, using primary human skeletal muscle
cells showed that ATV-LAC had a 14-fold higher potency to induce myotoxicity as
compared to its acid form [15]. Additionally, a previous study has indicated lactone/acid
ratio measurement as a specific diagnostic tool for statin-induced muscle toxicity [16].
Genetic propensity of an individual is a likely factor in the altered pharmacokinetics (PK)
that may result in statin-associated myopathy [13]. Genetic polymorphism associated
with OATP1B1 and OATP1B3 (SLCO1B1 and SLCO1B3), P-gp (ABCB1), BCRP
(ABCG2), bile salt export pump (ABCB11) and drug metabolizing enzymes (CYP and
UGT) significantly affect ATV PK [17]. The extent of ATV-LAC formation is
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significantly associated with UGT1A genetic polymorphisms that affect UGT1A3
expression [18] while the reverse reaction, ATV-LAC hydrolysis is influenced by PON1
and PON3 gene polymorphism [19].
Occurrences of severe rhabdomyolysis have been reported in patients with renal
transplant because of concomitant use of statins with immunosuppressants and other
medications [20-26] and associated co-morbidities. It is essential to investigate and
interpret patients’ demographic characteristics, genetic polymorphism as well as
physiological and pathological characteristics that significantly alter pharmacokinetic
properties of parent drug and its major metabolite in the kidney transplant recipients who
require lifetime treatment with several concomitant drugs including immunosuppressants
and who are at greater risk of developing adverse effects. Assessment of such factors will
allow clinicians to select the right dose of ATV for optimum therapy.
The objective of this study was to develop a combined population PK model of ATV and
ATV-LAC metabolite to allow the evaluation of chronic diseases, genetic polymorphisms
as well as other patient specific characteristics.
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Materials and methods
Study design
The open-label study was conducted in the kidney transplant and non-transplant
recipients with and without diabetes mellitus at several study locations. The study
protocol was approved by the Institutional Review Board of Rhode Island Hospital,
Providence, RI, University of Rhode Island, Kingston, RI and South County Hospital,
Wakefield, RI. The study procedures were explained verbally to the study participants,
and thereafter their signed informed consent was obtained. All participants underwent
normal physical examination on the day of the study and medical histories were
documented for all study subjects. Except ten participants all were on steady state
treatment with ATV in 5-80 mg dose range.

Patient population
The study population contained non-transplant (diabetic, n=46; non-diabetic, n=53) and
the stable kidney transplant (diabetic, n=22; non-diabetic, n=11) recipients. Male (n=77)
and female (n=55) participants over 18 years of age were included in the study. The
subjects with congestive heart failure as defined by the New York heart association
(NYHA) grades III and IV, liver dysfunction, pregnancy, undergoing active bacterial,
fungal or viral infections, receiving CYP3A4/5 inhibitors or inducers were excluded from
the study. The subjects with the kidney transplant were on a triple immunosuppressive
drug regimen comprised of tacrolimus or sirolimus oral tablets, prednisone and
mycophenolic acid either from mycophenolate mofetil (Cellcept™, Roche, Nutley, NJ) or
mycophenolate sodium (Myfortic, Novartis, East Hanover, NJ).
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Pharmacokinetic study
Blood samples (6 mL) were collected at various time points over 24 h post-dose. The
blood was collected by venipuncture in Vacutainer® tube containing fluoride/potassium
oxalate anticoagulant (Becton Dickinson, Franklin Lakes, NJ, USA). Plasma was
separated by centrifugation at 1500xg and stored at -80°C until analysis. In addition to
the PK study, additional blood samples were drawn to genotype each subject in EDTA
Vacutainer® tube (Becton Dickinson, Franklin Lakes, NJ, USA) tube and stored in -80 °C
until DNA extraction.

Quantitative analysis of ATV and ATV-LAC in plasma
Plasma levels of ATV and ATV-LAC were determined using a validated liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method [27]. Briefly, both the
analytes and their corresponding deuterium (d5) labeled internal standards were extracted
from 50 µL of human plasma using 200 µL of 0.1% v/v glacial acetic acid in acetonitrile
as protein precipitating solvent. The chromatographic separation of analytes was
achieved within 7.0 min using a Zorbax-SB Phenyl column (2.1 mm × 100 mm, 3.5 µm)
with a flow rate of 0.35 mL/min. The mobile phase consisted of a gradient mixture of
0.1% v/v glacial acetic acid in 10% v/v methanol in water (solvent A) and 40% v/v
methanol in acetonitrile (solvent B). Mass spectrometry detection was carried out in
positive electrospray ionization mode, with multiple reaction monitoring scan. The
calibration curves for both analytes were linear (R 2 ≥ 0.9975, n=3) over the concentration
range of 0.05-100 ng/mL.
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Genetic polymorphism study
Genomic DNA was extracted according to the procedure described in the manual using
QIAGEN kit (QIAamp DNA Blood Mini Kit; Qiagen, Hilden, Germany). The subjects
were genotyped for the following single nucleotide polymorphism (SNP):
CYP3A4 In6 C>T (rs35599367),
CYP3A5*3 219-237A>G (rs776746),
ABCB1 1236C>T (rs1128503), 2677G>T, A (rs2032582), 3435C>T (rs1045642),
ABCB11 1331C>T (rs2287622),
ABCC2 -24C>T (rs717620), 1249G>A (rs2273697), 3972C>T (rs3740066),
ABCG2 421C>A (rs2231142),
SLCO1B1 388A>G (rs2306283), 521C>T (rs4149056),
SLCO1B3 334T>G (rs4149117), 699G>A (rs7311358), 767G>C (rs60140950),
PON1 -108T>C (rs705379), -832G>A (rs854571), -1741G>A (rs757158) and
PON3 63C>T (rs13226149)
by allelic discrimination with a TaqMan Drug Metabolism Genotyping Assay on an
Applied Biosystems 7300 Real-Time PCR (Applied Biosystems, Foster City, CA).
CYP3A4*1B -285A>G (rs2740574) and UGT1A3*2 31T>C (rs3821242) and 140T>C
(rs6431625) were genotyped by polymerase chain reaction amplification and the
subsequent direct sequencing using Applied Biosystems 3130xl Genetic Analyzer
(Applied Biosystems, Foster, CA) as described previously [28, 29].

Population PK analysis
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Population pharmacokinetic analysis of plasma concentration-time profiles of ATV and
its major metabolite, ATV-LAC were performed through nonlinear mixed effects
modeling tool using NONMEM® (version 7.2.0, ICON Development Solutions, Ellicott
City, MD, USA) as described previously with modifications [30, 31]. A graphical user
interface, PLT Tools (PLTsoft, San Francisco, CA, USA) was used to facilitate
NONMEM analysis.
To account differences in the molecular weight of ATV and metabolite, the
concentrations of ATV-LAC were expressed as equivalent of the parent (the
concentration of the metabolite was multiplied by the ratio of the molecular weights of
ATV and ATV-LAC metabolite). Total of 639 concentrations (1-11 per patient) were
included in the population PK analysis.
The basic PK model of parent drug without covariates was developed by evaluating
various PK models including one-, two- and three- compartment as well as different
estimation methods including the first-order (FO), the first-order conditional estimation
(FOCE) and the FOCE with interaction (FOCE-INTER). The inter-subject variability was
assessed using additive, exponential and proportional models. Likewise, the residual
variability was evaluated using additive, exponential, proportional and combined
additive-proportional error models.
The correct PK model was selected according to the following criteria: (i) a minimum
value of the objective function; (ii) a low estimate of between- and within-subject
variability; (iii) physiological plausibility of the estimates; (iv) goodness-of-fit and (v)
normal distribution of weighted residuals.
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After the development of the base model for ATV, a combined parent-metabolite model
was developed by incorporating lactone concentrations based on the previously described
mechanism [6]. The mixed effects were determined from a combined model. The
influential covariates affecting the PK parameters of parent and metabolite were
examined through PLT Tools. Potential covariates were added one at a time and
reduction in the objective function value, and between-subject variability along with
improvement in the fit were recorded. The effect of continuous covariates including age,
body weight, glycosylated haemoglobin (HbA1c), glucose, total bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP),
lactate dehydrogenase (LDH), g-glutamyl transferase (GGT), cholesterol, high-density
lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, serum
creatinine, total protein and serum albumin on the PK parameter was modeled using a
power model scaled to median covariate value of the population. On the other hand, the
effects of categorical covariates including the presence diabetes mellitus status or renal
transplant as well as gender, ethnicity, concomitant use of prednisone, mycophenolic
acid, sirolimus, tacrolimus and genetic polymorphism were modeled using a proportional
model.
Forward stepwise addition of significant covariates was performed until no longer the
objective function value was reduced (<3.84, p<0.05, df=1). These covariates were then
incorporated in the base model to form the full model. Removal of each covariate from
the full model was carried out in backward elimination method, and increase in the
objective function value was examined. The covariate that increased the objective
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function value by 7.9 or more (p<0.005) upon removal from the full model was retained
in the model.
The validation of the final model was performed to assess its stability and predictive
performance using nonparametric bootstrap analysis and visual predictive check (VPC).
Visual predictive check is based on model-simulated data predictions including random
effects, which visually examine the distribution of observed plasma concentration-time
data and predictions at each sampling time. The ﬁnal model and parameter estimates were
used to simulate the data for 1000 virtual patients for VPC. A 95% prediction interval and
median of the simulated concentrations were plotted along with observed plasma
concentration–time data within 2.5th and 97.5th percentiles of the simulated modelsimulated data. For bootstrap analysis, new datasets (n=1000) of the same size as the
original dataset were generated by sampling random subjects with replacement from the
original dataset and each of them was fitted using the final model. Median and 95%
confidence interval of each PK parameter were calculated from bootstrap analysis.
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Results
A total of 639 concentrations including both atorvastatin acid (n=322) and lactone
metabolite (n=317) from 132 patients were available for the population PK modeling.
The detailed demographic information of study participants is listed in Table IV-1. The
mean oral dose of steady state treatment of ATV was 24.5±19.0 mg. Moreover, a single
40 mg oral dose of Lipitor was administered to the ten kidney transplant recipients.
Initially, a base model for ATV was determined, thereafter ATV-LAC metabolite was
added, and a combined parent-metabolite model was explored. Pharmacokinetic
characteristics were best described using a two-compartment model with first-order oral
absorption for ATV while a one-compartment with linear elimination was used for ATVLAC as described previously [30, 31]. A schematic diagram representing the structural
PK model for a combined parent drug and major metabolite used to model plasma
concentration time profiles of ATV and ATV-LAC is illustrated in Figure IV-1. The
model was developed based on the mechanism described by Jacobson et al. [6] with some
interconversion of lactone to an acid form. However, for simplicity, no other complex
pathways of elimination of ATV were incorporated in the model.
Subroutines ADVAN13 TRANS1, FOCE-INTER and double-precision model were
selected as they helped to meet the selection criteria described in the method section. The
interindividual and the residual variability of the PK parameters for both the parent drug
and metabolite were modeled using an exponential and proportional error model,
respectively.
Significant covariates for V2/F, CL/F, Q/F, CLM/F and VM/F obtained after performing
univariate analysis are listed in Table IV-II. Forward step wise addition of significant
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covariates resulted in the full model incorporating status of the kidney transplant and
LDH for CLM/F, and gender for VM/F. The final model obtained after performing
backward elimination included the same covariates as obtained in the full model. The
mean estimates of model parameters such as absorption rate constant (Ka), apparent
volume of distribution of ATV in the central compartment (V2/F), apparent oral clearance
of ATV to ATV-LAC (CL/F), apparent volume of distribution of ATV in the peripheral
compartment (V3/F), apparent inter-compartmental clearance of ATV (Q/F), apparent
total oral clearance of ATV-LAC (CLM/F), apparent volume of distribution of ATV-LAC
in the central compartment (VM/F), apparent inter-compartmental clearance of ATV-LAC
to ATV (QM/F) including bootstrap median and 95% confidence intervals of the final
model are shown in Table IV-III. The final model for the typical values of various
pharmacokinetic parameters is shown below:
Ka = θ1
V2 = θ2
CL = θ3
V3 = θ4
Q = θ5
CLM = θ6 × θ9

TRAT −1

VM = θ7 × θ10

×

LDH
167.5

θ11

GEND −1

QM = θ8

The goodness-of-fit plots of the final model for ATV and ATV-LAC are presented in
Figure IV-2 and IV-3, respectively. It can be depicted from the goodness-of-fit plots that
all the points are close to the line of unity indicating good agreement between observed
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and individual as well as population predicted plasma concentrations of parent and
metabolite. The model is successful to describe the observed PK data. No specific trend
was observed in the plot of conditional weighted residuals with interaction (CWRESI)
versus time after a dose of ATV or population predicted concentrations for both parent
and metabolite. The CWRESI are randomly distributed with a mean of close to zero and
most of them lay within ±2 units of the null ordinate of perfect agreement. The results of
VPC evaluation contained simulated (n=1000) concentration-time profiles for both ATV
and ATV-LAC at steady state and after a single dose are presented in Figure IV-4. The
prediction interval (2.5th and 97.5th percentiles) incorporated most of the concentrations
of both an acid and lactone forms of ATV and indicated that the final model provided an
adequate fit to observed data.
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Discussion
In this study, we found renal transplantation, LDH and gender as the significant
covariates for clearance and volume of distribution of lactone metabolite, respectively.
The assessment of demographic and clinical characteristics of patients indicated the
status of transplant as the most statistical significant covariate for CLM, and it decreased
between subject variability from 72% to 52%. Moreover, gender and LDH level
influences VM/F and CLM/F, which reduced inter-patient variability from 78% to 53% and
72% to and 59%, respectively.
The effect of kidney transplant covariate was examined as a dichotomous variable (nontransplant=1 transplant=2). According to our study finding, the clearance of ATV-LAC is
significantly decreased in patients with the kidney transplant. Nevertheless, an earlier
published population PK study [30] reported a decrease in clearance of ATV-LAC
metabolite in patients with diabetes mellitus. The study population only contained the
stable kidney transplant recipients with or without diabetes mellitus. Lack of nontransplant subjects limited its ability to assess transplant as a covariate. The present study
included of the stable kidney transplant (n=33) and non transplant (n=99) recipients.
Several different mechanisms could be proposed for lower metabolite clearance in
transplant patients including oxidative stress, pro-inflammatory cytokines and elevated
parathyroid hormone levels. Previous studies have reported coexistence of an
inflammatory condition with elevated oxidative stress in the stable kidney transplant
recipients [32-35]. Moreover, elevated parathyroid hormone levels remain in a significant
number of renal transplant recipients after transplantation due to persistent secondary
hyperparathyroidism [36-38].
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A few in vitro studies have demonstrated down regulation of CYP3A4, the main
metabolizing enzyme of ATV-LAC metabolite, by various cytokines such as interleukin
IL-1β, IL-6, [39] interferon-γ, and hepatocyte growth factor [40]. Furthermore, oxidative
stress reduces CYP3A activity, and the more likely mechanism involves P450
metabolism of fatty acid hydroperoxides [41] and activation of nuclear factor-κB leading
to subsequent protein denaturation [42]. A previous in vitro and rat studies described the
role of parathyroid hormone in the down regulation of CYP enzyme family [43].
Furthermore, transplant patients receive multiple interacting medications other than
immunosuppressive therapy such azole antifungals, amiodarone, macrolide antibiotics,
nefazodone, HIV protease inhibitors, mibefradil, digoxin, verapamil, nicotinic acid,
warfarin, and diltiazem. Concomitant use of these medications may affect the metabolism
and clearance of statins. Several cases of severe rhabdomyolysis have been reported in
the kidney transplant recipients secondary to concurrent use of statin with
immunosuppressant and other medications [20-22, 24-26].
The LDH level was also a significant covariate for the clearance of ATV-LAC. Likewise,
prior published studies also found LDH and AST liver enzyme levels as significant
covariates for the clearance of an acid and lactone forms of ATV, respectively [30, 31].
Atorvastatin acid undergoes significant first-pass effect and therefore altered liver
functions may affect its oral bioavailability. As LDH level increases, the clearance of
metabolite decreased exponentially, which suggests that patients with liver disorders may
have greater systemic exposure of lactone metabolite. Infections and hepatic disorders are
the common complications in the kidney transplant recipients attributed to impaired
resistance because of immunosuppressive treatment [44, 45]. Furthermore, few studies

122

have indicated elevated levels of liver enzymes in the kidney transplant recipients with
mycophenolate mofetil therapy [46, 47].
Significantly higher plasma levels of ATV-LAC metabolite in patients experiencing
statin-related myopathy were observed previously [14]. Moreover, ATV-LAC had a 14fold higher potency to induce myotoxicity as compared to an acid form [15]. These
previous results indicate that patients with reduced clearance of ATV-LAC are more
likely to experience ATV related muscle side effects such as myopathy. This finding
warrants careful treatment of ATV in the kidney transplant population.
The population PK analysis showed significantly higher volume of distribution of
metabolite in male as compared to female. The variability in the volume of distribution
of several drugs between females and males is attributed to several factors including
plasma volume, plasma proteins and tissue binding, fat proportion, body weight, organ
blood flow, body composition and body mass index. Atorvastatin acid is a highly proteinbound drug; more than 98% binds to plasma proteins [5]. Moreover, main plasma
proteins that bind to drugs in human plasma are altered by sex hormone and therefore
protein binding is affected by gender differences resulting in variability in volume of
distribution of drugs [48].
Genetic polymorphisms of various transporters and drug metabolizing enzymes (listed in
the method section) involved in the disposition of ATV, which significantly affects its PK
were evaluated. Single nucleotide polymorphism of PON1 and 3 enzymes were the only
significant covariates found for the clearance of ATV-LAC in univariate search.
Riedmaier et al. have demonstrated that polymorphisms of PON1 -108T>C and PON3,
63C>T esterases are associated with changes in ATV-LAC hydrolysis and increased
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expression of PON1 mRNA in human liver tissues [19]. Furthermore, SLCO1B1,
521T>C and ABCB11, 1331C>T were significant covariates for the clearance of parent
drug. However, statistical significance was not obtained for these covariates during
multivariate analysis. Additional studies with diverse and large population are necessary
to thoroughly assess the effects of SNP on the PK of both an acid and lactone forms of
ATV.
The current study has several limitations: (a) Because of lack of a diverse population,
probably it was not possible to thoroughly evaluate the effect of genetic polymorphism,
age and ethnicity on the PK properties of ATV and metabolite; (b) We did not determine
whether the transplant patients included in this study were affected by non-alcoholic
steatohepatitis due to lack of noninvasive method; (c) Sparse sampling limited the ability
of the model to accurately predict absorption phase of ATV; (d) absolute bioavailability
of ATV was not determined due to unavailability of intravenous data.
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Conclusion
In summary, a combined parent-metabolite population pharmacokinetic model of ATV
was developed. The pharmacokinetic analysis reported 50% reduction in clearance of
ATV-LAC in the kidney transplant recipients. This finding should be taken into account
while prescribing ATV treatment in the kidney transplant population. However, a further
study to investigate pharmacokinetic of ATV over a 24 h dosing interval in a large
number of the kidney transplant and non-transplant patients is required to confirm this
finding.
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Parent drug
Oral administration

Micro-constants:
K 23 =Q/V 2
K 20 =CL/V 2
K 32 =Q/V 3
K 42 =Q M/V M
K 40 =CLM/V M

Depot
compartment

Ka
Q/F

Central compartment
V 2 /F

CL/F
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V 3 /F

Q M/F

Metabolite
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V M/F
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Figure IV-1. Schematic diagram of the proposed structural combined parent-metabolite
pharmacokinetic model for orally administered ATV and its major metabolite, ATVLAC. A two-compartment model with first-order oral absorption and one-compartment
with linear elimination was used to describe the PK of ATV and ATV-LAC, respectively
with some interconversion between two forms. Elimination of ATV-LAC only from the
central compartment was assumed and no other pathways of elimination of ATV were
accounted. Ka = absorption rate constant; V2/F = apparent volume of distribution of the
parent drug in the central compartment; CL/F = apparent oral clearance of the parent drug
to the metabolite; V3/F = apparent volume of distribution of the parent drug in the
peripheral compartment; Q/F = apparent inter-compartmental clearance of the parent
drug; CLM/F = apparent total oral clearance of the metabolite; VM/F = apparent volume of
distribution of the metabolite in the central compartment; QM/F = apparent intercompartmental clearance of the metabolite to the parent drug.
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Figure IV-2. The goodness-of-fit plots of the final model for atorvastatin acid: (a) OBS vs PRED (b) OBS vs IPRED (c)
CWRESI vs PRED (d) CWRESI vs time post-dose at steady state. (e) CWRESI vs time after single dose. OBS = observed
concentrations of atorvastatin acid; PRED = population predicted concentrations of atorvastatin acid; IPRED = individual
predicted concentrations of atorvastatin acid; CWRESI = conditional weighted residuals with interaction. Logarithmic scale
was used for clarity.
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Figure IV-3 The goodness-of-fit plots of the final model for atorvastatin lactone: (a) OBS vs PRED (b) OBS vs IPRED (c)
CWRESI vs PRED (d) CWRESI vs time post-dose at steady state. (e) CWRESI vs time after single dose. OBS = observed
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Table IV-1. Characteristics of the patients included in the NONMEM analysis.
Mean
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Demographics
Gender [male/female]
Age [years]
Ethnicity [Caucasian/Hispanic/African American/others]
Diabetes [non-diabetic/diabetic]
Weight [kg]
Transplantation [non-transplant/transplant]
Time post transplant [months]
Atorvastatin acid dose in mg
Prednisone dose [mg/day]
Mycophenolic acid dose [mg/day]
Tacrolimus dose [mg/day]
Sirolimus dose [mg/day]
Clinical
Albumin [g/dl]
Protein, total [mg/dl]
Cholesterol, total [mg/dl]
High-density lipoproteins cholesterol [mg/dl]
Low-density lipoproteins cholesterol [mg/dl]
Triglycerides [mg/dl]
Creatinine [mg/dl]
Creatinine kinase [IU/l]
Glucose [mg/dl]
Hemoglobin A1c [%]
Lactate dehydrogenase [IU/l]
Aspartate aminotransferase [IU/l]
Alkaline phosphatase [IU/l]
Alanine aminotransferase [IU/l]
Gamma-glutamyl transferase [IU/l]

Median

Range

58

19-77

77/55
56.44
120/2/6/4
64/68
90.1
99/33
56.15
20
5.85
1000
2.16
1.79

88.6

45-145

47
25.7
5
1000
2
2

3-140
5-80
2.5-30
1000-2000
0.5-5
1-3

4.31
6.87
169.5
53.2
85.8
167.2
1.13
135.9
132.6
6.34
173
24.9
77.80
24.31
37.29

4.30
6.90
168
50.5
87.2
135.5
1.04
92.5
113
5.8
167.5
23.5
74
22
24.5

4-5
6-8
73-285
17-147
11-182
44-811
1-3
16-3118
65-601
5-12
81-324
12-93
32-184
6-85
6-492

Table IV-2. Significant covariates for the univariate and multivariate analyses.

Δ Minimum objective
function value

P values

Univariate analysis
Effect of transplant status on CLM/F
Effect of lactate dehydrogenase on CLM/F
Effect of dose of tacrolimus on CLM/F
Effect of PON3, 63C>T on CLM/F
Effect of PON1 -108T>C on CLM/F
Effect of dose of sirolimus on CLM/F
Effect of alanine aminotransferase on CLM/F

-41.4
-36.2
-18.5
-9.0
-7.5
-7.2
-7.2

<0.001
<0.001
<0.001
<0.005
<0.01
<0.01
<0.01

Effect of cholesterol on V2/F
Effect of status of transplant on V2/F
Effect of gender on V2/F
Effect of triglycerides on V2/F
Effect of ethnicity on V2 /F

-19.2
-14.5
-11.4
-11.3
-11.0

<0.001
<0.001
<0.001
<0.001
<0.001

Effect of dose of sirolimus on CL/F
Effect of SLCO1B1,521T>C on CL/F
Effect of status of transplant on CL/F
Effect of g-glutamyl transferase on CL/F
Effect of dose of tacrolimus on CL/F
Effect of ABCB11,1331C>T on CL/F
Effect of hemoglobin A1C on CL/F

-12.7
-11.0
-10.8
-9.1
-8.9
-6.8
-5.3

<0.001
<0.001
<0.005
<0.005
<0.005
<0.01
<0.01

Effect of gender on VM/F

-13.7

<0.001

Effect of total bilirubin on Q/F
Effect of total protein on Q/F

-14.5
-7.4

<0.001
<0.01

Multivariate analysis
Effect of transplant status on CLM/F
Effect of gender on VM /F
Effect of lactate dehydrogenase on CLM/F

+30.0
+19.4
+8.9

<0.001
<0.001
<0.005

CLM/F, apparent total oral clearance of ATV-LAC; V2/F, apparent volume of distribution
of ATV in the central compartment; CL/F, apparent oral clearance of ATV to ATV-LAC;
VM/F, apparent volume of distribution of ATV-LAC in the central compartment; Q/F,
apparent inter-compartmental clearance of ATV, PON, paraoxonase; SLCO1B1, gene
encoding organic anion-transporting polypeptide; ABCB11, gene encoding breast cancer
resistant protein
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Table IV-3. The parameter estimates for the atorvastatin and metabolite population
models and the results of bootstrap validation of the final model.
Model parameter (units)

Estimate

Bootstrap median
(95% CI)

ka (hr-1)
V2/F (L)
CL/F (L/hr)
V3/F (L)
Q/F (L/hr)
CLM/F (L/hr)
VM/F (L)
QM/F (L/hr)
Effect of lactate dehydrogenase on
CLM/F
Effect of gender on VM/F
Effect of transplant on CLM/F

0.771
481
1126
5462
343
506
2349
748
0.479

0.762 (0.489, 1.02)
456 (159, 1020)
1120 (723, 1550)
5220 (1990, 9410)
341 (164,682)
499 (401, 597)
2280 (1100, 4070)
754(407, 1171)
0.496 (0.356, 0.689)

0.327
-0.944

0.337 (0.140, 0.691)
-0.979 (-1.66, -0.352)

Random effects
Inter-individual variance (2)
2 V2/F
2 CL/F
2 Q/F
2 CLM//F
2 VM/F

2.99
0.340
1.41
0.531
0.712

2.90 (0.544, 1.99)
0.332 (0.580, 0.934)
1.42 (0.105, 0.971)
0.520 (0.978, 2.17)
0.677 (0.813, 1.38)

Intra-individual variability (σ2)
Atorvastatin acid (ng/mL)
Atorvastatin lactone (ng/mL)

0.373
0.287

0.373 (1.79, 2.12)
0.283 (1.73, 1.98)

CLM/F, apparent total oral clearance of ATV-LAC; V2/F, apparent volume of distribution
of ATV in the central compartment; CL/F, apparent oral clearance of ATV to ATV-LAC;
VM/F, apparent volume of distribution of ATV-LAC in the central compartment; Q/F,
apparent inter-compartmental clearance of ATV
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ABSTRACT
Aim: To develop a whole-body physiologically-based pharmacokinetic model to
predict oral pharmacokinetics of atorvastatin acid as well as rosuvastatin acid with
their respective metabolites in the stable kidney transplant patients with diabetes
mellitus using in silico and experimentally measured input parameters.
Subjects and methods: A clinical study was conducted in the stable kidney transplant
recipients with diabetes mellitus to obtain plasma concentration-time profiles of the
parent drug and its metabolites. The kinetic parameters of metabolic clearance of
atorvastatin acid previously determined using human liver microsomal fractions
obtained from donors with diabetes mellitus were integrated in the model. In vitro
dissolution studies of both statins were carried out in different pH media to assess pH
dependent release profile. Simulations were implemented using the built-in Advanced
Compartmental Absorption and Transit (ACAT) model and Population Estimates for
Age-Related (PEARTM) physiology in GastroPlusTM software package (Simulations
Plus, Inc., Lancaster, CA, USA). The essential input parameters to construct
physiologically-based

pharmacokinetic

model

of

statins

were

measured

experimentally, in silico predicted and/or obtained from the literature.
Results:
The simulated plasma concentration-time profiles of both statins and their metabolites
were in a good correlation with mean plasma concentrations observed in study
patients. Berezhkovskiy algorithm utilized to determine tissue distribution of
perfusion-limited tissues as it successfully estimated observed high volume of
distribution for both statins. Parameter sensitivity analysis revealed that systemic
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exposure of both statins is most sensitive to change in intestinal transit time. The
stochastic simulation performed using virtual trial feature of the software showed that
the observed mean plasma concentration-time curves of both statins lie between 90%
confidence interval, maximal and minimal simulated concentrations of ten virtual
patients.
Conclusion: A whole-body physiologically-based pharmacokinetic model was
constructed to simulate systemic exposure of orally administered atorvastatin acid and
rosuvastatin acid with their metabolites in stable kidney transplant patients with
diabetes mellitus. This study also demonstrated that disease specific in vitro metabolic
clearance data are superior for an appropriate prediction of systemic exposure of the
drug that undergoes extensive metabolism, which might have changed due to altered
activity of drug metabolizing enzymes in specific disease state.
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INTRODUCTION

The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are
widely prescribed medication for treatment of hypercholesterolemia. Statins effectively
decrease elevated levels of low-density lipoproteins and total cholesterol and hence the
mortality rate has been drastically reduced in all over the world thereby, it remains the
drug of choice to prevent coronary heart diseases.1 Several lipid-lowering agents from
statins class including, fluvastatin, atorvastatin, pravastatin, rosuvastatin, lovastatin,
simvastatin pitavastatin are commercially available. Atorvastatin acid (ATV) is the
largest-selling prescribed medication while rosuvastatin acid (RST) is the most
efficacious among all statins.2

An active acid form of atorvastatin undergoes extensive first-pass metabolism after an
oral administration (10-80 mg/day). The drug is highly bound to plasma protein
(>98%) with an absolute oral bioavailability of 14%.1 It is extensively metabolized
mainly by intestinal and liver cytochrome P450 (CYP) 3A4 enzyme and forms
pharmacologically active ortho- and para-hydroxylated (o-OH-ATV and p-OH-ATV)
metabolites.3 The parent drug and its hydroxy acid metabolites remain in equilibrium
with their respective pharmacologically inactive lactone forms (ATV-LAC, o-OHATV-LAC and p-OH-ATV-LAC),4 which have 83-fold higher affinity for CYP3A4
and exhibit higher metabolic clearance.3,

5

Thus, it has been postulated that the

elimination of the parent drug occurs primarily via hydroxylation of ATV-LAC rather
than hydroxylation of the parent drug.3 Moreover, previous study reported nearly equal
systemic exposure of lactone metabolite as compared to an acid form.6 The formation
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of lactone is attributed to glucuronidation via UDP-glucuronosyltransferase (UGT)1A1
and 1A3,7 low pH environment4 and intermediate product of coenzyme A-dependent
pathway.8 On the other hand, lactones are hydrolyzed either chemically or
enzymatically9 mainly by paraoxonase 1 and 3 and esterases.10-12 The results of in vitro
study from our group indicated a predominant role of CYP3A4 in the
biotransformation of ATV-LAC,5 which is in consistent with previous findings.3 The
parent drug and its metabolites mainly excreted into the bile and approximately 1% of
the administered dose is excreted through renal route.1

Rosuvastatin acid has a modest absolute bioavailability (approximately 20%). It is
reversibly bound to 88% of plasma protein and also exhibits limited metabolism.
Rosuvastatin acid mainly excreted unchanged (76.8% of the dose) in feces.13 It is
primarily metabolized by isoenzyme CYP2C9 and to the minor extent through
CYP2C19 and CYP3A4,14 thereby it generates pharmacologically active principal
metabolite, N-desmethyl derivative.13 Furthermore, the formation of an inactive 5Slactone metabolite of rosuvastatin acid (RST-LAC) occurs via the glucuronidation
pathway.14 Fecal (approximately 90% of the dose) and renal (approximately 10% of
the dose) are the major and minor route of excretion of RST, respectively.13

Hepatic uptake transporter, organic anion-transporting polypeptide (OATP) 1B1, plays
a major role in an active uptake of ATV and its metabolites.15, 16Atorvastatin acid and
its metabolites are also substrates for efflux transporters including P-glycoprotein (Pgp),17,

18

and breast cancer resistant protein (BCRP),19 which govern their intestinal

absorption and hepatic elimination. Similarly, RST is transported into the liver by
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multiple

uptake

transporters

including

OATP1A2,

OATP2B1,

OATP1B3,

OATP1B1.20, 21 It is also a substrate of various efflux transporters such as BCRP, P-gp,
and MRP2 that mediate its intestinal and biliary excretion.19, 21, 22

Statins are well tolerated by most patients although skeletal muscle-related toxicity is
the most common reported side effect that develops after commencing statin therapy.
Myotoxicity is ranging from a mild condition called myalgia to rare but potentially
fatal rhabdomyolysis usually requiring hospitalization. Because of elevated incidence
of statin-associated rhabdomyolysis, cerivastatin was voluntarily withdrawn from the
United States market in 2001.23 A meta analysis study conducted by the United States
FDA including 130, 865 patients indicated three times higher incidence of fatal
rhabdomyolysis in diabetic patients.24 Significantly higher plasma level of ATV-LAC
was found in atorvastatin-treated patients experiencing myopathy.25 Moreover, an in
vitro study conducted using human skeletal muscle cell culture exposed to an acid and
lactone forms of statin showed that lactone form is more toxic to muscle cells than an
acid form.26 Furthermore, Skottheim et al. suggested that the lactone/acid
concentration ratio can potentially be utilized as a specific diagnostic tool to determine
patients at higher risk of developing statin-induced skeletal muscle toxicity.27 Recently,
we published both in vivo and in vitro studies that assessed the effect of diabetes
mellitus on the biotransformation of ATV.5 We found 3.56 times reduced clearance of
ATV-LAC metabolite in the stable kidney transplant recipients with diabetes mellitus5
because of down regulation of CYP3A4, the main metabolizing enzyme of ATV-LAC
in this population.28 It is essential to construct physiologically-based pharmacokinetic
(PBPK) models for statins to simulate its distribution in the liver and skeletal muscle to
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estimate their pharmacological and toxicological effects in patients with diabetes
mellitus.

Recently, in silico prediction by advanced computation technology has been widely
preferred for drug discovery and development to reduce the time and investment of
research by decreasing the need of extensive experimental work. Mechanistic
modeling tools integrate various information about the drug including estimated in
silico physicochemical and biopharmaceutical properties, experimentally measured in
vitro drug metabolism kinetic parameters and intestinal permeability to predict fraction
absorbed, oral bioavailability, intestinal and hepatic extraction. Several software
packages are available for mechanistic simulation including GastroPlusTM, SimCYP,
PKSim and IDEA.
GastroPlusTM is a mechanistically based simulation software program design for the
prediction of advanced absorption, physiologically-based pharmacokinetics/dynamics,
in vivo and in vitro extrapolation and drug-drug interactions. GastroPlusTM software
uses the Advanced Compartmental Absorption and Transit (ACAT) model,29 which is
the modified version of previously elucidated the original Compartmental Absorption
and Transit (CAT) model30-32 to incorporate a whole-body related various
physiological parameters to each interconnected hypothetical compartment. The
ACAT model comprised of total eighteen compartments including nine enterocytes
and nine gastrointestinal compartments. The gastrointestinal compartment starts from
stomach; followed by six small intestinal compartments, caecum and colon. Each
compartment defines several events including disintegration, dissolution, release,
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precipitation, luminal degradation, absorption/desorption, gut wall metabolism, uptake
of the drug, which are repeated in each compartment as it travels through different
segments of the gastrointestinal tract. Furthermore, physiological values of
gastrointestinal pH, mean transit times, permeability, fluid volume, dimension, bile salt
and pore size are incorporated in each compartment. The inter-compartmental transit of
the drug is illustrated by integrated series of linear and nonlinear differential equations.
To perform each simulation, the drug specific input parameters including pH
dependent solubility, logP, pKa, particle size, dose, in vitro kinetic data of enzymatic
biotransformation and transport mechanisms were fed into the software.

The aim of the study was to build PBPK models for ATV and RST to predict plasma
concentration-time profiles and tissue distribution of the parent drug and its
metabolites in the stable kidney transplant subjects with diabetes mellitus using
physiological and drug-related parameters.
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MATERIALS AND METHODS
Study design
The open-label crossover pharmacokinetic study of ATV and RST was carried out in
the diabetic stable kidney transplant recipients. The study protocol was approved by
the Institutional Review Board of Rhode Island Hospital (Providence RI, USA). The
procedures of the study were explained verbally to the study subjects, and thereafter
their signed informed consent was obtained.
Patient population
The ten stable kidney transplant male (n=7) or female (n=3) subjects with documented
diabetes mellitus (type 1 or 2) were recruited. The study participants comprised of
mainly Caucasian population with 51 years of mean age and 90.39 Kg mean body
weight. The patients were receiving a triple immunosuppressant regimen consisting of
mycophenolic acid either from mycophenolate mofetil (Cellcept™, Roche, Nutley, NJ)
or mycophenolate sodium (Myfortic, Novartis, East Hanover, NJ), tacrolimus and
prednisone. Patients with severe clinical gastroparesis, liver diseases, pregnancy,
abdominal surgery (within past 3 months), and history of inflammatory bowel disease
were excluded from the study. Moreover, patients taking concomitant medications,
which may alter gastric pH and gastrointestinal motility, were not recruited in the
study.
Pharmacokinetic study
Study subjects were notified to stop their statin medication at least 3 days prior the
study. Moreover, they were instructed to fast the night before the study day. The
participants were subjected to routine physical examination including height, weight

147

and blood pressure measurement on each day of the study. Thereafter, patients
administered a single 20 mg oral dose of rosuvastatin calcium (Crestor®, AstraZeneca
Pharmaceuticals LP, DE, USA) along with their routine medications including
immunosuppressant regimens. All patients were served two standardized diabetic meal
at the end of 6 h and 10 h after administration of statin medications including morning
low fat breakfast bar. Blood samples were collected in vacutainer tubes containing
lithium heparin as an anticoagulant at various time points (0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,
10 and 12 h) post-dose. The blood samples were centrifuged immediately at 1400xg
and plasma samples were diluted 1:1 with 0.1 M, pH 4.0 sodium acetate.33 The study
samples were stored at −80°C until analysis. The similar study procedures were
followed by the same participants after administering a single 40 mg oral dose of
atorvastatin calcium (Lipitor®, Pfizer Inc, NY, USA) after at least two weeks. For 12 h
post-dose pharmacokinetics study of ATV, blood samples were collected in vacutainer
tubes containing fluoride/potassium oxalate as an anticoagulant.33 The blood samples
were immediately centrifuged at 1400xg and plasma samples were stored at −80°C
until analysis.
Quantitative analysis of ATV, RST and their metabolites in human plasma
Plasma levels of ATV and its metabolites (ATV-LAC, o-OH-ATV and o-OH-ATVLAC) were determined using previously validated liquid chromatography-tandem mass
spectrometry (LC-MS/MS) assay.33 Briefly, the analytes and corresponding deuterium
(d5) labeled internal standards were extracted from 50 µL of human plasma using 200
µL of 0.1% v/v glacial acetic acid in acetonitrile as protein precipitating solvent. The
chromatographic separation of the analytes was achieved using a Zorbax-SB Phenyl
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column (2.1 mm × 100 mm, 3.5 µm) within 7.0 min using a flow rate of 0.35 mL/min.
Mobile phase consisting of a gradient mixture of 0.1% v/v glacial acetic acid in 10%
v/v methanol in water (solvent A) and 40% v/v methanol in acetonitrile (solvent B).
Mass spectrometry detection was carried out in positive electrospray ionization mode,
with multiple reaction monitoring scan. Calibration curves for all the analytes over the
concentration range of 0.05-100 ng/mL were used.33 Likewise, quantitative
determination of RST and its metabolite, RST-LAC in human plasma was carried out
using a previously reported validated LC-MS/MS assay.34 In brief, all the analytes and
the corresponding deuterium-labeled (d6) internal standards were extracted from 50 μL
of

buffered

human

plasma

by

protein

precipitation.

The

analytes

were

chromatographically separated using a Zorbax-SB Phenyl column (2.1 mm×100 mm,
3.5 μm). The mobile phase comprised of a gradient mixture of 0.1% v/v glacial acetic
acid in 10% v/v methanol in water (solvent A) and 40% v/v methanol in acetonitrile
(solvent B). The analytes were separated at baseline within 6.0 min using a flow rate of
0.35 mL/min. Mass spectrometry detection was carried out in positive electrospray
ionization mode. Calibration curves for both the analytes were linear (R≥0.9964, n=3)
over the concentration range of 0.1–100 ng/mL for RST and RST-LAC. Mean
extraction recoveries ranged within 88.0–106%. Intra- and inter-run mean percent
accuracy were within 91.8–111%, and percent imprecision was ≤15%. Stability studies
revealed that all the analytes were stable in matrix during bench-top (6 h on ice–water
slurry), at the end of three successive freeze and thaw cycles and during storage at
−80°C for 1 month.
In vitro dissolution study
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In vitro dissolution studies of ATV and RST were carried out using USP apparatus IIpaddle type, LID-8D dissolution tester (Vanguard Pharmaceutical Machinery, Inc.,
Spring, TX, USA). A single tablet dosage form of 40 mg of ATV and 20 mg of RST
per dissolution bath was used for dissolution experiments. The dissolution study was
performed using 0.1 M hydrochloric acid (1.2 pH) and 0.05 M ammonium acetate
buffer with 3, 4.5, 6.8 and 8 pHs as dissolution media. The pH of each dissolution
media was adjusted using glacial acetic acid or ammonium hydroxide. The dissolution
of ATV was carried out at 75 rpm speed, and samples were collected at 5, 10, 15, 30,
45, 60, 90, 120, 150, 180, 210 and 240 min. Similarly, dissolution of RST was carried
out at 50 rpm speed and samples were collected at 10, 20, 30, 45, 60, 90 120, 150, 180,
210 and 240 min. The volume of dissolution medium was 900 mL, and it was replaced
with fresh buffer equilibrated at 37 °C after each sampling. All dissolution experiments
were carried out in triplicates. The collected samples were immediately kept on dry ice
to minimize interconversion between acid and lactone forms and were analyzed using
HPLC-UV assay with slight modification of the methods described by Macwan et al.33,
34

Physiologically-based pharmacokinetic (PBPK) model structures
Computer hardware and the software
The simulations for disposition and absorption were performed using GastroPlusTM
version 8.0.0002 simulation software (Simulations Plus, Inc., CA, USA) on a Dell
laptop computer with Intel core i3 CPU M350 (2.27 GHz).
A whole-body disposition
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A whole-body PBPK modeling approach was utilized through the ACAT model in
PBPKTM module of the software. A separate whole-body PBPK models were built for
the disposition of the parent drug and each metabolite, and these were coupled via
gut/hepatic metabolism and/or transport, allowing simultaneous simulations of both the
parent drug and its metabolites. Built-in age, body weight, height, and genderdependent Population Estimates for Age-Related physiologyTM (PEAR) module was
used to generate human physiology for 51 years (mean age of study subjects) old an
American male patient with body weight of 90.4 kg (mean weight of study subjects)
based on the study population. The PEAR is generated based on data from the National
and Nutrition Examination Survey.35 The volume, weight and rate of blood perfusion
of each body tissue were computed from default balance model.
Prediction of disposition parameters of ATV
Intestinal permeability
Experimentally measured human jejunal permeability of many drugs using in vivo
perfusion methods is very limited. Computer based in silico prediction based on
chemical structure of the drug is widely preferred. The permeability of the drug
changes as it transit through different regions of the gastrointestinal tract due to
alteration of several parameters including regional pH, surface area, ionization, density
of villi and microvilli. Built-in optimized logD model scales regional permeability
based on these parameters. Furthermore, regional gastrointestinal absorption of the
drug is determined by human in silico effective jejunal permeability (S+Peff) and the
concentration gradient at the apical membrane of the enterocytes. Integrated
ADMETTM predictor module of GastroPlusTM computed human S+Peff based on built-
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in quantitative structure-property relationship model. Apparent jejunal permeability of
ATV was studied by rat infusion technique36 and the calculated human effective
jejunal permeability (Peff) value was equivalent to estimate of ADMETTM predictor.
CYP3A4, UGT1A1/3, OATP1B1 and P-gp kinetic constants
Atorvastatin acid is predominantly metabolized in the liver and gut mainly by CYP3A4
enzyme. Recently, we determined enzymatic metabolism kinetics of an acid and
lactone forms of atorvastatin using human liver microsomal fractions (HLMs) obtained
from donors with and without diabetes mellitus.5 Briefly, microsomal fractions were
prepared as illustrated previously 28 from human livers obtained from donors with and
without diabetes mellitus (Xenotech LLC, Lenexa, KA, USA) and were stored at
−80°C until analysis. Several concentrations of an acid and lactone forms of
atorvastatin were incubated with prepared HLMs. At the end of incubation, ice-cold
acetonitrile containing an internal standard was added to cease the reaction. The
samples were centrifuged, and the supernatant was injected onto an analytical column.
The quantitative determination of ATV and its five metabolites were performed using
previously described LC-MS/MS assay with slight modifications.33 Enzyme kinetic
parameters (Km and Vmax) of ATV and ATV-LAC were calculated using GraphPad
Prism (GraphPad Software, San Diego, CA, USA).
For the simulations, in vitro average Km (5.21 µM) and the sum of Vmax values (2593.7
pmol/min/mg microsomal protein) were used as input parameters for the formation of
CYP3A4 mediated para- and ortho-hydroxylated acid metabolites that obtained upon
incubation of ATV with HLMs from livers of diabetes donors.5 Moreover, from
available literature data, an average Km of 14 µM7,
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and fitted Vmax values for the

formation of ATV-LAC metabolite mediated mainly through UGT1A3 and UGT1A1
enzymes were integrated in the model to account for glucuronidation mediated
metabolism of ATV. The enzyme kinetic parameters of CYP3A4 and UGT1A1 were
applied to both the gut and liver while UGT1A3 was only applied to liver tissue due to
negligible expression in the intestine.38 All in vitro Vmax values were scaled to in vivo
Vmax based on either GastroPlusTM built-in or literature based absolute quantification
data of each enzyme. To incorporate OATP1B1 mediated hepatic uptake clearance of
ATV, an average of 0.85 µM and 5.225 pmol/min/mg39,
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of in vitro Km and Vmax,

respectively were fed into the model. The fitted Vmax and average Km of 112.5 µM17, 18
were applied only to canalicular membrane of liver for P-gp efflux transporter. To run
simulations, liver was considered a permeability-limited tissue, on the other hand, the
rest of the body tissues were perfusion-limited.
Volume of distribution
PBPKTM plus module of GastroPlusTM was utilized to determine tissue:plasma partition
coefficients

(Kps)

of

perfusion-limited

tissues

(non-hepatic

tissues)

using

Berezhkovskiy’s algorithm,41 which calculated Kps based on free concentrations of the
drug in plasma/tissue as well as the volume fractions of lipids including phospholipids
and neutral lipids, and body water. However, the partition of the drug between blood
and interstitial space for permeability-limited liver was determined using Poulin and
Theil method (extracellular)42,

43

that calculated Kps based on hematocrit and the

fraction unbound in plasma as well as in tissues.
Systemic clearance
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Atorvastatin acid is significantly metabolized in both the gut and liver mainly by
CYP3A4 enzyme. Furthermore, it is a substrate of hepatic OATP1B1 uptake
transporter that can modulate clearance of the drug, which is eliminated extensively by
hepatic metabolism; therefore, hepatic elimination plays a major role in overall
clearance of ATV. In the present study, as mentioned previously, CYP3A4 mediated in
vitro metabolism of ATV in HLMs obtained from livers of diabetes donors’ were
interpolated to the model to illustrate metabolic clearance of ATV and the formation of
the two hydroxylated metabolites. The kinetic parameters were converted to per mg
protein using a conversion factor of 0.37 nmol total CYP/mg protein.44
Scaling of in vitro metabolic clearance data to in vivo clearance was based on
measured amount of microsomal protein per gm liver and average liver size. The in
vitro Vmax values were scaled to in vivo by considering 111 pmol of CYP3A4/mg
microsomal protein,45 17.3 pmol of UGT1A3/mg microsomal protein,46 33.2 pmol of
UGT1A1/mg microsomal protein,46 38 mg of microsomal protein/gm of liver tissue47
and 1400 gm of average weight of liver.48All the values were corrected for non specific
binding to microsomes by in vitro unbound faction of 40.5%49 for accurate prediction
of metabolic clearance.
Prediction of in vivo dissolution rate
Actual in vivo solubility could be different from in vitro aqueous buffer solubility
because of presence of bile salt and lipids in the intestinal fluids. Biorelevant solubility
was determined to account for altered solubility with changes in bile salt
concentrations in different regions of intestine. The most accurate prediction of
absorption of the lipophilic drugs can be made by measuring biorelevant solubility in
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biologically relevant gastrointestinal media such fasted state simulated intestinal fluid
(FaSSIF), fed state simulated intestinal fluid (FeSSIF) and fasted state simulated
gastric fluid (FaSSGF). An equilibrium solubility of ATV measured in FaSSIF was 0.3
mg/mL,50 and it was used to run simulations along with in silico solubility of 0.0011
mg/mL and 0.69 mg/mL in simulated gastric fluid (SGF) and FeSSIF dissolution
medium, respectively due to unavailability of experimentally measured values. We
utilized default Johnson dissolution model in GastroPlusTM to predict dissolution rate.
Gastrointestinal absorption model
The default human fed physiology and optimized logD model SA/V 6.1 in the ACAT
model of the software was selected to calculate the changes in the rate of passive
absorption from gut lumen to enterocytes of dissolved drug as it transit through the
gastrointestinal tract. The default properties of individual gut compartment such as pH,
transit time, volume, length, radii, bile salt concentration, surface area enhancement
factors, and radius of pores between two adjacent cells were implicated in the model.
The ACAT model parameters are listed in Table V-1. Liver blood flow rate was
increased to 120 L/h for fed condition.51
The absorption rate coefficient of the drug in each segment of the gastrointestinal tract
was determined based on human S+Peff. The relative distribution of CYP3A4 and P-gp
in nine compartments of the gastrointestinal tract in the ACAT model was explained
previously.44 The quantitative expression of UGT1A1 in different segments of the
gastrointestinal tract was assumed based on available limited information.38
Prediction of disposition parameters ATV major metabolites
ATV-LAC
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The pH dependent distribution coefficients for tissue partition were calculated based
on experimentally measured logD7.0 of 4.2 previously reported by Ishigami et al.52
Other properties such as pKa, fup (fraction unbound in plasma), blood/plasma
concentration ratio and human Peff estimated by ADMETTM were interpolated to the
model. Our recent work demonstrated metabolic clearance of ATV-LAC and the
formation of o- and p-OH-ATV-LAC metabolites by using HLMs obtained from livers
of donors with diabetes mellitus.5 An average Km of 6.0 µM5 and fitted Vmax were
utilized to simulate concentration-time profile of o-OH-ATV-LAC. An in vitro Km
value was corrected for unbound fraction using default Austin factor.
o-OH-ATV
In silico estimates of ADMETTM predictor were implicated in the model due to
unavailability of experimental data. Previous work identified glucuronide metabolite of
o-OH-ATV in bile of rat and dog.53 Furthermore, to reflect low permeability of
glucuronide metabolite, human S+Peff was decreased from 1.12 x 104 to 0.8 x 104 cm/s.
Moreover, like ATV, o-OH-ATV metabolite is also a substrate of hepatic OATP1B1
uptake and intestinal P-gp efflux transporter.54 Fitted Km and Vmax constants for
OATP1B1 and P-gp were applied to basolateral side of liver and apical side of gut,
respectively due to lack of data.
o-OH-ATV-LAC
Due to deficiency of experimentally measured input parameters, in silico estimates by
ADMETTM predictor were included for mechanistic modeling of o-OH-ATV-LAC.
Unlike, o-OH-ATV further metabolic clearance of o-OH-ATV-LAC was not reported
in the literature. To simulate limited absorption of o-OH-ATV-LAC, fitted Km and

156

Vmax parameters for P-gp efflux transporter at apical side of gut were included. An
active hepatic uptake of o-OH-ATV-LAC was not considered due to relative more
lipophilicity than an acid form.
Prediction of disposition parameters of RST
Intestinal permeability
Similar to ATV, human S+Peff determined by ADMETTM predictor module was
incorporated to run all simulations for prediction of RST oral absorption and
pharmacokinetics.
UGT1A1, UGT1A3, OATP and BCRP pharmacokinetic constants
Rosuvastatin acid exhibit minimal hepatic metabolism, however, to simulate
concentration-time curve of lactone metabolite that forms via glucuronidation, enzyme
kinetic constants for UGT1A1 (applied to the liver and gut) and 1A3 (only applied to
liver) available in literature were integrated in the model14. The significant contribution
of hepatobiliary transport in disposition of RST mediated by several sinusoidal hepatic
OATP uptake transporters and BCRP canalicular efflux transporter were incorporated
in mechanistic modeling. The simulations utilized an average Km (4.93 µM) and the
sum of Vmax (12.3 pmol/min/mg) of OATP2B1, OATP1A2 and OATP1B3 reported by
Ho et al.20 Liver was considered a permeability-limited tissue. Similarly, for BCRP
efflux transporter, Vmax of 304 pmol/min/mg and an average Km value of 0.473 µM22, 55
obtained from the literature21 were added to canalicular membrane of liver tissue. To
simulate limited intestinal absorption, an average Km of 0.473 µM22, 55 for BCRP efflux
transporter was fed to gut tissues along with fitted Vmax.
Volume of distribution
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Mechanistic tissue composition equations defined by Berezhkovskiy41 were selected
for calculation of Kps from blood into cells for perfusion rate limited tissues because it
provided better estimate of observed high volume of distribution as compared to
Rodgers and Rowland method.56, 57
Berezhkovskiy assumed homogenous distribution of the drug into tissue and plasma. It
calculated tissue-plasma partition coefficient based on experimentally measured or in
silico predicted compound specific biopharmaceutical properties mainly pKa, logP,
fup, blood/plasma concentration ratio and species-specific tissue composition. The
partition of the drug between blood and interstitial space for permeability-limited liver
tissue was estimated using Poulin and Theil method (extracellular).42, 43
Systemic clearance
Limited

metabolic

clearance

of

RST

through

lactonization

mediated

by

glucuronidation pathway involving mainly UGT1A1 and 1A314 enzymes was
integrated in the ACAT model for gut and PBPK tissues to estimate its overall
clearance. As mentioned in the previous section, in vitro enzyme kinetic constants
were scaled to in vivo by assuming 17.3 pmol of UGT1A3/mg microsomal protein,46
33.2 pmol of UGT1A1/mg microsomal protein,46 38 mg of microsomal protein/gm of
liver tissue47 and 1400 gm of average weight of liver.48 Similarly, in vitro data for
multiple OATP transporters mediated active uptake clearance were applied to
permeability-limited liver tissue.20 The value was scaled to in vivo assuming 85 mg
membrane protein/gm liver.58 The relative regional distribution of BCRP efflux
transporter at the apical side of gut was studied earlier by Englund et al.59 Renal
clearance was estimated from fup and glomerular filtration rate.
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Prediction of in vivo dissolution rate
Experimentally measured in vitro dissolution release vs time profile was incorporated
and default Johnson dissolution model was employed. In silico estimates of solubility
in SGF, FaSSIF and FeSSIF dissolution medium were used for mechanistic modeling
due to lack of data.
The physiologically-based ACAT model of the human gastrointestinal tract
Because of cross over study design, the same subjects received 20 mg of Crestor ®;
therefore, human fed physiological model was selected as described in the prior section
of atorvastatin acid. The ACAT physiological model parameters employed in the
simulation of RST and RST-LAC are showed in Table V-2.
Gastrointestinal absorption model
In silico human Peff was chosen for PBPK model building of RST. Lactonization of
RST is mediated by UGT1A1 enzyme in both the gut and liver. The relative expression
of UGT1A1 in each compartment of the gastrointestinal tract in the ACAT model was
determined based on prior information.38 Furthermore, intestinal absorption at apical
side that is governed by BCRP efflux transporter was included by feeding its
expression levels throughout the gastrointestinal tract59 along with kinetic constants.
Prediction of disposition parameters RST metabolite
RST-LAC
Because of unavailability of human Peff and other biopharmaceutical properties such as
pKa, fup, blood/plasma concentration ratio and reference solubility, estimates of
ADMETTM predictor module were used to perform simulations. The logD7.4 of 1.2 was
reported previously.60
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Virtual trial simulations
The population simulator mode in GastroPlusTM permits the user to evaluate the
combined effects of inter-individual variability in population physiology and the
predicted disposition parameters along with formulation/compound specific properties
using a whole-body PBPK model linked with Monte Carlo simulation. A stochastic
simulation generates variability in each variable by random sampling of each variable
parameter from predefined distribution for each simulation. The trial was performed
for ten virtual patients, which is equal to the number of patients participated in our
clinical study. The virtual trial studies were conducted using GastroPlusTM standard
physiological conditions and compound-specific characteristics, which were sampled
randomly from log-normal distributions via Monte Carlo method. Moreover,
predefined coefficient variations that randomly created based on their mean values in
GastroPlusTM were used in simulations.
Parameter sensitivity analysis
Parameter sensitivity analysis feature of GastroPlusTM was utilized to assess the
sensitivity of predicted disposition parameters to key input elements. The key input
parameters, which are likely to affect plasma concentration-time curve based on
available literature information were separately varied over a broad range of values to
conduct parameter sensitivity analysis.
Sensitivity of pharmacokinetic parameters of ATV including maximum plasma
concentration (Cmax), time to reach Cmax (Tmax) and area under the plasma
concentration-time curve (AUC) were assessed with changes in transit time of the
stomach and small intestine, stomach pH, kinetic parameters of CYP3A4 and
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OATP1B1. Similarly, using PBPK model of RST, the effect of variations in input
parameters including transit time of the stomach and small intestine, stomach pH, Km
and Vmax of BCRP and OATP1B1 on simulated pharmacokinetic parameters was
evaluated.
Unit converter
Metabolism and transporter module in GastroPlusTM comprises a convenient unit
converter. Built-in unit converter is a conversion tool for simple unit conversion that
converts units of all Km (mg/L) and Vmax (mg/s/mg-enzyme) values obtained from the
literature to get suitable units of inputs for simulations in GastroPlusTM.
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RESULTS
PBPK modeling of ATV and its three metabolites
GastroPlusTM default PBPKTM module along with in vitro clearance data was used to
describe oral absorption and pharmacokinetics of ATV and its three metabolites.
In

silico

or

experimentally

measured

physiochemical/biopharmaceutical

properties
Intestinal permeability
The ADMETTM predictor estimated value of intestinal permeability based on chemical
structure of the compound predicted the disposition parameters of ATV.
pKa, blood/plasma concentration ratio, fup and logD
Several biopharmaceutical properties of the drug including blood/plasma concentration
ratio, fup and logD strongly influence hepatic bioavailability and thus hepatic
clearance.
Blood/plasma concentration ratio of 0.25 for ATV reported in the literature was
selected for the modeling.61 Atorvastatin acid is highly bound to plasma protein. The
plasma unbound fraction of 2% was reported by Lennarnas et al.1 The pKa value of 4.6
was obtained from Pfizer (in house data). The logD7 of 1.53 previously measured by
Ishigami et al.52 was utilized in the simulations. For mechanistic modeling of all three
metabolites, in silico estimates of physiochemical properties were utilized due to lack
of experimentally measured values. The key physicochemical and biopharmaceutical
parameters are presented in Table V-3.
PBPK Modeling
Prediction of systemic clearance
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Previously our group demonstrated in vitro metabolism of an acid and lactone forms of
ATV using HLMS. The clinical observations were collected from patients with
diabetes mellitus; therefore, model building was performed using metabolic intrinsic
clearance values of diabetes livers reported by Dostalek et al.5 These in vitro values
were scaled to calculate in vivo Km and Vmax except for in vitro Vmax of ATV-LAC as
explained in detail in the method section. An attempt was made to assess the effect of
metabolic intrinsic clearance data of ATV for non diabetic livers5 on its disposition. As
expected, the model under-predicted the observed plasma concentration-time profile.

Transporter mediated an active uptake clearance is the rate-limiting step for overall
hepatic elimination of ATV;62 therefore, permeability-limited liver was selected in the
proposed model to predict overall hepatic clearance. Metabolic and uptake clearance
pathways for overall elimination of ATV incorporated in the model successfully
described the observed clinical plasma concentration-time profile of the parent drug
following oral dosing within 20% error (Table V-5) together with three metabolites
depicted from Figure V-1a and Figure V-1b.
Prediction of volume of distribution
Initially Rodgers and Rowland equations56,

57

were assessed for Kps calculation of

perfusion-limited tissues. However, the estimated volume of distribution of ATV was
very low as compared to observed; therefore, Berezhkovskiy algorithm was utilized to
calculate Kps to determine tissue distribution of perfusion-limited tissues as it
adequately predicted observed large volume of distribution of ATV. The estimated
volume of distribution determined based on in silico Kps, tissue volumes and blood
perfusion successfully explained extensive peripheral tissue binding of ATV.1
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In vitro dissolution study and prediction of in vivo solubility
Atorvastatin acid was completely dissolved in dissolution medium with high pH such
as ≥6.8 as shown in Figure V-2a. The dissolution studies performed at low pHs
including 1.2 and 3 indicated poor dissolution along with the formation of lactone form
(Figure V-2b), which was in accordance with results shown by Kearny et al.4 The
formation of ATV-LAC was higher at very low pH, 1.2 as compared to pH 3 and its
absence at higher pH reflected instability in basic medium (Figure V-2c). The
systemic exposure of ATV was under-predicted when measured in vitro dissolution vs
time data was integrated in dissolution model could be because of significant
differences between its aqueous and biorelevant solubility.
Gastrointestinal absorption model
A whole-body PBPK simulation approach in GastroPlusTM allowed determining the
relative contribution of different gastrointestinal regions to the overall absorption of
the drug. In silico simulated compartmental absorption of ATV in the human
gastrointestinal tract following an oral administration of 40 mg tablet resulted in total
fraction of dose absorption of 99.6%. The predicted highest absorption (58.1%) of
ATV occurred in jejunum followed by duodenum (17.7%) and ileum (13.6%) of total
fraction of dose absorbed.
Virtual trial simulations
Simulations after an oral dosing of 40 mg of ATV in ten virtual patients were
compared with mean observed plasma concentration-time curve. The result of virtual
trial simulations is presented in Figure V-3. The figure shows mean plasma
concentrations vs time profile of ten virtual patients along with observed
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concentrations. Moreover, green shaded area represents 90% confidence interval of the
simulated data around the mean of the predictive values. The solid blue, dashed, and
dotted lines show individual simulated results that include 100, 95, 90, 75, 50, 25, and
10% of the range of simulated data. The observed mean plasma concentration-time
curve lay between 90% of confidence interval, maximal and minimal virtual patients
and was adequately well illustrated by the generated concentration-time curves of
virtual population.
Parameter sensitivity analysis
The results of parameter sensitivity analysis indicated that AUC and Cmax parameters
relatively slight sensitive to in vitro transporter kinetic parameters contrary, insensitive
to in vitro enzymatic clearance data. The parameter sensitivity analysis identified that
AUC and Cmax parameters were the most sensitive to changes in small intestinal transit
time and stomach pH, respectively.
PBPK modeling of rosuvastatin acid and its lactone metabolite
GastroPlusTM default PBPKTM module in combination with the drug-related properties
and in vitro clearance data was employed to predict oral pharmacokinetics of RST and
its lactone metabolite.
In silico estimated or experimentally measured physiochemical and/or
biopharmaceutical properties
Intestinal permeability
The human Peff of RST and RST-LAC, estimated by ADMET PredictorTM module of
GastroPlusTM based on quantitative structure–property relationship was 0.74 x 10-4 and
1.09 x 10-4 cm/s, respectively.
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pKa, blood/plasma concentration ratio, fup and logD
Rosuvastatin acid is a hydrophilic statin and logD7.4 of -0.3360 was used for simulation
to reflect its poor membrane permeability. The fup (9.4%) and blood/plasma
concentration ratio (0.56) reported by Jones et al. were incorporated in the model.63
The key physicochemical and biopharmaceutical parameters for simulations are
included in Table V-4.
PBPK Modeling
Prediction of systemic clearance
The recent in vitro study published by Jones et al. measured hepatic metabolic and
uptake clearance of various OATP substrates including RST using HLMs and
sandwich culture human hepatocytes, respectively.63 According to study results, no
measurable CYP enzyme mediated metabolism in HLMs was found for RST, was in
agreement with observations of previous work64 indicating its insignificant
metabolism. Furthermore, study reported by Prueksaritanont et al. demonstrated
glucuronidation metabolism of RST and the subsequent formation of lactone
metabolite mainly by UGT1A1 and UGT1A3 enzymes.14 Moreover, carrier-mediated
uptake clearance by several hepatic OATP transporters is the major clearance pathway
for RST.65 An average Km and the sum of Vmax for multiple OATP transporters
including OATP1A2, 2B1 and 1B3 reported by Ho et al.20 were chosen to determine
overall hepatic uptake clearance. These in vitro values were scaled as explained in
detail in the method section to calculate in vivo Km and Vmax to determine overall
systemic clearance. There was a good agreement between model predicted and
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clinically observed mean plasma concentration-time profile (within 1.5 fold) of RST
following an oral dosing (Figure V-4 and Table V-5).
Prediction of volume of distribution
Rodgers and Rowland equations were assessed for Kps calculation of perfusion-limited
tissues in the beginning. However, the predicted volume of distribution of RST was
very low than the observed value; therefore, Berezhkovskiy algorithm was utilized to
calculate Kps to determine tissue distribution of perfusion-limited tissues as it well
described the observed large volume of distribution of RST. The estimated volume of
distribution calculated based on in silico Kps, tissue volumes and blood perfusion
adequately explains extensive peripheral tissue binding of RST.1
In vitro dissolution study and prediction of in vivo solubility
Rosuvastatin

acid

is

a

biopharmaceutics

classification system

(BCS)

and

biopharmaceutical drug disposition classification system (BDDCS) class III drug with
high solubility and low permeability. It was completely dissolved in dissolution
medium of all pH ranges as shown in Figure V-5a and b. The minor formation of
lactone form occurred at pH 1.2 as shown in Figure V-5c.
Default Johnson dissolution model, which represents the Nernst-Bruner dissolution
equation along with in vitro release input used to compute RST dissolution rate.
Gastrointestinal absorption model
The PBPK module of GastroPlusTM permits to assess the relative contribution of
various regions of the gastrointestinal tract to the absorption of the drug. In silico
simulated human gastrointestinal compartmental absorption of RST following an oral
administration of 20 mg tablet predicted maximum absorption of total fraction of
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absorbed dose in jejunum followed by ileum and duodenum regions of the small
intestine (data are not presented).
Virtual trial simulations
Like ATV, simulated plasma concentration-time profiles followed by administration of
an oral dose of 20 mg of RST in virtual subjects were compared with observed plasma
concentration-time profile as described above. The observed plasma concentrationtime curve lay between 90% of confidence interval, maximal and minimal virtual
patients (Figure V-6). The observed plasma concentration-time graph matches
adequately by the created concentration-time curves of virtual population.
Parameter sensitivity analysis
The result of parameter sensitivity analysis indicated that AUC and Cmax
pharmacokinetics parameters were the most sensitive to changes in small intestinal
transit time. Moreover, they are less likely to be affected by changes in stomach pH
and are not sensitive to change in stomach transit time, kinetic parameters of BCRP
and OATP1B1 transporters (data are not shown).
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DISCUSSION

The objective of the study was to develop a whole-body PBPK model that
mechanistically characterized observed plasma concentration-time courses of two
widely prescribed statins, which disposition governs by various complex phenomenon
including gut-liver first-pass effect and/or biliary secretions and active hepatic uptake.
A whole-body PBPK modeling of both statins were performed using GastroPlusTM
software through single simulation mode by required input parameters, which were
experimentally measured, in silico estimated and/or obtained from the available
literature. The present mechanistic model accurately described the observed
concentrations in spite of the complex mechanism governing the absorption and
elimination especially in case of ATV.
Atorvastatin acid, a BCS and BDDCS class II50 drug, is highly soluble and permeable
and therefore, complete absorption was predicted.1 Atorvastatin acid, a hydroxy acid
form with an acidic pKa of 4.6 showed significant pH dependent Caco-2 permeability
with highest permeability at low apical pH. The pH in the proximal portion of the
small intestine is low as compared to the distal end; therefore, the region specific rate
of absorption of ATV estimated from in silico simulations was higher in the duodenum
and jejunum as compared to ileum and caecum. Jejunum being the highest absorption
site as compared to duodenum could be because of large surface area due to the
presence of more villi and microvilli. Unlike ATV, both hydrophilicity and BCRP
intestinal

efflux

transporters

played

a significant role

absorption of RST at apical side of intestinal lumen.
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Atorvastatin acid is metabolized mainly by CYP3A4 and UGT1A1/3 in both the gut
and liver. The lactone form of atorvastatin is more lipid soluble as compared to an acid
form based on their reported differences in logD7.0.52 The major mechanism governing
hepatic distribution of an acid and lactone forms of atorvastatin were an active uptake
and passive diffusion, respectively, which is in accordance with their distribution
coefficient at physiological pH.66 Relative importance of hepatic OATP influx
transporters for an active uptake of ATV was demonstrated. The results indicated
hepatic uptake process as rate-limiting step for its hepatic clearance.62 Moreover, in
vitro studies that characterized metabolic clearance5 and hepatic transport39,

40, 66

indicated an active hepatic uptake as a rate-determining step in overall hepatic
elimination; therefore, a permeability-limited liver model was selected to elucidate
hepatic disposition of ATV. Mechanistic modeling of ATV integrating only in vitro
metabolic clearance data resulted in significant under-prediction of oral clearance,
which is accordance with previous study.67 The proposed whole-body PBPK model
adequately predicted observed data considering the significant active hepatic uptake
clearance. A previously reported PBPK model indicated permeability-limited hepatic
disposition of various statins such as simvastatin68 pravastatin,69 which is in
accordance with our observation. Moreover, an appropriate selection of available
literature data for metabolic and uptake clearance allowed the model to predict
observed plasma concentration-time profile satisfactorily without the need of
additional scaling factors.

The overall hepatic intrinsic clearance of permeability-limited liver can be expressed
by the following equation based on a clearance concept70 :
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CLint, overall = PSu, influx ×

CLint, met
PSu, efflux + CLint, met

Where,
CLint, overall= overall hepatic clearance
PSu,influx= membrane permeability–surface area products of free drugs across the
basolateral membrane for the influx process
PSu,efflux= membrane permeability–surface area products of free drugs across the
basolateral membrane for the efflux process
CLint, met= Intrinsic metabolic clearance

When PSu,efflux is significantly greater than CLint, met, and transfer of the drug from in
and out of cells are similar then overall hepatic clearance is determined by CLint, met.
Moreover, overall clearance predominantly driven by an active uptake clearance, when
CLint, met is considerably more than PSu,efflux and therefore, an alteration of metabolic
clearance might not have any significant impact on overall systemic exposure.

A clinical study observed similar plasma levels of an acid and lactone forms of
atorvastatin.6 In vitro studies indicated metabolic clearance of lactone metabolite
mainly through CYP3A4 as one of the major mechanisms for elimination of ATV.3, 5
Furthermore, our group revealed a significant reduction (3.56 times) in clearance of
ATV-LAC in the stable kidney transplant recipients with diabetes mellitus and
thereafter, observed significantly increased plasma levels of ATV-LAC due to down
regulation of primary metabolizing enzyme, CYP3A4. As a result, an in vitro enzyme
kinetic study conducted by Dostalek et al. revealed statistically significant reduction in
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clearance of hydroxylated metabolites for both an acid and lactone forms of ATV in
HLMs of donors with diabetes.5

For mechanistic modeling of ATV, observed plasma concentrations were obtained
from the kidney transplant subjects with diabetes mellitus. To reflect significantly
reduced clearance of an acid and lactone forms of ATV in diabetes study participants,
in vitro data obtained from HLMs of donors with diabetes mellitus was selected.
Besides our group, to the best of our knowledge, only a single in vitro study
determined enzyme kinetic parameters for metabolic clearance of lactone form
together with an acid form of atorvastatin. However, the detail characteristics of liver
tissues were not defined.3 The model under-predicted the observed concentration-time
curve of ATV when enzyme kinetic data for metabolic clearance of an acid form
obtained from HLMs of donors without diabetes mellitus were integrated (data are not
shown). Moreover, the optimized Vmax value was significantly lower than
experimentally measured in vitro value. The possible reasons could be : 1) the
simulated concentrations in the cytoplasm of hepatocytes could be different from
concentrations in HLMs; 2) contribution of isoform of CYP enzymes was not
considered71; 3) substantial differences in activities of enzymes in non physiological
media72; 4) incorrect presumption of a rapid equilibrium between blood and
hepatocytes73; 5) inter-individual differences between in vivo and in vitro livers
attributed to inherent variability.74

We demonstrated that metabolic clearance data generated from HLMs of donors from
patients with diabetes mellitus was superior for the prediction of concentration-time
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graph of ATV in this population. Atorvastatin acid is also significantly metabolized to
ortho- and para-hydroxylated glucuronides.53 Ortho-hydroxy atorvastatin acid
undergoes significant glucuronidation and excreted into bile of rat and dog.53 It is
believed that ortho-hydroxy glucuronidated metabolite pumped back out into the
intestinal lumen and may exhibit enterohepatic recirculation.53 They are believed to be
a substrate of hepatic OATP uptake transporter because of its relatively low
lipophilicity. The P-gp efflux transporter at intestinal apical side was applied to reflect
limited intestinal absorption of observed levels of o-OH-ATV metabolite.54 Similarly,
restricted intestinal absorption of o-OH-ATV-LAC was predicted by considering
efflux by P-gp at intestinal apical side.

Metabolic clearance is insignificant for elimination of RST. However, predicted
biotransformation in lactone metabolite via UGT pathways was consistent with our
clinical observations. Like ATV, various studies indicated dominant contribution of
multiple hepatic OATP uptake transporters in hepatic elimination of RST.16, 20, 21, 75, 76
Moreover, a canalicular efflux transporter, BCRP, efficiently facilitates its biliary
excretion.19, 22, 55 A permeability-limited liver model was chosen to determine overall
hepatobiliary disposition of RST. The model over-predicted observed plasma
concentrations when BCRP mediated intestinal transport was not incorporated. This
observation suggested significant contribution of BCRP transporters in intestinal
absorption.

Parameter sensitivity analysis revealed that small intestinal transit time and gastric pH
can significantly affect the AUC and Cmax of the ATV, respectively. Delayed small
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intestinal transit time and significant intragastric pH differences in patients with
diabetes have been reported previously.77, 78 These physiological changes may result in
higher systemic exposure of ATV that can increase the risk of muscle toxicity in
diabetes population.79

Similar to ATV, parameter sensitivity analysis was performed to understand the effect
of various input parameters on AUC and Cmax of RST. The analysis showed that
systemic exposure is the most sensitive to changes in small intestinal transit time.
Delayed small intestinal transit time may have considerable implication on therapeutic
and toxicological properties of RST in population with diabetes mellitus. On the other
hand, previous study reported that changes in hepatic uptake activities markedly affect
plasma concentration-time course of pravastatin in rat80 and human.69 The PBPK
model of pravastatin, a hydrophilic statin resembles RST was constructed using ten
virtual healthy volunteers.69 However, the present PBPK modeling was performed in
transplant patients with diabetes mellitus and was capable to capture influential
gastrointestinal parameters that might have changed in disease conditions and can
affect systemic exposure of statins.
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CONCLUSION

In summary, a mechanistic modeling approach was used to predict oral
pharmacokinetics of ATV and RST with their respective metabolites using a blend of
input parameters obtained from in silico, in vivo and in vitro measurements without the
need for scaling factors. The present PBPK model of ATV that integrated in vitro
enzyme kinetic data generated using HLMs from donors with diabetes was superior for
the prediction of plasma concentration-time curve of ATV in patients with diabetes
mellitus. In vitro kinetic parameters obtained from tissues of donors with specific
disease that may alter the activity of drug enzyme metabolizing enzyme and
transporters as a result influence the pharmacokinetics may be superior for accurate
prediction of absorption and metabolism in specific population.
The present work demonstrated the ability of the ACAT model within GastroPlusTM to
simulate observed plasma concentration-time profiles of statins for, which intestinalhepatic metabolism and/or various influx-efflux transporters play a prominent role in
their disposition. This work demonstrated the mechanistic and model-driven
application of in vitro uptake and efflux kinetic data for predicting transporter
mediated disposition of statins. A generic whole-body PBPK based modeling approach
can advance the reasonable predictions of the parent drug with their metabolites in
particular population.
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Figure V-1a. Simulated and observed human oral mean plasma concentration-time
profiles for atorvastatin acid and atorvastatin lactone metabolite
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Figure V-1b. Simulated and observed human oral mean plasma concentration-time
profiles for an acid and lactone from of ortho-hydroxy atorvastatin metabolites
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Figure V-2 (a) Mean (n=3) dissolution profiles of atorvastatin acid in different pH
media. (b) Mean (n=3) concentrations of an acid form of atorvastatin in dissolution
media with pH 1.2, 3, 4.5, 6.8 and 8 (c) Mean (n=3) concentrations of lactone form of
atorvastatin in dissolution media with pH 1.2 and 3
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Figure V-3. Virtual trial simulation for ten subjects following a 40 mg oral dose of
atorvastatin acid. Solid line shows the mean of simulated concentrations of ten
subjects. Square with error bar represents the clinical observations. The green
highlighted area represents 90% confidence interval of simulated concentrations data.
The solid blue, dashed, and dotted lines represent individual simulated results that
incorporate 100, 95, 90, 75, 50, 25, and 10% of the range of simulated data.
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Figure V-4. Simulated and observed human oral mean plasma concentration-time
profiles for rosuvastatin acid and its lactone metabolite.
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Figure V-5. (a) Mean (n=3) dissolution profiles of rosuvastatin acid in different pH
media. (b) Mean (n=3) concentrations of an acid form of rosuvastatin in dissolution
media with pH 1.2, 3, 4.5, 6.8 and 8 (c) Mean (n=3) concentrations of lactone form of
rosuvastatin in dissolution media with pH 1.2
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Figure V-6. Virtual trial simulation for ten subjects following a 20 mg oral dose of
rosuvastatin. Solid line shows the mean of simulated concentrations of ten subjects.
Square with error bar represents the clinical observations. The green highlighted area
represents 90% confidence interval of simulated concentrations data around mean. The
solid blue, dashed, and dotted lines represent individual simulated results that
incorporate 100, 95, 90, 75, 50, 25, and 10% of the range of simulated data.
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Table V-1. The ACAT physiological model compartment parameters of default fed human physiology used in simulations of
atorvastatin acid and three metabolites in GastroPlusTM .
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Compartment

ASF
(cm-1)

pH

Stomach
Duodenum
Jejunam1
Jejunam2
Ileaum 1
Ileaum 2
Ileaum 3
Ceacum
Ascending colon

0.0
2.774
2.760
2.675
2.583
2.534
2.435
1.160
1.508

4.9
5.4
5.4
6.0
6.6
6.9
7.4
6.4
6.8

Transit
time
(h)
1.00
0.26
0.95
0.76
0.59
0.43
0.31
4.50
13.5

Volume
(mL)
1000
48.25
175.3
139.9
108.5
79.48
56.29
52.92
56.98

Length Radius
P-gp
(cm)
(cm)
expression
30
15
62
62
62
62
62
13.75
29.02

10
1.60
1.50
1.34
1.18
1.01
0.85
3.50
2.50

0.0
0.538
0.645
0.723
0.770
0.838
0.908
1.000
1.000

CYP3A4
expression

UGT1A1
expression

0.0
2.09E-3
3.26E-3
3.26E-3
1.03E-3
1.03E-3
1.03E-3
3.1E-4
3.1E-4

0.0
6.3E-4
1.0E-3
1.0E-3
3.2E-4
3.2E-4
3.2E-4
2.0E-4
2.0E-4

Table V-2. ACAT physiological model compartment parameters of default fed human physiology used in simulations of
rosuvastatin acid and lactone metabolite in GastroPlusTM .

Compartment
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Stomach
Duodenum
Jejunam1
Jejunam2
Ileaum 1
Ileaum 2
Ileaum 3
Ceacum
Ascending colon

ASF
(cm-1)
0.0
2.778
2.763
2.674
2.584
2.540
2.456
0.164
0.232

pH
4.9
5.4
5.4
6.0
6.6
6.9
7.4
6.4
6.8

Transit time
(h)
1.00
0.26
0.95
0.76
0.59
0.43
0.31
4.50
13.5

Volume
(mL)
1000
48.25
175.3
139.9
108.5
79.48
56.29
52.92
56.98

Length
(cm)
30
15
62
62
62
62
62
13.75
29.02

Radius
(cm)
10
1.60
1.50
1.34
1.18
1.01
0.85
3.50
2.50

BCRP
expression
0.0
0.60
0.60
0.60
1
1
1
0.40
0.40

UGT1A1
expression
0.0
6.3E-4
1.0E-3
1.0E-3
3.2E-4
3.2E-4
3.2E-4
2.0E-4
2.0E-4

Table V-3. Summary of key biopharmaceutical properties and in vitro data of atorvastatin acid (ATV), atorvastatin lactone
(ATV-LAC), ortho-hydroxy atorvastatin acid (O-OH-ATV) and ortho-hydroxy atorvastatin lactone (O-OH-ATV-LAC).
Parameter
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Molecular weight
logP/logD7.4
pKa acid
Fraction unbound in plasma (%)
Blood/plasma concentration ratio
Human Peff (X10-4 cm/s)
Reference solubility (mg/mL) @ pH
Dose (mg)
Mean particle radius (µM)
Mean precipitation time (s)
Diffusion coefficient (X10-4 cm/s)
CYP3A4 Km (µM)
CYP3A4 Vmax: gut/PBPK
[(mg/s)/(mg/s-mg enzyme)]
UGT1A1 Km (µM)
UGT1A1 Vmax: gut/PBPK
[(mg/s)/(mg/s-mg enzyme)]
UGT1A3 Km (µM)
UGT1A3 Vmax: PBPK
(mg/s-mg enzyme)
OATP1B1 Km (µM)
OATP1B1 Vmax : PBPK
[(mg/s)/(mg/s-mg transporter)]
P-gp Km (µM)
P-gp Vmax: gut or PBPK
[(mg/s)/(mg/s-mg transporter )]
a=Estimated by ADMET PredictorTM
b=Fitted value
NA=not applicable
*= Data obtained from Pfizer Inc

ATV
Value
558.65
1.53@pH 7
11.36/4.6
2
0.25
1.11
0.021@2.1
40
25
900
0.51
1.179
1.699/3.8x10-3

Source
a

3.168
2/0.07

7, 37

3.168
0.007

7, 37

0.0095
0.584x10-5

39, 40

1.257
0.0005
(PBPK)

17

52

a/*
1
61

a
4

NA
a
a
a
5
5

b

b

39, 40

b

ATV-LAC
Value
Source
540.64
a
52
4.2@pH 7
11.16
a
2.71
a
0.66
a
1.48
a
-3
4.4X10 @7
a
NA
a
25
a
900
a
0.53
a
5
0.604
-5
5
0.069/10

O-OH-ATV
Value
Source
574.65
a
4.42
a
10.97/9.14/4.7
a
0.93
a
0.54
a
0.8
b
0.17@4.17
a
NA
a
25
a
900
a
0.51
a
NA
NA
NA
NA

O-OH-ATV-LAC
Value
Source
556.64
a
5.22
a
10.83/9.02
a
4.51
a
0.65
a
1.48
a
-3
9.84X10 @6.8
a
NA
a
25
a
900
a
0.53
a
NA
NA
NA
NA

NA
NA

NA
NA

3.057
0.1/0.007

b
b

NA
NA

NA
NA

NA
NA

NA
NA

3.057
0.07

b
b

NA
NA

NA
NA

NA
NA

NA
NA

1.535
0.012

b
b

NA
NA

NA
NA

NA
NA

NA
NA

25.03
0.3
(Gut)

b
b

20.03
0.02
(Gut)

b
b

Table V-4. Summary of key biopharmaceutical properties and in vitro data of rosuvastatin acid and rosuvastatin lactone used
in the PBPK simulations.

Parameter
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Molecular weight
logP/logD7.4
pKa acid or base
Fraction unbound in plasma (%)
Blood/plasma concentration ratio
Human Peff (X10-4 cm/s)
Reference solubility (mg/mL) @ pH
Dose (mg)
Mean particle radius (µM)
Mean precipitation time (s)
Diffusion coefficient (X10-4 cm/s)
UGT1A1 Km (µM)
UGT1A1 Vmax: gut/PBPK [(mg/s)/(mg/s-mg enzyme)]
UGT1A3 Km (µM)
UGT1A3 Vmax: PBPK (mg/s-mg enzyme)
BCRP Km (µM)
BCRP Vmax: gut/PBPK [(mg/s)/(mg/s-mg transporter)]
OATP Km (µM)
OATP Vmax: PBPK (mg/s-mg transporter)
* and # = Base pKa estimated by ADMET PredictorTM
a = Estimated by ADMET PredictorTM
NA= not applicable

Rosuvastatin
Value
481.55
-0.33@ pH 7.4
4.2/1.7*/-3.17*
9.4
0.56
0.74
0.79@3.72
20
25
900
0.57
11.72
0.07077/0.00092
11.72
0.00023
0.471
0.007/0.000293
2.942
7.13X10-5

acid
Source
a
63
63

/a/a

63
63

a
a
NA
a
a
a
14
14
14
14
22, 55
21
20
20

Rosuvastatin lactone
Value
Source
463.53
a
60
1.2@7.4
#
#
1.31 /-3.33
a
9.13
a
0.76
a
1.09
a
0.12@7
a
20
NA
25
a
900
a
1.2
a
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

Table V-5. Summary of observed and predicted pharmacokinetic parameters of atorvastatin acid and rosuvastatin acid
following an oral administration.
Parameter

Atorvastatin acid
Rosuvastatin acid
Observed Predicted PPE (%) Observed Predicted PPE (%)
Mean Cmax (ng/mL)
17.88
14.74
17.6
6.26
6.28
0.30
Mean Tmax (h)
2
1.72
14.0
6
3.96
34.0
Mean AUC0-t (ng/mL.h)
103.58
103.32
0.30
55.07
57.90
5.10

PPE=Percentage prediction error: [| (Predicted-Observed)/ Observed|]*100
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